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ABSTRACT OF THE DISSERTATION
Axonal Damage in Repetitive Concussive Traumatic Brain Injury:
Characterization and Contributing Factors
by
Rachel Elise Bennett
Doctor of Philosophy in Biology and Biomedical Sciences
Neurosciences
Washington University in St. Louis, 2014
Professor David Brody, Chair

There are an estimated 1.6-3.8 million concussions in the United States annually.
Individuals who experience a single concussion are at low risk for long-term consequences.
However, there is mounting evidence that experiencing multiple concussions can lead to
persistent symptoms, cognitive impairment, and increased risk for neurodegenerative disease.
The underlying pathophysiology of concussions is not well understood.
To study the mechanisms that lead to these long-term consequences, a mouse model of
repetitive concussive traumatic brain injury (rcTBI) was developed. Initial studies sought to
characterize the histological and functional changes that occur after two closed-skull impacts in
mouse. Similar to human traumatic brain injury, rcTBI produced axonal injury evident by
amyloid precursor protein, neurofilament, and silver staining abnormalities in the absence of
gross structural changes or cell loss. Microglia and astrocytes both became activated and were
prominent in injured white matter by 7 days. Behaviorally, injury resulted in acute Morris Water
Maze deficits that were not completely recovered by 7 weeks post-injury. Functionally, the
velocity of axonal compound action potentials was slowed in both myelinated and unmyelinated
axons. These alterations were accompanied by changes in white matter that were detectable
by in vivo diffusion tensor magnetic resonance imaging (MRI). At 7 days post-injury, mean
xiii

diffusivity and the diffusion of water parallel to axons in the corpus callosum and external
capsule was reduced. However, these parameters did not correlate with increases in silver
staining or microglial activation and indicate a need to develop better histological methods for
assessing axonal injury after mild trauma. Future experiments will be conducted to quantify
axonal injury by array tomography, a method outlined here briefly.
The second goal of this work was to determine what factors might contribute to axonal
injury in concussion. Specifically, the hypothesis that microglia may increase axonal injury
acutely following rcTBI was tested. The CD11b-TK mouse line, a valganciclovir-inducible model
of microglial depletion, was used to reduce microglia within the corpus callosum and external
capsule by 35%. Quantification of silver staining determined that this had no effect on axonal
injury at 7 or 21 days after rcTBI. Further reduction by 56% also did not alter axonal injury
detectable by silver staining, APP or neurofilament labeling, or by electron microscopy. We
additionally tested several pharmacological compounds to determine whether they could reduce
the microglial response. None of the compounds tested—including minocycline, (RS)-2-Chloro5-hydroxyphenylglycine (CHPG), brilliant blue g (BBG), and microRNA-124 (miRNA-124)—were
able to reduce the number of iba-1-positive microglia present in the corpus callosum after injury,
which were quantified by stereology. Silver staining was unaffected. Use of the targeted toxin,
Mac-1-Saporin, was found to dramatically reduce microglial number but also result in nonspecific neuronal loss days 7 after rcTBI. Collectively, these experiments indicate that
microglia appear to play a neutral role in regards to axonal injury acutely after repeat
concussion. To test the role of microglia in the long-term, additional tools to manipulate the
microglial response will need to be developed.
Last, the contribution of Apolipoprotein E to axonal injury after moderate-severe
traumatic brain injury was assessed in a transgenic mouse model carrying three human familial
AD mutations (PS1M146V, tauP301L, and APPSWE). The Apolipoprotein E4 (APOE4) genotype is a
risk factor for poor outcome following traumatic brain injury, especially in young patients. By
xiv

analogy to APOE4’s effects on the risk of Alzheimer’s disease, one hypothesis is that APOE
genotype influences amyloid-beta (Aβ) and tau deposition following injury. Surprisingly, the
amount of amyloid-beta and tau as measured by stereology was similar between mice
possessing the APOE2, 3, or 4 allele. However, APOE4 mice had significantly greater numbers
of APP-positive axons. These results suggest that the APOE4 genotype may have a primary
effect on the severity of axonal injury in the setting of acute traumatic brain injury.
Altogether, this work presents the characterization of a mouse model of repetitive
concussive traumatic brain injury that can be utilized to determine what factors contribute to
pathophysiological changes and to aid in the design of future therapeutics.
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CHAPTER 1
Introduction

1.1 TRAUMATIC BRAIN INJURY
Annually, there are more than 2.4 million traumatic brain injuries (TBI) in the US alone,
producing an estimated lifetime total cost of $60 billion to the economy (Coronado, et al. 2011;
Coronado, et al. 2012). Of these, 75% of all TBIs may be mild TBIs, or concussions, costing
nearly $17 billion (Centers for Disease Control and Prevention 2003). Leading causes of
traumatic brain injuries are falls, motor vehicle accidents, and direct head impact during work,
sports, or recreational activities (Coronado et al. 2011). Children and young adults 10-19 years
old are particularly prone to mild TBI and concussion, and account for 71% of all sports and
recreational TBI emergency department (ED) visits and hospitalizations (Gilchrist, et al. 2011).
Of these, 70% are males. Overall, it is difficult to estimate the total number of mild TBIs
including concussions that occur each year in the United States given that not all are severe
enough to result in ED visits or hospitalizations, though estimates range from 1.6-3.8 million
annually (Thurman, et al. 1998; Langlois, et al. 2006). Thus, the burden of TBI and concussion
is considerable, and identification of new therapeutic strategies is imperative.
TBIs can be classified along a spectrum of mild to moderate to severe brain injury,
though exact clinical definitions are the subject of debate. Traditionally, clinicians use the
Glasgow Coma Score (GCS) to assess level of coma and consciousness (Teasdale, et al.
1974). Scores of 3-8 indicate a severe traumatic brain injury and are often the result of motor
vehicle accidents or penetrating skull injuries that are characterized by contusions to the brain,
hemorrhage, vasogenic and cytotoxic edema, and can be accompanied by skull fracture.
Moderate brain injuries may have some or all of the characteristics of severe injury and GCS
1

scores ranging between 9-12 (Rimel, et al. 1982). In both severe and moderate brain injury,
abnormalities are typically evident by computed tomography (CT) scan or magnetic resonance
imaging (MRI). Finally, mild brain injuries and concussion, a form of mild TBI, are characterized
by alterations to mental status as a result of acceleration/deceleration forces or a direct impact
to the head or body (McCrory, et al. 2009). Injury may be present with or without small
contusions, hemorrhages, and a <30-minute loss of consciousness. GCS scores range from
13-15 and CT or conventional MRI abnormalities are most often absent (Rimel et al. 1982;
Newton, et al. 1992; Mittl, et al. 1994; Iverson, et al. 2000; Bazarian, et al. 2006).

1.2 CONSEQUENCES OF TRAUMATIC BRAIN INJURY
Long-term changes associated with traumatic brain injury have a broad range and likely
depend on the specific injuries sustained by each individual. In some, TBI appears to
accelerate age-related cognitive decline (Moretti, et al. 2012). In others, TBI may contribute to
the development of Alzheimer’s disease, which is supported by both retrospective and
prospective studies that point to moderate-severe TBI as a leading environmental risk factor for
AD (Mortimer, et al. 1991; Plassman, et al. 2000; Fleminger, et al. 2003). A recent study using
uniform data sets from the National Alzheimer’s Coordinating Centers (NACC) determined that
individuals who suffer from traumatic brain injury (TBI) with persistent symptoms are more 3
times more likely than individuals with no history of TBI to develop dementia of the Alzheimer’s
type (Sayed, et al. 2013). Additionally, a number of psychiatric disorders are associated with
moderate-severe traumatic brain injury including schizophrenia and depression, particularly
among young individuals injured at 11-15 years of age (Orlovska, et al. 2013). These long-term
effects appear to be distinct from changes associated with mild TBI.
Immediately after a concussion, headache, inability to focus, dizziness, and sleep
disturbances are frequent complaints (McCrory et al. 2009). Generally, 91% of individuals will
be asymptomatic after 1 week (McCrea, et al. 2003). However, in some, symptoms persist for
2

months or years and as many as 20% or more of these may not return to work within a year of
injury (van der Naalt, et al. 1999; Iverson 2005; Nolin, et al. 2006; Daneshvar, et al. 2011). In
particular, concussed athletes who return to play within a week and experience a second
concussion are at greater risk for persistent symptoms and worse outcome (Guskiewicz, et al.
2003). Increased risk of second impact syndrome is also a concern, a rare condition which
involves severe, usually fatal, brain injury despite a minor impact (Saunders, et al. 1984; Cantu
1998). Further, individuals who have experienced multiple concussions in their lifetime are at
risk for developing Chronic Traumatic Encephalopathy (CTE), a disorder characterized by
accumulation of the protein tau particularly around blood vessels and at the depths of sulci, and
by alterations in behavior often resulting in violent or aggressive mood swings and increased
risk-taking (McKee, et al. 2013b). CTE is best characterized in boxers (i.e. dementia
pugilistica), but there is increasing awareness of incidence in football players, wrestlers, and
hockey players as well as military servicemen (Corsellis, et al. 1973; Roberts, et al. 1990;
Omalu, et al. 2005; Omalu, et al. 2006; McKee, et al. 2009; Goldstein, et al. 2012; McKee et al.
2013b). What specific pathological features give rise to persistent symptoms and, potentially, to
CTE following concussions are unknown.

1.3 AXONAL PATHOPHYSIOLOGY IN TRAUMATIC BRAIN INJURY
While severe injuries deform brain tissue leading to gross structural alterations, cell loss,
and compromise blood brain barrier integrity, mild injuries appear to be disruptive to axons. To
understand the biomechanical forces acting on the brain, some of the earliest studies of TBI
were conducted using gelatin models of brain tissue subjected to angular acceleration
(Holbourn 1943). Later, experiments conducted in both gelatin models and in primates
determined that rapid rotational acceleration of the head results in sheer strain forces that are
sufficient to produce axonal injury in the absence of other pathologic abnormalities (Gennarelli,
et al. 1982; Margulies, et al. 1990). Optic nerve stretch experiments provide further evidence
3

that these forces lead primarily to cytoskeletal changes with loss of axonal microtubules and
neurofilaments immediately after injury (Maxwell, et al. 1997). Cell culture models have also
supported this idea, demonstrating that stretching results in microtubule breakage and leads to
axonal degeneration (Smith, et al. 1999; Tang-Schomer, et al. 2010; Tang-Schomer, et al.
2012). In these studies, severing of even a single microtubule bundle can result in the
accumulation of proteins and organelles normally transported down the length of the axon
(Tang-Schomer et al. 2012).
Other events also take place immediately following axonal injury that can compromise
axon integrity and ultimately lead to neurodegeneration. Mechanical injury disrupts ionic
homeostasis, leading to high extracellular potassium (K+), excitatory glutamate release, and
intracellular calcium (Ca2+) influx (Giza, et al. 2001). This reduces local ATP concentrations as
cells attempt to restore ionic homeostasis. These changes in turn activate caspases, calpains,
phosphatases, and kinases that can cleave sodium channel proteins, alter neurofilament
spacing, and induce mitochondrial swelling in the minutes to hours following injury (Maxwell, et
al. 1995; Okonkwo, et al. 1998; Iwata, et al. 2004; Saatman, et al. 2010).
Histologically, damaged axons are typically visualized by labeling with amyloid precursor
protein (APP) which is normally carried by fast axonal transport along the length of the axon but
can be found in stereotypical axonal swellings after both severe or mild traumatic brain injury
(Gentleman, et al. 1993; Blumbergs, et al. 1994; Graham, et al. 1995). These swellings usually
have a beads-on-the-string or tadpole-shaped morphology and can be seen in the brain within
hours of injury and up to months or even years after the initial insult (Sherriff, et al. 1994; Chen,
et al. 2009; Johnson, et al. 2013a). At these later time points, it is unclear whether axonal
swellings belong to axons that were injured during the initial insult and have not resolved or
whether they are newly injured axons arising from some secondary process of degeneration. In
addition to APP, axonal disruption has also been visualized by silver staining and using
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antibodies to neurofilament heavy and light chain proteins (Oppenheimer 1968; Strich 1970;
Gennarelli et al. 1982; Yaghmai, et al. 1992; Grady, et al. 1993).
Specific to concussion, few histological studies exist due to the non-fatal nature of the
injury. However, a classic study revealed silver staining abnormalities and microglial activation
in the brains of concussed individuals (Oppenheimer 1968). Another study found APP-positive
axonal injury in the white matter tracts of five concussed individuals who died 2-99 days postinjury of other causes (Blumbergs et al. 1994). More recently, McKee and colleagues have
observed several cases of CTE where axonal injury was evident by SMI-32, an antibody to
neurofilament, indicating a persistent injury to axons that may be a cause or an effect of CTE
(McKee et al. 2009; Goldstein et al. 2012). Additional evidence for axonal injury in concussion
comes from diffusion tensor MRI studies that have confirmed white matter injury in small cohorts
of athletes (Lipton, et al. 2008; Niogi, et al. 2008; Wilde, et al. 2008). Interestingly, in these
studies, changes evident by MRI correlated with post-concussive symptoms. Last, animal
studies have also been key to our understanding of concussion. Studies in mice, rats, and pigs
have confirmed that axonal injury arises as a result of concussive impacts (Laurer, et al. 2001;
DeFord, et al. 2002; Creeley, et al. 2004; Raghupathi, et al. 2004; Friess, et al. 2007). Neuronal
loss is minimal in these injury models and gliosis appears to be a second common pathological
event.

1.4 SUMMARY
Altogether, there is growing realization of the costs of traumatic brain injuries—and of
concussion in particular—to society. Better understanding of the pathological events that take
place after concussion is key to developing therapeutics that will minimize long-term disabilities.
As axonal disruption is evident across the spectrum of TBI at both acute and chronic timepoints,
axon injury may provide the substrate for persistent symptoms and pathological change in TBI
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patients. My thesis work sought to better understand concussion by focusing on axonal injury.
Overall, the goals of this research were to 1) Evaluate an experimental model of concussion in
mouse 2) Determine how axons are affected by repetitive concussive injury and 3) Evaluate
factors that may contribute to axonal injury including the microglial response and expression of
the Apolipoprotein E4 allele.
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CHAPTER 2
Modeling Repetitive Concussion in Mouse

2.1 INTRODUCTION
Mild repetitive brain injuries are a growing health concern, particularly among children
and adolescents participating in sports. Males participating in high school football for example,
experience concussive injuries at a rate of 0.47 per 1000 athlete exposures and nearly 20% will
experience recurrent concussions (Gessel, et al. 2007). Prospective studies in high school and
collegiate athletes have determined that experiencing multiple concussive impacts can lead to
cognitive deficits in these individuals (Collins, et al. 2002; Guskiewicz et al. 2003; Iverson, et al.
2004) . The cognitive effects of concussions are best described in boxers, where as many as
17% may develop persistent symptoms that may be associated with Chronic Traumatic
Encephalopathy, a devastating neurodegenerative disease (Roberts et al. 1990; McKee et al.
2009). However, despite the increased incidence of concussion and the growing number of
individuals suffering from multiple concussions, little is known about the effects of these injuries
on the brain.
To better understand the underlying mechanisms of adverse effects, several groups
have developed mouse and rat models of concussive injury. Most models use one of three
methods of injury 1) weight drop 2) fluid percussion injury or 3) pneumatic/electromagnetic
impact. In weight drop injury models in both rats and mice, the head is typically fixed in a
stereotaxic frame and a 15-150g weight is dropped from the height of 30-60 cm onto the fixed or
unfixed head of the anesthetized animal (Marmarou, et al. 1994; Tang, et al. 1997a, b; Han, et
al. 2000; DeFord et al. 2002; Zohar, et al. 2003; Milman, et al. 2005; Tashlykov, et al. 2007;
Israelsson, et al. 2009; Meehan, et al. 2012; Mannix, et al. 2013). This injury model was
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originally developed by Marmarou and colleagues to induce moderate-severe brain injury in rats
but has since been adapted to produce mild injuries in mice (1994). However, skull fracture is
common and the exact number of impacts is variable as the weight can “bounce” several times
on the animal’s head before coming to a rest.
In fluid percussion injury, a craniotomy is performed and a skull cap attached to a fluid
reservoir is glued in place. Dixon et al. originally adapted this technique to produce traumatic
brain injury in rats (1987). To produce injury water is rapidly injected, and the physical force of
the fluid striking the brain causes injury. Several groups have utilized this technique to study
“mild” and repetitive brain injuries but fundamentally, this invasive technique is not likely to truly
represent uncomplicated concussive injury (Spain, et al. 2010; Cao, et al. 2012; Shultz, et al.
2012; Selwyn, et al. 2013) .
Other groups have used pneumatic or electromagnetic devices in recent years to impact
the skull (Laurer et al. 2001; Uryu, et al. 2002; Longhi, et al. 2005; Creed, et al. 2011; Hylin, et
al. 2013). These devices produce single, rapid impacts to the skull and injury severity can be
altered by adjusting the depth of impact or the number of impacts delivered to a single animal.
Though the head is fixed, these injuries likely represent the most analogous injuries to human
concussion available in rodents. However, certain aspects of human concussion are unlikely to
be represented in these lissencephalic animals.
Injuries in large animals such as pigs use a separate device that rapidly rotates the head
to produce injury (Raghupathi et al. 2004; Friess et al. 2007). Similarly, the classic studies of
Gennarelli and colleagues where macaques were subjected to rapid head acceleration also
model concussive forces (Gennarelli et al. 1982). For face validity, experimental models in pigs
and primates resemble human mild TBI the closest, recapitulating the biomechanical forces that
act upon the brain to produce injury. However, ethical and practical concerns limit the use of
these animals in widespread concussion research.
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Literature regarding experimental concussion models in rat and mouse to date has been
summarized in Table A1 of the Appendix. Altogether, in rat and mouse models of concussion,
one clear limitation of previous studies is the high rate of contusions and skull fractures that are
produced. Thus, many studies of “concussive” or mild TBI are performed in models of
complicated mild TBI, which represents a small overall fraction of human clinical TBI cases. Of
the injury models that do resemble uncomplicated concussion in that there are no fractures or
gross lesions to the brain, single injuries are reported to result in subtle, transient changes in
behavior and APP immunohistochemistry while 2 or more repetitive injuries resulted in more
persistent injury and impaired performance on behavioral tasks (Laurer et al. 2001; DeFord et
al. 2002; Creeley et al. 2004; Longhi et al. 2005). Indeed, studies have reported striking
behavioral alterations after injury despite relatively little pathology as seen by
immunohistochemistry (Laurer et al. 2001; DeFord et al. 2002; Creeley et al. 2004). However,
few studies have investigated axonal pathology despite its prevalence in human TBI including
concussion (Oppenheimer 1968; Blumbergs et al. 1994; Johnson, et al. 2013b). Thus, it is
possible that the disparity between histological abnormalities and behavioral performance may
be due either to a lack of sensitive assays for axonal injury or it may be that concussive injury
results in electrophysiological changes and not structural alterations. This work sought to test
these hypotheses in a mouse model of repetitive closed-skull injury—a model that does not
produce gross brain lesions and uses young 6-8 week old wild-type mice. Several histological
methods were employed to visualize injury induced changes and compound action potentials
were measured in the corpus callosum to characterize axonal injury.
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2.2 METHODS
Animals
Male C57Bl/6j wild-type mice (Jackson, cat# 000664) 6 to 8 weeks of age were used for
all experiments. Mice were fed food and water ad libitum and housed under a 12-hour light dark
cycle. All experiments were approved by the Washington University Animal Studies Committee.

Electromagnetic Repetitive Closed-Skull TBI
Mice were randomly assigned to either rcTBI or sham injuries so that each cage of 5
mice contained both groups. Anesthesia was induced using 5% isoflurane and the mouse was
placed in a stereotaxic frame with rounded Kopf head holders (David Kopf Instruments).
Isofluorane was then maintained at 2% for the duration of the experiment using a nose cone.
Body temperature was controlled at 37°C using a fee dback temperature controller (Cell
Microcontrols). Heads were shaved, swabbed with betadine, and a midline skin incision was
made to expose the skull.
Impacts were performed using an electromagnetic impactor fitted with a custom tip
(Figure 2.1). To construct the impactor tip, rubber spheres were purchased from Precision
Associates, Inc. (molded ball 0.375 diameter, 50 Duro salmon silicon) and cut in half. The cut
side was glued to the base of a 9mm steel impactor tip. The impactor was lowered at a 20°
angle so that the tip was just touching the skull at -1.8 mm bregma, -3.0 mm to midline. A hand
lens was used to verify the position and an impact was performed at a depth of -3.3 mm (5.0
m/s, 100 ms dwell time). Immediately after injury, mice were removed from head bars and
anesthesia until normal breathing was restored. Skin was then sutured closed, antibiotic
ointment was applied, and mice were allowed to recover on a warming pad before being
returned to their cages. 24 hours following the initial impact, a second, identical injury was
performed. Skull fractures were not common using this rubber tip (<3%), but all mice with skull
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fractures were excluded from experiments. Sham-injured mice underwent the same surgical
procedures but did not receive impacts

Behavioral Testing using the Morris Water Maze
All experiments were performed blinded to injury group identity and all mice had
indistinguishable sutures on their heads. The water maze used was 109 cm in diameter and the
platform was 11 cm in diameter. Hidden platform testing began 48 hours after the second injury
and was performed on 4 days with 4 1 minute trials per day. A probe trial was conducted on
day 4 after the final hidden platform test. For the probe, the platform was removed and the
location of the mouse was tracked for 30 seconds. Following the probe, a visible platform test
was also conducted by placing the platform in a new location so that is slightly above the water
and marked with a pole. Mice were given 1 minute to find the visible platform.

Histopathology
Mice were killed by isofluorane overdose followed by cardiac perfusion with ice-cold
phosphate-buffered saline containing 0.3% heparin. Brains were removed and fixed in 4%
paraformaldehyde for 24 hours and equilibrated in 30% sucrose for at least 24 hours. A
freezing microtome was used to cut 50 µm coronal slices beginning at the anterior portion of the
corpus callosum ending at the posterior portion of the hippocampus. For all histological
analysis, sections were sampled every 400 µm.
Cresyl violet staining was performed to assess tissue for contusion and cell loss. For
amyloid-precursor protein and NF200, immunohistochemistry was performed as previously
described (Mac Donald, et al. 2007a; Mac Donald, et al. 2007b). In brief sections were rinsed in
Tris-buffered saline (TBS) twice, incubated in 0.03% H202 in TBS for 10 minutes, rinsed twice in
TBS, and then blocked for 1 hour in normal goat serum in TBS containing 0.25% Triton-X (TBSX). Following blocking, sections went into rabbit anti-APP (1:1000, Invitrogen), rabbit anti11

NF200 (1:20,000, Sigma Aldrich), mouse anti-SMI-32 (1:1000, abcam), rabbit anti-iba-1
(1:1000, Wako), chicken anti-gfap (1:1000, Millipore), or rabbit anti-cleaved capase 3 (1:1000,
Cell Signaling) and sections were incubated overnight at 4°C with gentle shaking. For SMI-32,
after blocking, sections were incubated in 1:10 goat anti-mouse Fab IgG (Jackson
Immunoresearch) in TBS for 30 minutes. Sections were then rinsed twice in TBS and incubated
overnight in SMI-32. After the overnight incubation, sections are rinsed with TBS twice,
incubated for 1 hour in goat anti-rabbit (APP, NF200, cleaved caspase 3, iba-1; Vector
Laboratories), anti-chicken (gfap) or anti-mouse (SMI-32). After incubation with secondary
antibodies, sections were rinsed again, then incubated in streptavidin-horseradish peroxidase
(1:400, Vector Labs) for 1 hour. Labeling was visualized with 3-3‘diaminobenzidine
tetrahydrochloride (DAB; Sigma Aldrich), sections were mounted on slides, and coverslipped
with Cytoseal XYL (Thermo Scientific). For mouse anti-RM014, sections were blocked in 1:10
mouse serum in TBS-X. RM014 antibody was prepared by incubating it with biotinylated goat
anti-mouse Fab IgG (Jackson ImmunoResearch) at room temperature for 20 minutes. The
antibody-biotin IgG complex was then diluted in blocking solution at a working concentration of
1:1000 and applied to sections overnight. Immunohistochemistry was then performed as
described above with the omission of the secondary antibody.
Silver staining was performed using the FD NeuroSilver Kit II (FD NeuroTechnologies)
according to the manufacturer's instructions with the following modifications. Sections were
post-fixed again for 5 days in 4% PFA before staining and were only incubated in solution C
once for 2-minutes. Brain sections were stained in batches so that all batches contained
animals from both injury groups to avoid bias due to variability in staining intensity between
batches.
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Quantitative Analyses of Histopathology
All histopathological analysis was performed blinded to injury status. For silver staining
measurements, section images were captured using the Nanozoomer Whole Slide Imaging
System (Olympus). 3-4 sections from each mouse beginning with the anterior-most section
containing both blades of the dentate gyrus were included in densitometric analysis. These
sections spanned approximately bregma -1.1 to -2.3 mm (24). The ipsilateral corpus callosum
and external capsule were defined as the area from midline extending laterally to a horizontal
line dividing the hippocampus and thalamus. ImageJ (NIH, Bethesda, MD) was used for
quantitation of the staining and was expressed in arbitrary units, ranging from 0 (minimum) to
255 (maximum).
Stereological quantification was performed using StereoInvestigator version 8.2 software
(MBF Bioscience). The optical fractionator method was employed for quantification of total
numbers of Iba1-positive cells with activated microglial morphology per mm3 of tissue. Details
on these stereological methods have been described (22). Briefly, 4 sections per mouse (each
separated by 400 µm) were used for ipsilateral cortex and thalamus and sections per mouse
were used for estimations in corpus callosum. A grid of 180 µm × 180 µm and a counting frame
of 80 µm × 80 µm were used. Gunderson coefficients of error were less than 0.1.

Electrophysiology
Separate mice were injured or underwent sham procedures for electrophysiology
experiments. Artificial cerebrospinal fluid (aCSF) was prepared fresh daily (120 mM NaCl, 3.5
mM KCl, 26 mM NaHCO3, 1.25 NaH2PO4, 10 mM Glucose). Slicing solution was prepared by
adding 0.5 mM CaCl2 and 7 mM MgCl2 to aCSF. Holding solution was prepared by adding 2.5
mM CaCl2 and 1.3 mM MgCl2 to aCSF. All solutions were sterile filtered and bubbled with
carbogen (95% oxygen, 5% CO2) for 1 hour prior to use.
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To prepare 300 µm slices for electrophysiology, mice were deeply anesthetized with
isofluorane and sacrificed by decapitation. Heads were immediately immersed in ice cold
slicing solution. Brains were carefully dissected and rinsed in slicing solution before razor
blades were used to trim away the anterior and posterior regions of the brain leaving a coronally
sectioned block of tissue corresponding approximately to 0 to -3.5 mm bregma. Cyanoacrylate
glue was used to secure the posterior trimmed face of the tissue block to the pedestal of the
Leica VT1200 vibratome, which was immersed in slicing solution with gentle bubbling. Sections
were cut with a blade oscillation amplitude of 1.1 mm and forward speed of 0.06 mm/s. 3-4
sections were cut per animal and transferred by pipette to an incubation chamber containing
holding solution at 32-34°C with constant bubbling. Slices were allowed to equilibrate for 1-4
hours before recording.
During recording, slices were continuously perfused with room temperature oxygenated
holding solution. An upright Nikon Eclipse E600FN microscope and digital camera controlled by
Metamorph software was used to image slices and determine electrode positioning. A
stimulating electrode with a tip diameter of 100 µm was made from 1.5 mm outer diameter
borosilicate theta glass. Recording electrodes with tip resistances of ~2 MΩ were made from
1.2 mm outer diameter borosilicate glass. All recordings were acquired using a MultiClamp
700B amplifier (Molecular Devices) and MultiClamp 700B Commander software. Data was
collected at 3000 samples/sweep/signal (15 ms), with a 2 kHz sampling interval and were
digitized using a Digidata 1322A 16-bit A/D converter (Molecular Devices). Stimulating currents
100 µs in duration were produced using a WPI A365 stimulus isolator (World Precision
Instruments).
For measurement of compound action potentials electrodes were placed 1 mm apart in
corpus callosum on opposite sides of midline with the stimulating electrode ipsilateral to injury.
Electrode depth was adjusted to achieve maximum signal per slice. Input-output curves of
CAP amplitude were acquired by making 8 sweeps and the stimulus intensity was adjusted from
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0 mA to 4 mA in 0.5 mA steps. The maximum amplitude was calculated by averaging CAP
amplitude values at 3-4 mA. Amplitude measures were made by drawing a line from connecting
the peaks of the CAP response and measuring perpendicularly from this line to the trough of the
CAP to determine the height in mV. Following amplitude measurements, refractoriness was
determined by varying the interpulse interval from 8 ms down to 1.5 ms in 0.5 ms steps. Half
maximum stimulus intensities were used for all refractoriness measures. Refractoriness was
determined by subtracting a control response (single stimulus) from the paired-pulse response
and dividing this by the control response. This value was multiplied by 100%. To measure
axonal velocity, half maximum CAP recordings were made moving the recording electrode 1.5
mm, 1 mm, or 0.5 mm away from the stimulating electrode. The latency from the stimulus
artifact to the peak of the action potential was measured and plotted versus the distance
between electrodes. The slope of the line was used to determine the velocity in ms-1.

Statistical Methods
All analyses were performed using Statistica 6.0 (StatSoft, Tulsa, OK). Shapiro-Wilks
normality tests were performed to determine if data fit Gaussian distributions. In cases where
data were found to be non-normally distributed, nonparametrics statistical analyses were used.
Repeated measures ANOVA was used to compare hidden platform Morris water maze
performance between groups. Student’s t tests and Mann-Whitney U-tests were used to
compare all other variables. P values less than 0.05 were considered significant. Error bars
represent SEM.
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2.3 RESULTS
2.3.1 Repetitive Closed Skull Injury Impairs Morris Water Maze Performance
Similar to Laurer et al. 2001, an impactor tip was fitted with rubber and used to deliver
deli
consistent, concussive insults directly to the skull of the mouse ((Figure
Figure 2.1 A, B).
B Overall, this
resulted in <5 % mortality rate and <3 % skull fractures. Mice with skull fractures were not
included in the study. All mice experienced a brief peri
period
od of apnea lasting no longer than 20
seconds immediately following
lowing impact and exhibited tonic clonic convulsions for up to 30
seconds following injury.

Figure 2.1 Electromagnetic repetitive closed
closed-skull injury.. (A) Mice are anesthetized and
placed in a stereotaxic frame. (B) Head bars are used to hold the head in place while an
electromagnetic device fitted with a rubber tip impacts the skull over the left somatosensory
cortex.
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Mice subjected to two concussive impacts demonstrated impaired performance
performanc in Morris
Water Maze (MWM) during the week following injury (rcTBI n=10, sham n=11; Figure 2.2 A-H).
A
Mice were tested in the MWM on days 3
3-6,
6, where day 0 indicates the first day of injury. Under
these conditions, repeated measures ANOVA of hidden platf
platform
orm testing revealed a statistically
significant effect of day (p<0.0000), injury (p<0.0000), and a day x injury interaction (p=0.0101).
Overall, injured mice spent more time than shams searching for the hidden platform (42.92 ±
3.49 s versus 18.70 ± 2.68 s; p<0.0001, student’s t test) and traveled farther to find the platform
(p<0.0001, student’s t test). However, they also had reduced velocity compared to shams
(p=0.0002, student’s t test), which may be indicative of slight motor deficits. Both shams and
a
injured mice were able to find the visible platform, confirming impaired eyesight was not a factor
contributing to worse performance. Sham mice also completed the probe trial successfully, a
test of spatial memory, but injured mice did not perform bett
better than chance.

Figure 2.2 Morris Water Maze performance is impaired acutely (7 days) in rcTBI mice.
Mice received 2 closed skull impacts (rcTBI) or no impacts (sham) and were tested 3 days after
the first injury. (A) Sham injured mice but not rcTBI mi
mice
ce learned over the 4 day testing period
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to find the hidden platform. Mean (B) time (C) distance and (D) velocity to the hidden platform
were also impaired in rcTBI mice compared to sham controls. (E) Sham mice performed better
than chance on the probe trial, but rcTBI mice did not. Mean (F) time (g) distance and (h)
velocity to the visible platform. (** p<0.005, ***p<0.0005).

A second cohort of mice was then randomized to either rcTBI (n=9) or sham (n=9)
groups. Morris Water Maze testing beginning 44 days after first injury did not reveal any day x
injury interaction (Repeated measures ANOVA p=0.1705, Figure 2.3 A). However, analysis of
the mean time for injured mice to find the hidden platform revealed a significant difference from
shams (student’s t test p=0.0051, Figure 2.3 B). No differences in distance traveled (p=0.0845,
Figure 2.3 C) or velocity (p=0.1663, Figure 2.3 D) was observed. All mice found the visible
platform and too the same amount of time (p=0.4266, Figure 2.3 F), traveled the same distance
(p=0.4329, Figure 2.3 G), and swam at the same speed (p=0.6107, Figure 2.3 H) to find it.
However, neither group performed better than chance on the probe trial, which may indicate a
problem with the MWM experimental setup (Figure 2.3 E). Overall, these results indicate that
while mice appear to be relatively normal, they may still exhibit signs of cognitive impairment at
7 weeks post-injury. Further testing will be required to definitively characterize behavioral
changes at this time point.
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Figure 2.3 Morris Water Maze impairments are mostly recovered by 7 weeks post-injury.
Mice that received rcTBI or sham treatment were tested in water maze beginning 44 days after
the first injury. (A) Sham injured mice and rcTBI mice learned to find the hidden platform over a
4 day testing period. Mean time (B) to the hidden platform but not distance traveled (C) or
velocity (D) was impaired in injured mice compared to shams. Mice did not perform better than
chance on a probe trial (E). All mice found the visible platform quickly (F) and injury did not
affect distance (G) or velocity (H) measurements.

2.3.2 No Evidence of Histological Abnormalities or Cell Loss
Sections from sham mice and rcTBI mice were assessed for histological abnormalities
by cresyl violet staining 7 days post-injury (Figure 2.4 A-H). No areas of ischemic injury,
hemorrhage, or contusion were present in any region in any of the samples. The hippocampal
CA3 and polymorphic layer of the dentate gyrus are susceptible regions to brain injury but did
not show any cell loss at 7 days post-injury (Figure 2.4 E, F). A stereological comparison of the
number of cells in this area confirms this observation; these data can be found elsewhere
(Shitaka, et al. 2011). Subtle increases in the cellularity of the corpus callosum were observed
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in rcTBI mice compared to shams (Figure 2.4 H). Adjacent sections were also stained for
cleaved caspase 3, an indicator of cellular apoptosis (Figure 2.5 A, B). No labeling was
observed in rcTBI mice at 7 days post-injury. Tissue from a mouse subject to middle cerebral
artery occlusion (MCAo), a model of cerebral ischemia, confirm the sensitivity of this antibody to
apoptotic cells (Figure 2.5 C).

2.3.3 Gliosis after Repetitive Closed Skull Injury
At 7 days post rcTBI or sham injury, sections from mice that performed water maze
(n=10 and n=11, respectively) were labeled for iba-1, a marker of microglia and macrophage
(Figure 2.6 A, B, E). The number of iba-1-positive cells present in the corpus callosum and
external capsule was quantified by stereology. A significant difference between shams versus
rcTBI mice was observed at 7 days post-injury (one-tailed student’s t test p<0.0001; Figure 2.6
E). For a detailed timecourse of iba-1 in the corpus callosum and other regions, see Shitaka et
al (2011). In a separate cohort of mice, GFAP-positive astrocytes were quantified by optical
density in shams (n=6) and rcTBI (n=6) mice 7 days after injury (Figure 2.6 B, D, F). In these
mice, the amount of GFAP labeling was significantly increased after injury (p=0.0077, Figure
2.6 F).
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Figure 2.4 Cresyl violet staining in sham and injured mice does not reveal any gross
histological abnormalities. Sections from sham mice (A, C, E, G, I) and rcTBI mice (B, D, F,
H, J) were stained with cresyl violet 7 days post injury. No cell loss was seen in sections (A),
cortex (B), hippocampal dentate gyrus/CA3 (E, F), corpus callosum (G, H), or thalamus (I, J).
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Figure 2.5 Apoptosis is not evident by cleaved caspase 3 labeling in injured mice.
Sections from rcTBI mice were stained for cleaved caspase 3, a key protein involved in
apoptosis. No labeling was seen in any sections from mice at 7 days (A, B). Inset in (B) is
higher magnification view of box in (A), a region of injured external capsule. By contrast,
labeling was prominent in a mouse sacrificed 24 hours after MCAo, a model of cerebral
ischemia (C).
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Figure 2.6 Microglia and astrocytes increase 7 days post-injury. Sections from sham (A, C)
or rcTBI (C, D) mice were labeled for iba-1 (A, B) or gfap (C, D). Insets are from region boxed
in (A). Iba-1 was quantified by stereology (E) to determine the total number of iba-1 positive
cells in the corpus callosum and external capsule ipsilateral to injury. Gfap was quantified by
optical density (F) which measures the total area fraction containing gfap-positive astrocyte
processes. (***p<0.0001, **p<0.01)
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2.3.4 Axonal Injury after Repetitive Closed Skull Injury
Silver staining was also performed on mice used in behavioral experiments and
sacrificed 7 days post-injury (Figure 2.7 A, B, C). Silver staining was increased in shams
versus controls at this timepoint (two-tailed student’s t test p<0.0001, Figure 2.7 C). Silver
staining is thought to label protein aggregates and has been shown to reflect ultrastructural
abnormalities visible by electron microscopy (Shitaka et al. 2011). An additional timecourse of
silver staining changes can be found in Shitaka et al. (2011).

Figure 2.7 Silver staining reveals increased axonal injury in rcTBI mice 7 days postinjury. Silver staining was performed on sham (A) and rcTBI (B) mice. Insets are from region
of corpus callosum boxed in (A). Optical density of silver staining (black precipitate) was
preformed after subtracting background (gold granules) from each image (C). (***p<0.0001)
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Mice were sacrificed at 2 days (n=5) or 7 days (n=10, from behavioral experiments) after
the first injury and a qualitative survey was carried out for axonal injury markers including
amyloid precursor protein (APP), NF200, RM014, and SMI-32 (Figure 2.8 A-P). APP is
normally transported along the axon and accumulates in swellings after axonal injury. NF200,
RM014 and SMI-32 are antibodies to neurofilament. NF200 labels 200 kDa heavy-chain
neurofilaments. RM014 has been used to detect areas of neurofilament compaction in
traumatic brain injury (Stone, et al. 2001). SMI-32 detects non-phosphorylated neurofilament
heavy chain, which has been reported to indicate areas of axonal injury (Budde, et al. 2008;
McKee et al. 2009). All antibodies labeled prominent axonal varicosities in pericontusional
corpus callosum in a controlled cortical impact (CCI) mouse model of moderate-severe brain
injury (Figure 2.8 A, E, I, M). No axonal swellings were detectable in sham injured mice
sacrificed at 7 days (Figure 2.8 B, F, J, N), though diffuse background labeling was evident in
SMI-32 labeled sections (Figure 2.8 N). Additionally, in all mice including shams, NF200
labeled fibers of the cingulum bundle, which displayed normal axonal morphology distinct from
injury (not shown). Clearly abnormal axons were evident in external capsule at 2 days after
rcTBI using antibodies to APP, NF200, and SMI-32 (Figure 2.8 C, G, O). However by 7 days
post-injury, only sparse axonal swellings could be found using these same markers (Figure 2.8
D, H, P). No RM014 labeling was found at 2 days or 7 days in these sections (Figure 2.8 K, L).
At both injury timepoints, changes to axons were only apparent in external capsule overlying the
lateral ventricle ipsilateral to impact (shown) which may represent a particularly vulnerable
region in this injury model.
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Figure 2.8 Additional markers of axonal injury. Representative images of axonal injury from
1 day CCI (A, E, I, M), 7 day sham (B, F, J, N), 2 day rcTBI (C, G, K, O) or 7 day rcTBI (D, H, L,
P) mice. Sections were labeled for amyloid precursor protein (A, B, C, D) or with antibodies to
neurofilament NF200 (E, F, G, H), RM014 (I, J, K, L), and SMI
SMI-32
32 (M, N, O, P). Images in CCI
mice were captured from pericontusional corpus callosu
callosum.
m. All other images were taken from
external capsule underlying the site of impact (or sham injury) near the lateral ventricle.

2.3.5 Electrophysiological Integrity of Corpus Callosum Axons 7 days after Injury
Axonal conduction was measured by slice elec
electrophysiology.
trophysiology. Compound action
potentials (CAPs) were evoked by placing a stimulating electrode in the center of the corpus
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callosum in the injured hemisphere and were recorded in the corpus callosum opposite of
midline (Figure 2.9 A). Peaks corresponding to both myelinated (N1) and unmyelinated (N2)
axonal populations were detectable and could be abolished with application of the sodium
channel blocker tetrodotoxin (TTX; Figure 2.9 B, C).
The height of the CAP response was measured for quantitative analysis in sham (n=7)
and rcTBI (n=8) mice (Figure 2.10 A-E). This revealed no significant differences between sham
and injured mice in both myelinated (one-tailed student’s t test p=0.0508, Figure 2.10 B) or
unmyelinated fibers (one-tailed student’s t test p=0.4296, Figure 2.10 C). Varying the stimulus
intensity from 0 to 4 mA generated input-output curves for each population of axons (Figure
2.10 D, E).
Velocity was also determined by varying the distance between stimulating and recording
electrodes and measuring the latency to the peak of each CAP (Figure 2.11 A-E). A significant
difference in the velocity of both myelinated (one-tailed student’s t test p=0.0331, Figure 2.11
D) and unmyelinated (one-tailed student’s t test p=0.0072; Figure 2.11 E) axons was observed.
Refractoriness, the ability of an axon to fire action potentials in quick succession, was
also measured by varying the interpulse interval from 8 ms to 1.5 ms (Figure 2.12 A-C). As the
interpulse interval became shorter, fewer axons were able to fire action potentials and the
amplitude of the second CAP became smaller (Figure 2.12 B, C). This property did not appear
to be altered by injury in either axon population.

27

Figure 2.9. Electrophysiological recording of compound action potentials in mouse
corpus callosum. (A) A stimulating electrode (asterisk) was placed in the corpus callosum
underlying the site of injury and a recording electrode was placed 1 mm away in corpus
callosum opposite midline. (B) 100 µs stimulation (arrow) resulted in a brief stimulus artifact
followed by an early peak corresponding to myelinated axons (N1) and a later peak
corresponding to unmyelinated axons (N2). (C) Both peaks could be eliminated through
application of 250 nm TTX to block sodium channels.
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Figure 2.10 No change in compound action potential amplitude 7 days post-injury. (A)
Representative trace (average of 8 sweeps) showing myelinated (N1) and unmyelinated (N2)
axon response. Amplitude was measured by drawing a line between peaks (solid red line) and
measuring from this line to the trough of the CAP (dashed line). The maximum amplitude of the
CAP was determined for both myelinated (B) and unmyelinated (C) axons. A range of stimulus
currents from 0-4 mA was used to generated input-output curves for myelinated (D) and
unmyelinated (E) axons (Dotted line is non-linear fit). (Error bars are standard error of the
mean)
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Figure 2.11 Velocity is reduced in both myelinated and unmyelinated axons 7 days postinjury. Moving the recording electrode to 0.5 (A), 1 (B), or 1.5 mm (C) from the stimulating
electrode altered the latency to the peak of the CAPs. Velocity was determined by measuring
the time from stimulus to CAP peak in the myelinated (D) and unmyelinated (E) fibers. (Error
bars are standard error of the mean, *p<0.05, **p<0.01)
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Figure 2.12 Axonal refractoriness was not altered by injury. (A) Altering the interval
between two stimuli (arrows) at half maximum generated two CAP responses. The height of the
second CAP response is plotted as the percentage of the initial CAP height for both myelinated
(B) and unmyelinated (B) axons. (Dotted line represents non-linear fit, error bars are standard
error of the mean)
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2.3.6 Electrophysiological Integrity of Corpus Callosum Axons 1 day after Injury
Compound action potential measurements were repeated in a second cohort of mice
that was sacrificed immediately following the second sham (n=3) or rcTBI (n=5) injury (1 day
after the initial impact). Input-output curves were generated for each axon population (Figure
2.13 A, B) and the maximum CAP amplitude was measured. The amplitude of myelinated
axons was unchanged (one-tailed Mann-Whitney test p=0.3929, Figure 2.13 C) but the
amplitude of the unmyelinated response appeared to be significantly reduced (one-tailed
student’s t test p= 0.0283, Figure 2.13 D). Velocity measurements were not significantly altered
in myelinated (one-tailed student’s t test p=0.0883) or unmyelinated (one-tailed student’s t test
0.3414) axons at this early timepoint (Figure 2.13 E, F).
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Figure 2.13 Compound action potential amplitude and velocity measurements at 1 day
post-injury. Input-output curved in sham and injured myelinated (A) and unmyelinated (B)
axons. Solid line represents non-linear fit. Maximum CAP amplitude is not altered in
myelinated (C) but is altered in unmyelinated (D) axons in injured mice. No differences were
observed in velocity measurements (E, F). (Error bars represent standard error of the mean,
**p<0.01, n.s. = not significant).

2.4 DISCUSSION
Here, we characterize the consequences of repetitive closed-skull injury in mouse and
the resulting behavioral, histological and physiological white matter abnormalities. After two
concussive impacts, mice were observed to have impaired spatial learning and memory
immediately following injury which was mostly recovered by 7 weeks. Acutely after injury,
prominent gliosis was observed by iba-1 and gfap labeling in addition to axonal injury evident by
silver staining, APP, NF200, and SMI-32. Further, unmyelinated axons had reduced CAP
amplitude at 1 day and both myelinated and unmyelinated axons had impaired velocities at 7
days post-injury compared to shams. Altogether, this confirms that repetitive closed-skull
injuries produce subtle but measurable pathologies and suggests this is a useful model for
investigating concussion.
This data are scientifically relevant because few studies to date have investigated
models of concussive-type injuries and the relationship between concussion and axonal injury.
Strengths of this study include the development of a reliable concussion model that does not
produce contusions, gross histological abnormalities, or overt cell loss. This model also
reproduces axonal injury and gliosis, two key characteristics that have been observed across
the spectrum of traumatic brain injury severity (Oppenheimer 1968; Blumbergs et al. 1994;
Oehmichen, et al. 1999; Johnson et al. 2013a; Johnson et al. 2013b). As demonstrated in
Morris Water Maze, this is also a useful model to study the evolution of behavioral changes
long-term. Altogether, the injury model reported here appears to represent several aspects of
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uncomplicated concussive traumatic brain injury which accounts for the majority of all traumatic
brain injuries that occur each year in the United States.
These results are consistent with those reported by other groups using similar injury
models. Other models of concussive brain injury have demonstrated similar behavioral
impairments in Morris Water Maze, in addition to other tasks not reported here such passive
avoidance and depression behaviors (DeFord et al. 2002; Zohar et al. 2003; Creeley et al. 2004;
Longhi et al. 2005; Milman et al. 2005). Histologically, few studies have examined axonal
pathology after concussive injury. However, APP immunohistochemistry has been performed in
other mouse models, and similar to results here, only small areas of APP-positive axons were
seen acutely after injury (Laurer et al. 2001; Creed et al. 2011). Here, we expand upon these
observations using multiple injury markers. We observed that the greatest amount of injury was
evident immediately following impacts (2 days after the first injury). While areas of dense
labeling could be found in white matter immediately below the impact site, injury appeared
relatively focal compared to the widespread changes visible by silver staining. Thus, in this
model, silver staining appears to be a particularly sensitive technique for visualizing axonal
injury after concussion. Electron microscopy has been performed in this injury model to confirm
that silver staining does in fact reflect ultrastructural changes in axons and is reported in Shitaka
et al. as well as in Chapter V (2011).
Electrophysiological findings presented here contrast with those reported in Creed et al,
which used a similar impact device fitted with a large metal impact tip to strike the skull at
midline, between lambda and bregma (2011). In their report, single concussive injury resulted
in reduced amplitude of the myelinated CAP at both 1 day and 14 days post-injury and
increased refractoriness of unmyelinated axons at 14 days. Velocity measurements were not
reported. Here, the main electrophysiological finding in this repetitive concussive model was
reduced velocity of both populations of axons 7 days post-injury. That we did not detect a
reduction in the amplitude of myelinated fibers (though a small, non-significant decrease may be
35

present) likely reflects different injury severity as similar numbers of mice and electrophysiology
methods were used in both studies. Indeed in Creed et al., apoptosis in neurons was visible by
fluorojade b in the cortex and hippocampal dentate gyrus, which may indicate that the single
concussive impact produced more damage than the repetitive injuries reported here (2011).
This study does have limitations. First, and most concerning, is that sham mice failed
the probe trial in the 7 week experiment. While differences in mean time to the hidden platform
were observed between rcTBI and sham groups we cannot rule out that that this result did not
occur by chance. However, if both groups failed to learn across the four days of the trial due to
experimental design, the results would be biased towards not finding any differences between
groups. Thus, slight impairments in spatial learning and memory seem to persist out to 7
weeks post-injury, but this experiment will need to be repeated again in the future to confirm
these findings. Second, additional electrophysiology experiments should be performed to
confirm these findings. Including groups of mice subject to 3 or more concussive impacts or
moderate-severe traumatic brain injury would aid in our understanding of the ability of
electrophysiology to resolve alterations in axonal conductance due to injury. Also, given the
small n of the 1 day electrophysiology experiment, it should be repeated to confirm that velocity
is not impaired at early this early timepoint. Third, analysis of injury was limited to corpus
callosum and external capsule. Over relevant changes may be occurring in grey matter regions
and at synapses in particular. However, assaying injury processes taking place in these areas
was outside the scope of the present study.
Finally, like other rodent injury models, not all aspects of human concussion are
modeled. In mouse repetitive closed-skull injury, compression forces are exerted upon the brain
rather than rotational acceleration/deceleration forces. At present it is unknown how aspects of
axonal injury may be altered by these different types of biomechanical forces. Recently a
ballistic model of concussion in rat was reported that results in rapid rotational
acceleration/deceleration of the head—comparisons between injury modalities may provide
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future insights (Davidsson, et al. 2011). Another aspect of human concussion not modeled here
is the effect of multiple subconcussive impacts of the resulting pathology. In a study of high
school football players wearing a Head Injury Telemetry system, an average of 652 impacts
were recorded per player over a 14-week season (Broglio, et al. 2011). Though only a small
subset of impacts resulted in concussion, how a large number of blows to the head may “prime”
the brain is unknown.
The finding that microglia are increased dramatically after injury has important
therapeutic implications. Activated microglia have been observed in human traumatic brain
injury several years after the initial insult (Ramlackhansingh, et al. 2011; Johnson et al. 2013a).
In other injury models and in vitro systems they appear to play an important role in phagocytosis
of axonal debris acutely following injury and in secretion of neurotrophic factors (Batchelor, et al.
2002; Hosmane, et al. 2012). Ultimately, however, it is unknown whether these cells are
helpful, harmful, or neutral in regards to concussive injury and axonal degeneration process in
particular. Determining their role is one clear direction of these studies, as concussion therapies
may be designed to augment or inhibit microglial activation.
Another intriguing finding is that axonal velocity was reduced 7 days following repetitive
concussion. One possible implication is that such functional alterations after concussive injury
may contribute to post-concussion symptoms experienced by patients. In particular, complaints
related to cognitive function are common, and information processing speed has been reported
to be reduced in individuals who suffer mild TBI or multiple concussions (Gronwall, et al. 1975;
O'Jile, et al. 2006; Johansson, et al. 2009; Dean, et al. 2013). While other factors including
inflammatory processes and mechanical damage to synapses are likely to contribute to these
deficits in processing speed, changes in white matter including axonal conductance velocity
may be important considerations (Fjell, et al. 2011; Mazerolle, et al. 2013). Given these results,
future studies should be performed to determine how long alterations in axonal conductance
velocity persist following injury. In other injury models, functional deficits appear to resolve by
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14 days post-injury (Reeves, et al. 2005). Determining how physiological changes contribute to
behavioral alterations in this model is an important future direction of these studies.
Likewise, silver staining, iba-1, and gfap are dramatically increased after injury and these
markers may indicate an underlying histological basis for behavioral and functional changes that
occur after concussive TBI. A full characterization of the size, location, timecourse, and nature
of injured axons may provide insight into the susceptibility of specific axonal populations to
injury. For example, in other studies it has been reported that antibodies that label APP or
neurofilament accumulations reveal different subsets of injured axons (Stone et al. 2001;
DiLeonardi, et al. 2009). Further analysis will be required to determine if this is a feature of
repetitive closed-skull injury. Additionally, mice time sacrificed between 2 and 7 days post-injury
may also provide more clues to the temporal vulnerability of axons. For example, single
concussive impacts in this model do not produce significant silver stain-positive axonal injury
compared to shams, but two injuries separated by 1 day produce argyrophillic accumulation
(Shitaka et al. 2011). Determining the window of vulnerability of axons to a second impact is an
on-going subject of research in the lab and repeating APP and neurofilament
immunohistochemistry at finer temporal resolution may aid our understanding of this process.
Such studies have real clinical implications as currently there is evidence that suffering multiple
back-to-back concussions can contribute to worse long-term outcome from injury, but the
vulnerability of the brain to second injury is not well understood (Guskiewicz et al. 2003).
In sum, the rcTBI model is a useful tool for investing the pathophysiology of concussion,
particularly as it relates to axonal injury. We propose to use this model to screen therapeutic
compounds that may reduce behavioral and functional alterations and that reduce the
vulnerability of the brain to second impact (Scheff, et al. 1999; Okonkwo, et al. 2003; Zhang, et
al. 2012) . This model may also be useful for radiological-pathological correlation studies to
determine the significance of changes evident by advanced in vivo imaging methods (Bennett,
et al. 2012). Additionally, we will use transgenic mice and pharmacological compounds to
38

determine the interaction between iba-1 positive microglia/macrophage and axonal
degeneration. Other studies may uncover unique factors that contribute to axon injury following
concussion and provide novel therapeutic targets.
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CHAPTER 3
In Vivo Diffusion Tensor Imaging Detects Axonal Injury in a Mouse
Model of Repetitive Closed-Skull Traumatic Brain Injury

3.1 INTRODUCTION
Traumatic axonal injury (TAI) is a hallmark of traumatic brain injury (TBI), and may be a
leading cause of cognitive impairment and disability following head injury (Smith, et al. 2003b).
Few methods exist for detecting TAI, with a positive diagnosis usually taking place post-mortem
following histological analysis for accumulated amyloid precursor protein (APP), an integral
membrane protein that is normally transported along the length of the axon (Blumbergs et al.
1994; Sherriff et al. 1994; Geddes, et al. 2000).
Increasingly, diffusion tensor imaging (DTI) has been used as a non-invasive method for
detecting TAI in vivo (Niogi, et al. 2010). DTI measures the directional diffusion of water. In
white matter, this diffusion is restricted by the orientation of axon bundles. In regions such as
the corpus callosum, water preferentially diffuses along a single axis and has high anisotropy
(Le Bihan 2007). When white matter is injured, as in traumatic brain injury, the characteristic
diffusion of water is altered.
We have previously validated DTI signal changes after TBI with histology for APPpositive injured axons. In these studies, which used a mouse model of moderate-severe TBI,
areas with reduced relative anisotropy and axial diffusivity were shown to contain greater
numbers of APP-positive swellings (Mac Donald et al. 2007a; Mac Donald et al. 2007b).
However, from these studies and others, it is not clear whether DTI is sensitive to mild injuries
without contusion where the mechanisms of axonal injury may be different.
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Recently, our group developed a model of mild repetitive closed-skull TBI (rcTBI) in
mouse to study the pathological changes underlying concussion. In this model, young male
mice are subject to two concussive impacts within a 24-hour period. Interestingly, only sparse
APP-positive axons were visible following injury, though axonal degeneration was evident by
both silver staining and electron microscopy and coincided with a prominent microglial response
and clear deficits in spatial learning and memory (Shitaka et al. 2011).
As DTI is a quantitative method for assessing the integrity of white matter regions, we
sought to apply this technique to this mild repetitive closed-skull TBI model to determine if APPnegative axonal injury results in detectable DTI changes 24 hours and 7 days after impact.
Results from these experiments have important implications for the use and interpretation of DTI
following mild TBI.

3.2 METHODS
Animals
Six- to eight-week C57BL/6j mice were purchased from Jackson Laboratories and
housed in standard cages under a 12-hour light/dark cycle with approval from the Animal
Studies Committee at Washington University in Saint Louis. Mice were divided into 3 groups: 7
day sham injury with sacrifice 7 days later, rcTBI with sacrifice 24 hours later, and rcTBI with
sacrifice 7 days later Each group initially consisted of six mice. The final n for the rcTBI 24
hour group was 4; a scan of one mouse in this group failed for technical reasons and a second
was excluded due to a small hemorrhage within white matter. Repetitive closed-skull injury was
performed as described previously (Shitaka et al. 2011). Briefly, mice were anesthetized with
inhaled isofluorane and placed in a stereotaxic frame. A midline incision was made to expose
the skull and the 9 mm rubber impactor tip was aligned with Bregma. The tip was then moved
to the location of the impact (A/P: -1.8 mm, M/L: -3.0 mm) and an electromagnetic impactor (My
NeuroLabs) was used to drive an impact to a depth of 3.3 mm. Body temperature was closely
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monitored and maintained throughout the procedure. Following the impact, the incision was
sutured closed, antibiotic ointment was applied, and mice were allowed to recover on a heat pad
before returning to their cage. Sham-operated mice received the same treatment but an impact
was not delivered. This procedure was repeated at 24 hours for a total of two impacts per
mouse. Mice in the 24 hour scan group were immediately taken for DTI after the second
impact.

Diffusion Tensor Magnetic Resonance Imaging
All scans were performed using a previously published method (Mac Donald et al.
2007b). Mice were anesthetized with isofluorane maintained at 1% throughout the duration of
the scan while circulating warm water preserved a constant body temperature. Images were
acquired with a 4.7T scanner (Oxford Instruments 330) and actively shielded gradient coil (180
mT/m, 400 ms rise time) interfaced with a Varian Unity-INOVA console controlled by Sun
Microsystems Ultra-60 Sparc workstation. The following acquisition parameters were used:
TR= 3s, TE= 40ms, and FOV/Resolution 20 x 20 mm / 192 x 192. Voxel size during acquisition
was 104 µm X 104 µm X 0.5 mm (zero padded to 256 x 256). A multislice spin-echo sequence
was modified to include a Stejskal-Tanner gradient-sensitizing pair in order to acquire coronal
diffusion weighted images. Diffusion gradients were applied in six directions. B-values used
were 0 and 764. Each scan required approximately 3 hours. Software written in Matlab
(Mathworks, Natick, MA) was used to calculate the six elements of the diffusion tensor and to
determine relative anisotropy (RA; overall measure of the asymmetry of diffusion), axial
diffusivity (AD, λ1; diffusion along a primary direction), radial diffusivity (RD, λ┴; diffusion
perpendicular to the primary direction), and mean diffusivity (MD).
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Diffusion Tensor Imaging Analysis
Imaging analysis was performed using Image J. The sync windows plugin was used to
trace the regions of interest (ROI) on RA, AD, RD, and MD images simultaneously. The ROIs
were carefully defined by anatomical boundaries with the anterior-most boundary being the first
section containing hippocampus and the posterior boundary being the last section where the
corpus callosum crosses at midline. This resulted in a total of 3 slices per mouse. Corpus
callosum and external capsule ipsilateral to midline were included in the white matter ROI with
the ventral boundary being drawn at the interface between the hippocampus and thalamus
(Figure 3.1 A red outline). Dorsal cortex ipsilateral to midline was selected as a second ROI
using the same boundaries (Figure 3.1 A, yellow outline) Signal intensity within each ROI was
measured across slices and weighted by the number of voxels in each sketched region to obtain
RA, AD, RD, and MD measures.

Histology
Immediately following each scan, mice were sacrificed by isofluorane overdose,
perfused with 0.3% heparin phosphate-buffered saline (PBS), and brains were removed and
placed in 4% paraformaldehyde (PFA) for 24 hours. After fixation, brains were equilibrated in
30% sucrose PBS and cut into 50 µm-thick sections using a freezing microtome. Sections
were then either rinsed in PBS and stored in 4% PFA for 5 days for silver staining or underwent
processing for Iba-1 immunohistochemistry. Evaluation was conducted on sections taken at
400 µm intervals along the anterior-posterior axis of the brain. For silver staining, a Neurosilver
Kit (FD Neurotech) was used according to the manufacturer’s instructions with the exception of
a single two-minute incubation with solution C as previously described (Shitaka et al. 2011). For
APP and Iba-1 staining, endogenous peroxidases were quenched with 0.03% H2O2, blocked in
3% normal goat serum in 0.25% Triton-X tris-buffered saline (TBS-X), and incubated overnight
in 1:1000 rabbit anti-Iba-1 (Wako) or 1:1000 rabbit anti-APP (Invitrogen) in 3% normal goat
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serum (NGS) TBS-X. Antibody binding was visualized using 1:1000 goat anti-rabbit (Vector
Laboratories) in TBS-X, followed by 1:400 AB complex (Vector Laboratories), and DAB
substrate enhanced with nickel chloride (Sigma). All sections were mounted onto slides and
digitally scanned using an Olympus Nanozoomer Whole-Slide Imaging System to generate
photomicrographs.
Iba-1 stereology and silver stain quantification in corpus callosum was performed as
published in Shitaka et al (2011). In short, ROI parameters were the same as used for DTI
analysis. Image J was used to measure silver staining by densitometry. The optical
fractionator probe in StereoInvestigator (Microbrightfield) was employed to count the number of
Iba-1-positive cells. A grid size of 180 x 180 µm and counting frame of 80 x 80 µm ensured
that the Gunderson’s coefficient of error was <0.1 for all counts.

Statistical Methods
Prism 5.0 (GraphPad) was used for statistical analysis. All DTI data were analyzed by
one-way ANOVA followed by Bonferroni’s multiple comparisons test.

For histology, a one-

tailed t test was performed as it was expected that silver staining and Iba-1 positive cells would
increase following injury as previously published (Shitaka et al. 2011). Linear regression and
Pearson’s product moment correlation was performed to determine the relationship between
DTI and histological measures. In all cases, only p-values less than 0.05 were considered
significant.
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3.3 RESULTS
3.3.1 DTI of white matter
Separate cohorts of mice were scanned using DTI 7 days after sham treatment or 24
hours or 7 days after the first closed-skull traumatic brain injury (Figure 3.1 A-F). Analysis of
corpus callosum and external capsule 24 hours after injury revealed no significant changes in
DTI measurements compared to shams (Figure 3.1 C-F). At 7 days, relative anisotropy and
radial diffusivity remained unchanged (Figure 3.1 C. D), but a statistically significant decrease in
axial diffusivity was apparent compared to shams (p<0.01) and injured mice at 24 hours
(p<0.01; Figure 3.1 E). Decreased mean diffusivity was also evident compared to sham
(p<0.05) and injured mice at 24 hours (p<0.01; Figure 3.1 F).
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Figure 3.1
1 Diffusion tensor imaging in rcTBI mice. (A) The regions of interest (red, yellow)
were defined by anatomical boundaries (blue) and were used for quantitative analysis of
diffusion tensor images. (B) Representative images of ipsilateral rela
relative
tive anisotropy (RA) and
axial diffusivity (AD) in both a sham and an rcTBI mouse at 7 days. White indicates higher
signal intensity and greater RA or AD. (C, G) Relative anisotropy (D, H) Axial diffusivity. (E, I)
Radial diffusivity. (F, J) Mean diff
diffusivity. (C-F) White matter. (G-J)
J) Cortex (*p<0.05, **p<0.01,
***p<0.001, one-way
way ANOVA with Bonferroni post
post-test,
test, error bars represent ±SEM. Square
symbol in 7 day group indicates a mouse with histologically mild injury, a possible outlier.)
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3.3.2 DTI of cortex
Considering injury results in significant histological abnormalities in cortex in addition to
the white matter, analysis of DTI signal within cortex ipsilateral to injury was also performed.
As cortex is an isotropic structure, little RA was observed within cortex in any injury group
(Figure 3.1 G). No change between sham and injured mice at 7 days was apparent in AD, RD,
or MD (Figure 3.1 H-J). However, AD, RD, and MD were significantly increased in injured mice
at 24 hours compared to both shams (p<0.05) and injured mice at 7 days (p<0.01; Figure 3.1
H-J).
Given the changes in white matter AD and cortical MD, it was possible to separate the
three injury groups based on these parameters (Figure 3.2). One potential outlier in the 7 day
injury group overlapped with sham mice and has been marked with a unique symbol in all
figures as this mouse appeared to have minimal injury when analyzed by both DTI and
histology.

47

Figure 3.2 Mean diffusivity
ity in cortex versus axial diffusivity in white matter separates
mice into distinct injury groups. (Open Square symbol in 7 day group indicates a mouse with
histologically mild injury, a possible outlier.)

3.3.3 Histological findings
Immediately following DTI scans, mice in the sham and injured cohorts were sacrificed
and tissue was processed for APP, Iba
Iba-1,
1, and silver staining. As previously reported (Shitaka et
al. 2011), only occasional APP-positive
positive swellings were detectable in injured mice and were
virtually indistinguishable from shams with this marker ((Figure 3.3 A-D).
). Quantification of Iba-1
Iba
and silver staining within corpus callosum and external capsule revealed levels similar to those
observed in Shitaka et al (Shitaka
Shitaka et al. 2011
2011) in both sham and 7 day injured mice (Figure
(
3.4
A-D).
). This indicates that the additional 3 hou
hours
rs of anesthesia during the MRI scan does not
appear to substantially affect these histological markers. Mice sacrificed at the 24 hour
timepoint did not have Iba-1
1 or silver stain abnormalities, as previously reported (Shitaka et al.
2011),, and were not included in the stereological analysis.
Interestingly, the density of silver staining in the corpus callosum and external capsule
correlated strongly with RA (r=-0.
0.8639, p=0.0265; Figure 3.4 E). Silver staining
ining did not
statistically significantly correlate with AD (r=-0.6293, p=0.1806), RD (r= 0.5920, p=0.2157),
p=0.2157 or
MD (r=-0.0402, p=0.9397). Iba-1
1 immunoreactive microglial cell counts were also not
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significantly correlated with any o
of the DTI measures: RA (r=-0.7506,
7506, p=0.0856),
p=0.0856 AD (r=0.3865, p=0.4491), RD (r=0.6238,
6238, p=0.1856), MD (r=0.1574, p=0.7658).

Figure 3.3 APP immunohistochemistry. (A, B) Injury did not result in APP positive axons in
the corpus callosum of mice analyzed at 24 hours or (C) 7 days following impacts and were
similar to (D) sham mice. (E) A mouse subject to moderate controlled cortical impact (CCI)
brain injury and sacrificed
acrificed at 24 hours served as a positive control for APP staining (red box
indicates location of B-E,
E, scale bar in A=500 µm, scale bar in B=50 µm).
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Figure 3.4
4 Axonal injury and microglial activation in 7 day rcTBI. (A) Sham operated mice
had little silver stain (black precipitate, left panel) and few Iba
Iba-1-positive
positive cells (right panel) in the
corpus callosum (scale bar=500 µm). (B) Silver staining (left panel) and increased numbers of
Iba-1-positive cells (right panel)
l) were evident in the corpus callosum of mice 7 days post-injury.
post
Quantification of silver by densitometry (C, arbitrary units A.U.) and of Iba
Iba-1
1 by stereology (D)
confirmed observed changes (*p<0.05, **p<0.01, Student’s one
one-tailed
tailed t test). (E) Silver staining
s
strongly correlated with changes in relative anisotropy at 7 days post
post-injury
injury (Pearson’s
correlation, two-tailed,
tailed, solid line represents linear regression, dotted lines represent 95%
confidence interval. Square symbol in 7 day group indicates a mou
mouse
se with a histologically mild
injury, a possible outlier).
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3.4 DISCUSSION
Here we present findings that mild repetitive closed-skull injuries in mice result in
detectable changes by DTI. Importantly, these DTI abnormalities are present despite of a lack
of APP-positive histology, which has been considered a “gold standard” for identifying traumatic
axonal injury. Previous studies from our group have shown that the numbers of APP-positive
axonal varicosities correlate strongly with RA in a model of moderate-severe traumatic brain
injury (Mac Donald et al. 2007b). In this work, we show RA correlates just as strongly with the
degree of silver staining in the corpus callosum of mildly injured mice.
Both axial diffusivity and mean diffusivity have been widely used to assess axonal
degeneration in the central nervous system (Pierpaoli, et al. 2001). In our model, both of these
parameters were reduced within white matter in the injured 7 day group compared to shams.
Notably, neither silver stain, a marker of protein aggregates, nor Iba-1-positive microglial cells
correlated well with AD and MD changes. While both protein aggregation and microglial
pathology may have contributed to some of the reduced diffusivity, weak correlations between
these measures indicate other histological markers are needed that better reflect AD and MD
changes. In addition, because Iba-1 did not correlate with any DTI parameter, it is important to
note that this method may not be suitable to resolving microgliosis. Other imaging modalities
may therefore be required to detect this prominent microglial response in vivo
(Ramlackhansingh et al. 2011; Wang, et al. 2011).
Given the coincident decrease in axial diffusivity and mean diffusivity, it is interesting that
no significant changes in relative anisotropy were seen. This is different from TBI with
contusion, where AD is reduced, overall diffusivity is unchanged or increased, and
subsequently, RA is reduced (Mac Donald et al. 2007b). In this model, it is possible that a
larger sample size may resolve the non-significant reduction in RA. Alternately this could
indicate that in mild injuries, analysis of single components of the diffusion tensor may be more
sensitive than RA.
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Increased radial diffusivity is another common feature of DTI in TBI and in other models
with prominent demyelination or edema (Song, et al. 2003; Mac Donald et al. 2007a; Klawiter, et
al. 2011). We observed no significant change in this parameter in our model, which is in line
with previous observations by electron microscopy that revealed myelin degradation is not
characteristic of this mild injury (Shitaka et al. 2011).
Unlike white matter, imaging of cortex revealed an acute, transient increase in AD, RD,
and MD, likely reflecting edema. While these changes were significant at 24 hours, they were
resolved by 7 days post-injury. This is potentially useful for determining time since injury. Here,
increased mean diffusivity in cortex and unaltered AD in white matter characterized mice
imaged 24 hours following initial injury, whereas normalized MD in cortex and decreased AD in
white matter characterized mice imaged 7 days post-injury.
These results highlight the evolving nature of traumatic brain injuries, as the DTI
changes within white matter were not immediately apparent at 24 hours but were distinct 7 days
following injury. Similarly, earlier characterization of this model has shown that Iba-1 and silver
stain abnormalities also develop 3-7 days after injury (Shitaka et al. 2011). Thus, it is likely that
DTI measurements are reflective of a progressive degenerative process taking place within the
corpus callosum and external capsule of these injured mice. Clinically, this may also mean that
DTI days or weeks after mild head injury may be more informative for detecting and diagnosing
axonal injury. However, given our observed alterations in AD and MD were approximately 10%,
it is unclear whether these changes would be significant within a human population where
normal white matter diffusion may vary greatly between subjects. This may be one explanation
why DTI in human mild TBI patients has resulted in conflicting reports of the observed changes
in DTI signal (Zhang, et al. 2010; Cubon, et al. 2011; Henry, et al. 2011).
There are several limitations of this work. First, sample sizes are small and to fully
validate this model, larger groups will be required. However, given the small sample and the
relatively mild injuries studied, it is encouraging that these DTI changes are evident and
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correlate with histological abnormalities. Second, this research is limited by the histological
markers chosen for analysis. To fully characterize this model, markers for neurofilament,
myelin, and activated astrocytes might further inform the nature of these DTI alterations.
Quantitative electron microscopy may be the ultimate “gold standard” but is beyond the scope of
the current work. Third, mice that received a single injury were not assessed here, and so we
did not determine whether single injury alone results in DTI signal change. We have previously
demonstrated that mice subject to single injuries do not have significantly more silver staining or
microglial activation compared to shams at 7 days post-injury thus it is unlikely that a single
impact would be detectable by DTI (Shitaka et al. 2011). Fourth, the interval between injuries
was kept fixed at 24 hours; further studies will be required to determine the effect of different
intervals between injuries. As a final note, the imaging protocol used was not optimized for
measuring MD changes.
Despite these limitations, this study shows that DTI is capable of detecting populations
of degenerating axons in the absence of APP pathology. Future studies will be required to
determine the distinct DTI signatures of axonal degeneration following repeated mild injuries in
order to differentiate injury phenotypes that may or may not include disrupted APP transport.
Full validation of detection methods and interpretation of DTI signal changes will be important to
providing meaningful evaluation and targeted therapeutics for patients with multiple concussive
injuries.
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CHAPTER 4

Array Tomography for the Detection of Axonal Injury

4.1 INTRODUCTION
A barrier to analysis of axonal injury in repetitive concussive traumatic brain injury
(rcTBI) is the ability to resolve small injured axons by light microscopy. This is due in large part,
to the low signal to noise of very small structures that are at or below the resolution of light
microscopy. In humans and macaques, axon diameters within the corpus callosum range
between 0.2 to >6 µm (Lamantia, et al. 1990; Aboitiz, et al. 1992). In rodents, axonal diameter
is smaller, typically in the 0.1 to 1 µm range (Kim, et al. 1996; Olivares, et al. 2001). Following
traumatic brain injury in mice, swollen axons in corpus callosum can become very large (5 µm or
more), and are clearly visible with standard immunohistochemistry using antibodies to amyloid
precursor protein (APP) and neurofilaments. However, several observations have led us to
hypothesize that immunohistochemistry and light microscopy may not reflect the true amount of
axonal injury present after TBI in mouse, particularly after mild concussive injuries.
First, standard immunohistochemistry techniques for APP and neurofilaments reveal
only small areas of axonal injury at 2 days after the first injury that appear to resolve by 7 days
(Chapter 2, Figure 2.8). However, axonal injury is evident by silver staining and has been
confirmed by electron microscopy timepoints later than 2 days (Shitaka et al. 2011). Electron
microscopic analysis of repetitive concussive TBI (rcTBI) has confirmed that injured axons are
present throughout the ipsilateral corpus callosum and external capsule at 7 days post-injury
(Shitaka et al. 2011, Chapter 5 Figure 5.8). These axons display compaction of cytoskeletal
elements, organelle accumulation, and axolemma collapse. A key observation is that few of
these injured axons appear to have diameters greater than 1 micron, and most are less than
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500 nanometers—at or below the resolution of standard light microscopy techniques. Indeed
other investigators have documented cases of axonal injury without axonal swelling, and it may
be possible for axon degeneration to proceed without the classic “beads-on-a-string”
morphology (Stone et al. 2001). Additionally, in this mild injury model, white matter
abnormalities are apparent by diffusion tensor imaging, where mean (MD) and axial diffusivity
(AD) are both significantly reduced at 7 days post-injury. Neither MD nor AD correlate with the
amount of silver staining or iba-1 labeling for microglia (Bennett et al. 2012). The inability to
explain DTI measures by standard histological techniques further supports the idea that we are
underestimating the amount of axonal injury in rcTBI by these methods.
To test this hypothesis, we adapted array tomography for measuring axonal injury.
Array tomography was developed in the lab of Stephen Smith to quantitatively measure
synapses in the cortex (Micheva, et al. 2007). In array tomography, improved spatial resolution
is achieved along the z-axis through physical sectioning on an ultramicrotome, which greatly
improves the signal to noise ratio and allows identification of individual synapses (Micheva et al.
2007; Kay, et al. 2013). While this technique has not been rigorously validated by quantitative
EM, the use of several antibodies to label pre- and post-synaptic densities and the careful coregistration of fluorescent labels with scanning electron micrographs has confirmed the spatial
correlation of immunofluorescence with ultrastructural details (Micheva et al. 2007). Further, the
advantages of this technique over traditional electron microscopy are the ability to assay large
volumes of tissue in a relatively high-throughput fashion, to label multiple proteins of interest,
and to perform these experiments with a standard epifluorescent microscope.
Here, we outline a method for using array tomography to examine axon injury. We show
preliminary data using this technique to resolve injured and uninjured axons at a level of
resolution not previously possible except with electron microscopy. Altogether, this is a
promising new method for quantitative analysis of axons that could be applied to many fields
beyond traumatic brain injury.
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4.2 METHODS
Animals
Male C57Bl/6j mice were purchased from Jackson Laboratory between 6-8 weeks of age
(stock#000664). Two male APP knockout mice were obtained from Jackson Laboratory at 2
months of age (stock# 004133). Two 12-month-old male TauP301S mice and two 3-month-old
tau knockout mice were also used for these experiments and were bred in house. All animals
were housed in accordance with the Animal Studies Committee at Washington University in
Saint Louis. Mice were provided with food and water ad libitum and were maintained under a
12 hour light/dark cycle.

Surgical procedures
Mice were subject to closed-skull sham injury or rcTBI injury as previously described
(n=5 per group, Chapter 2). A second group of mice underwent controlled cortical impact
injuries at a depth of 1.0 mm (n=2) or 1.5 mm (n=4), which has been described elsewhere
(Brody, et al. 2007). Briefly, mice are anesthetized, placed in a stereotaxic frame, and a midline
incision is made. A 5 mm craniotomy is performed over the left parietal cortex. An
electromagnetic impactor fitted with a 3 mm metal tip is positioned M/L -1.2 mm relative to
midline and +1.5 mm lambda. Impacts are delivered at 5 m/s with a dwell time or 100ms. After
irrigation with phosphate buffered saline (PBS) a plastic skull cap is glued in place, the midline
incision is sutured closed, and the mice are allowed to recover on a heat pad before being
returned to their cage.

Tissue embedding and sectioning for array tomography and electron microscopy
Tissue embedding and sectioning was performed as described by others with minor
modifications (Kay et al. 2013). Briefly, animals were sacrificed by deep anesthesia with
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isofluorane followed by cardiac perfusion with 10 milliliters room temperature 0.3% heparin in
0.01 M PBS. This was immediately followed by perfusion with 10 milliliters 4%
paraformaldehyde (cat# 15710 E.M.S), 0.025% sucrose in 0.01 M PBS. Brains were removed
and placed in fixative for 20-30 minutes and then were sectioned into 1 mm thick coronal slabs
using a razor blade and a brain slicing matrix. Corpus callosum and external capsule ipsilateral
to injury was then dissected into 5 x 2 x 1 mm blocks which were further post-fixed for 1-2
hours. Following fixation, blocks were dehydrated in an ascending ethanol series (50%, 70%,
95%, 100%, 100%). Each dehydration step was performed for 5 minutes with gently shaking
using chilled solutions. Blocks were then placed in one wash with equal parts 100% ethanol
and LR White (cat# 14381 E.M.S) followed by two washes in 100% LR White. Blocks were
allowed to equilibrate overnight at 4°C in LR White and were then placed in gelatin capsules
(cat#70100, E.M.S.) and cured overnight in a 53°C o ven. Gelatin could be removed by gentle
heating in a 60°C water bath.
Arrays were produced using a histo Jumbo diamond knife (Diatome). To collect ribbons,
the top and bottom edges of each tissue block was painted with a thin layer of Weldwood
contact cement (DAP products) mixed with equal parts xylene. Ribbons were collected on
gelatin subbed coverslips, air-dried, and stored at room temperature prior to immunofluorescent
labeling.
For parallel electron microscopy studies, after perfusion, 1 mm thick coronal slabs of the
contralateral, uninjured hemisphere was placed in 1% PFA, 1% glutaraldehyde in 0.01 M
phosphate buffer overnight. Three slabs were prepared per mouse, beginning at the anteriormost end of the hippocampus. Sections were then incubated in 1% osmium tetroxide,
dehydrated in ethanol, and embedded in Polybed 812 (cat# 08792, Polysciences, Inc.) as
previously described. Semithin sections were cut with glass knives and stained with toluidine
blue to identify the region of interest and ultrathin sections 70-90 nm were cut and stained with
Reynold’s lead citrate and 4% uranyl acetate.
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Immunofluorescence
For immunofluorescent labeling, a PAP pen was used to draw a hydrophobic barrier
around the tissue ribbon. Sections were then incubated in 50 mM glycine in Tris buffered saline
(TBS) for 5 minutes. TBS-glycine was aspirated off and a blocking solution containing 0.05%
Tween, 0.1% bovine serum albumin (BSA) in TBS was applied for 20 minutes. Following
blocking, primary antibodies were applied and coverslips were placed in a humidified chamber
at 4°C overnight. The following day, tissue was wa shed in TBS and incubated in secondary
antibody in blocking solution for 1 hour at room temperature protected from light. Tissue was
then washed again in TBS and 5 µg/ml 4',6-Diamidino-2-Phenylindole, Dihydrochloride (DAPI;
cat #D1306, Invitrogen) in TBS was applied for 5 minutes followed by a final wash in TBS.
Coverslips were mounted on glass slides in Vectashield fluorescent mounting medium (cat# H1000, Vector Laboratories). See tables 4.1 and 4.2 for a complete listing of primary and
secondary antibodies and dilutions that have been tested in array tomography sections and
optimized for immunofluorescent labeling. All immunofluorescence was imaged using a Zeiss
Axiovert 200 laser scanning confocal microscope with a 40x 1.2 NA water immersion lens or a
Zeiss Axioskop 2 MOT Plus wide-field fluorescence microscope with a 63x 1.4 NA oil immersion
lens.

Electron microscopy in uninjured sham mice
All electron micrographs were captured using a Joel 100C electron microscope. Three
grids were prepared and analyzed per mouse (n=5 mice). Images of axonal cross-sections
were captured at a direct magnification of 6,000x beginning at the base of the cingulum and
continuing to the lateral edge of the tissue section. Tissue sections were placed on grids with
125 µm holes. To avoid user bias, one field of axons was sampled from each grid square. The
axonal field closest to grid bar nearest to midline was chosen. Areas of sectioning artifacts,
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folds, and transversely or longitudinally cut axons were avoided. This resulted in 5-8 images
per section and 80 images total.

Quantitative measurement of axonal diameters
Image J (NIH) was used for all image analysis. In each electron micrograph, a 5 x 5 µm
area was selected in the center of the image for measuring axon diameters. A scaled line was
drawn across the narrowest portion of the axon, excluding the myelin sheath, and this
measurement was recorded. All cross-sectional axons with distinct borders were measured
from each image, excluding those touching the edge of the image. In total, this analysis
included an area of 400 µm2 (16 fields each 5 x 5 µm) out of an estimated total area of 0.5 mm2
(from measurement of toluidine blue stained semithin sections) per mouse. This includes
ipsilateral corpus callosum and external capsule immediately below the injury site ±1.5 mm
anterior-posterior.
Approximately the same volume of tissue was analyzed by capturing 4 images from a
single 70-90 nm section per animal (n=5 uninjured sham mice) corresponding to the area of
corpus callosum beneath the cingulum and extending to the lateral edge of the external capsule.
Within each image, four 5 x 5 µm areas of cross-sectional axons were randomly selected for.
This resulted in a total of 16 areas for analysis from each mouse. Rabbit anti-tubulin
immunofluorescence was performed using a goat anti-rabbit Alexa 488 secondary antibody. In
image J, a line was drawn across the middle of the narrowest portion of each fluorescent point
and the full width at half max (FWHM) was determined from the intensity profile. These
measures were rapidly collected from several axons per field using a publically available Image
J macro (courtesy John Lim, v.3 available at http://imagej.1557.x6.nabble.com/FWHM-on-lineselection-td5004777.html).
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Creating projection images of axons
Images of immunofluorescent arrays were captured and processed in Image J as
previously described for synapses in Kay et al. 2013 and the macros that have been developed
for simplifying this process can be found in the supplementary information of their publication.
In short, images of serial sections are first compiled in a stack (see Macro 1, supplemental
material Kay et al. 2013) and then the multistackreg Image J plugin is used to align each section
(courtesy Brad Busse, available at http://bradbusse.net/downloads.html). For axons, tubulinlabeled images were used for all alignments and the transformation file was applied to all
subsequent channels. Following alignment, max z-projection images were created from each
stack, channels were merged and converted to color, and the resulting image was cropped to
the area of interest.
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Table 4.1 Primary antibodies for imaging axons by array tomography.
Primary Antibody

Company

Cat. No.

Size

Dilution

Notes

NE1022

100 µl

1:100

Labels many axons, not injury specific

NE1023

100 µl

ab24571

250 µl

1:20 or
1:100
1:200

Preferentially labels injured axons

SMI-34

Calbiochem
(Millipore)
Calbiochem
(Millipore)
Abcam

Labels many axons, not injury specific

MBP

Abcam

ab7349

1 ml

1:100

Good myelin labeling

APP

Invitrogen

51-2700

200 µl

1:50

Rabbit polyclonal to
α-tubulin
Rabbit polyclonal anti-200
kDa neurofilament
Phospho-tau (pS202)

alphatubulin
NF200

Abcam

ab18251

50 µg

1:200

Seems to label injured axons and
many vesicle structures. Some
punctate background labeling was
apparent in APP-/- tissue
Labels all axons

SigmaAldrich
Pierce

n4142

200 µl

1:200

Labels many axons, not injury specific

MN-1020

100 µg

1:50

Phospho-tau (pS202)

CP13

1:50

Paired helical filaments

PHF1

Mouse monoclonal to
stathmin 3

STMN3,
SCLIP

ab76678

ascites
fluid, 5 ml
ascites
fluid, 5 ml
ascites

Labels tau aggregates, no labeling in
Tau-/Labels tau aggregates, no labeling in
Tau-/Labels tau aggregates, no labeling in
Tau-/Punctate labeling in neurites

Mouse anti-neurofilament H
phosphorylated
Mouse anti-neurofilament H
non-phosphorylated
Mouse anti-neurofilament
200 kDa + 160 kDa
Rat monoclonal to myelin
basic protein
Rabbit polyclonal anti-β-APP

Short
Name
SMI-31
SMI-32

AT8

Courtesy
P.Davies
Courtesy
P.Davies
calbiochem
(millipore)
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1:50
1:50

Table 4.2 Secondary antibodies used for array tomography.
Secondary Antibody
Donkey anti-rabbit Alexa 488
Goat anti-rat Alexa 488
Goat anti-mouse 488
Goat anti-mouse Alexa 594
Donkey anti-rabbit Cy3

Company
Invitrogen
Invitrogen
Jackson
Immunoresearch
Invitrogen
Jackson
Immunoresearch
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Cat. No.
A21206
A11006
115-546-146

Size
0.5 ml
0.5 ml
0.75 mg

Dilution
1:200
1:200
1:200

A11032
711-165-152

0.5 ml
0.5 mg

1:200
1:200

4.3 RESULTS
4.3.1 Adapting array tomography for the detection of injured axons
Overall the workflow is similar to that reported for analysis of synapses (Figure 4.1)
though there are additional considerations to take into account for the preparation of arrays for
analysis of axons. Most importantly, orienting tissue blocks in the gelatin capsules for
embedding needs be done with care so that the maximum amount of white matter can be
sectioned later. Second, because axons have clear orientations, it is important to consider this
in downstream analysis. For example, axons cut crosswise will appear punctate while axons
cut longitudinally will appear as short segments that have different X-Y locations in each
section. Assaying axons so that isotropic volumes are measured in each array or sampling from
a sufficient number of randomly selected areas throughout the tissue may be the best approach
to avoiding orientation-dependent sampling bias.

Figure 4.1 Array tomography workflow. (1) Sections are embedded in LR white media in
gelatin capsules (inset) and an ultramicrotome is used to produce 70-90 nm section ribbons
using a histojumbo diamond knife. (2) Standard immunofluorescent techniques are used to
label each ribbon and images from sections are captured using a 63x lens on an epifluorescent
microscope. (3) Each image can then be further subdivided into smaller regions for analysis,
excluding cell bodies and tissue processing artifacts.
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Several antibodies were tested and their sensitivity to the detection of axons and axonal
injury was determined (Tables 4.1 and 4.2). We found an antibody to tubulin that appears to
robustly detect axons in the mouse corpus callosum and external capsule. Using this antibody
we were able to resolve individual axons by array tomography (Figure 4.2 A-L and 4.3 B). By
comparison, we were not able to resolve single axons by conventional laser scanning confocal
microscopy of tubulin immunofluorescence in thick sections (Figure 4.3 A).

Figure 4.2 Example of a short array containing uninjured mouse external capsule labeled
with anti-tubulin and Alexa 488. (A-K) Images of eleven 70 nm thick ultrathin sections labeled
with anti-tubulin and Alexa 488. Images have been co-registered so that each represents the
same 19.5 x 19.5 µm area. (L) A projection of the 11 image stack shows a reconstruction of
individual, longitudinally/transversely cut axons within this stack.
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Figure 4.3 Side by side comparison of tubulin labeling in thick sections and ultrathin
sections. (A) A confocal X-Y projection image of a section of uninjured mouse corpus
callosum mouse cut at a 50 µm thickness on a freezing microtome and labeled with anti-tubulin
and Alexa 488. (B) A confocal X-Y projection image of an ultrathin section from a similar region
of corpus callosum cut at 90 nm on ultramicrotome and labeled with anti-tubulin and Alexa 488.
(C and D) are X-Z images showing the improved spatial resolution along this axis.

4.3.2 Comparison of tubulin-labeled ultrathin sections with electron microscopy
To determine how tubulin labeling in ultrathin sections reflects axonal ultrastructure,
corpus callosum and external capsule in one hemisphere from sham injured mice (n=5) was
prepared for array tomography and the opposite hemisphere was prepared for electron
microscopy (Figure 4.4 A-F). Axon diameters were measured in both electron micrographs and
fluorescent images. A total area of 0.002 mm2 was analyzed in each case. By electron
microscopy, we were able to measure the diameters of 2612 axons and in ultrathin sections,
1178 axons. A frequency distribution of these measures shows that the 25 % percentile for
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Figure 4.4 Electron microscopy versus tubulin-labeled ultrathin sections in uninjured
wild-type mouse corpus callosum and external capsule. (A-C) Electron micrographs or (DF) tubulin-Alexa 488 fluorescence images were obtained of axonal cross-sections and were
used for axon diameter measurements. (G) Frequency distribution of axon diameter
measurements from electron micrographs (EM) and ultrathin sections used in array tomography
(AT). An equal tissue area was examined by each technique. A total of 5 mice were included in
this analysis, with the right hemisphere being prepared for EM and the left for AT.
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axon diameters was 0.14 µm, the median was 0.23 µm, and the 75% percentile was 0.39
(Figure 4.4 F). In tubulin-Alexa 488-labeled ultrathin sections, the 25% percentile was 0.26 µm,
the median was 0.30 µm, the 75% percentile was 0.36 µm. In all, this indicates that tubulin
labeling does not identify all axons and, in particular, very small diameter fibers are not imaged.
Specifically, some smaller diameter axons may appear larger due to spatial low-pass filtering.

4.3.3 Axonal Injury Markers in Ultrathin Sections
Axonal injury markers were tested in sections containing corpus callosum and external
capsule from mice subject to a moderate controlled cortical impact (CCI) traumatic brain injury
and sacrificed at 24 hours (n=2). Markers to phosphorylated or non-phosphorylated heavy
chain neurofilaments and amyloid precursor protein (APP) resolved structures resembling
classic axonal varicosities (Figure 4.5 and 4.6). However, labeling in APP knockout mice
subject to controlled cortical impact (n=2) indicates that the antibody used is not specific to APP
(Figure 4.5 C inset).
Further, when tested in an uninjured sham mouse, SMI-31 appeared to label uninjured
axonal segments (Figure 4.7 A). This injury nonspecific labeling was also seen using other
neurofilament antibodies such as NF200 and SMI-34 (data not shown). SMI-32 alone appeared
to not be present in uninjured sham mice (Figure 4.7 B). Thus, SMI-32 was used in
subsequent studies as an axon injury specific marker. Other investigators have reported similar
results using SMI-31 and SMI-32 (Budde et al. 2008).

67

Figure 4.5 Axonal injury markers SMI-31 and APP in 24 hour 1.0 mm CCI external
capsule. (A) DAPI labeling indicates cell nuclei. (B) SMI-31 Alexa 488 labeled axons. (C) APP
Cy3 labeled axons (inset is from CCI injured APP knockout mouse). (D) Composite image of
DAPI, SMI-31, and APP.
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Figure 4.6 Axonal injury markers SMI-32 and APP in 24 hour 1.0 mm CCI external
capsule. (A) DAPI labeling indicates cell nuclei. (B) SMI-32 Alexa 488 labeled axons. (C) APP
Cy3 labeled axons. (D) Composite image of DAPI, SMI-31, and APP.

Figure 4.7 Axonal injury markers SMI-31 and SMI-32 in uninjured sham external capsule.
(A) SMI-31 labels axons in an uninjured mouse while (B) SMI-32 does not. Green is SMI-31 or
SMI-32, red is tubulin Cy3, and blue is DAPI.
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4.3.4 Preliminary data using SMI-32/Tubulin to measure axonal injury after TBI
To measure axonal injury in TBI, tissue blocks containing corpus callosum and external
capsule from uninjured sham (n=5), repetitive concussive TBI (n=5), and 1.5 mm CCI (n=4)
mice were prepared 7 days post-injury. Sections from each were stained for anti-SMI-32 to
label areas of injury and anti-tubulin to label all axons (Figure 4.8). In sham mice, little to no
SMI-32 was detected and tubulin-labeled axons did not appear to be swollen or distorted
(Figure 4.8 A, B). Mice subjected to rcTBI had areas of small punctate SMI-32 labeling as well
as regions of SMI-32/tubulin co-localization (Figure 4.8 C, D). In moderate TBI, clear disruption
of axons was evident with large SMI-32 swellings appearing with or without tubulin colocalization. Further, the overall amount of tubulin appeared to be greatly reduced. This
indicates that quantitative measurement of total axonal injury may be represented by positive
SMI32 staining, tubulin staining loss, or a ratio between SMI-32 and tubulin labeling.
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Figure 4.8 Projection images of arrays (20-30 sections each) from external capsule
labeled with the axonal injury marker SMI-32 (red) and tubulin (green). (A, B) Axons from
uninjured wild-type mice displayed little SMI-32 labeling. (C,D) Mice subjected to mild repetitive
concussive traumatic brain injury had punctate areas of SMI-32 labeling and occasional colocalization of SMI-32 and tubulin in swollen axons at 7 days. (E,F) Larger axonal varicosities
>3 µm in diameter were apparent in a model of 1.5 mm CCI moderate traumatic brain injury at 7
days. Tubulin loss was also evident.
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4.3.5 Other markers for array tomography
In addition to assaying classic markers of axonal injury in white matter, we also tested
antibodies to myelin basic protein (MBP) and to the microtubule associated protein tau. AntiMBP prominently labeled myelinated axons in white matter tracts (Figure 4.9). The tau
antibodies PHF1, AT8, and CP13 were all tested in tissue from aged mice carrying a familial
frontotemporal dementia mutation (TauP301S). These phospho-tau antibodies all detected
perinuclear aggregates in entorhinal cortex (PHF1 shown, Figure 4.10). No tau labeling was
seen in the cortex of tau knockout mice (PHF1 shown, Figure 4.10 C inset).

Figure 4.9 Myelin basic protein and tubulin labeling in the external capsule of an
uninjured wild-type mouse. (A) DAPI labeling indicates cell nuclei. (B) Myelin basic proteinAlexa 488 labeled axons. (C) Tubulin-Alexa 594 labeled axons. (D) Composite image of DAPI,
myelin basic protein, and tubulin. Inset shows an enlarged view of the box in (D), where
individual myelinated axonal cross-sections are clearly visible.
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Figure 4.10 PHF-1 tau and tubulin labeling in the entorhinal cortex of a 12-month-old Tau
P301S mouse. (A) DAPI labeling indicates cell nuclei. (B) Tubulin Alexa 488 labeled axons.
(C) PHF1 Cy3 labeled axons. Inset shows the absence of PHF1 labeling in cortec from a tau
knockout mouse (D) Composite image of DAPI, tubulin, and PHF1.

4.4 DISCUSSION
Here we apply the powerful technique of array tomography to the detection of injured
axons. This promising method appears to distinguish injury in axons with diameters greater
than ~200 µm in the repetitive concussive and moderate-severe TBI models compared to
uninjured shams. Further, a wide range of antibodies were tested that can be used in several
downstream applications beyond the field of traumatic brain injury.
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Previously, array tomography has been used to quantify synaptic density near amyloid
plaques in mice, to quantifying synapses in human AD patients with or without the APOE4
allele, to investigate mitochondria distribution in the soma and neurites of mutant tau mice, to
reconstruct tau-containing axons and synapses in a reversible tauopathy model, and to examine
morphological changes in mouse blood vessels and aortic aneurysms (Koffie, et al. 2009;
Kopeikina, et al. 2011; Koffie, et al. 2012; Saatchi, et al. 2012; Kopeikina, et al. 2013; Polydoro,
et al. 2013; Pooler, et al. 2013). To date, this is the only investigation of which we are aware
using this technique to study axonal injury specifically. The ability to qualitatively and
quantitatively examine axonal pathology is broadly relevant to several injury and
neurodegenerative disease studies which currently rely on traditional histological measures and
in vivo MRI techniques to investigate axonal injury. However, use of standard techniques only
reflects axonal injury if it results in large scale changes. Here, we show by electron microscopy
that most mouse axons in corpus callosum and external capsule are smaller than 500
nanometers, which is well below the typical resolution of these techniques. Using array
tomography we were able to resolve individual axons with diameters near 200 nm or greater.
Further, in these small axons we were able to detect axonal injury in mice that were
subjected to repetitive concussive TBI and were sacrificed at 7 days. These results are in
accordance with silver staining abnormalities and electron microscopy data in this injury models
which indicates widespread axonal damage in spite of the lack of traditional
immunohistochemistry findings (Shitaka et al. 2011). Thus, it would appear that array
tomography may be useful for future studies investigating axonal injury in this model. This
technique has the advantage of being more quantitative than silver staining, which is measured
semi-quantitatively by optical density. Also, array tomography is less costly than electron
microscopy as it can be performed with a standard epifluorescent microscopy. Further,
compared to electron microscopy, this technique has higher throughput and allows for a greater
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volume of tissue to be processed at a time. It also has the advantage that many antibodies are
available which to aid in the study of specific proteins in axonal injury.
However, there are several limitations that should be addressed. First, while arrays can
provide high spatial resolution data that conventional histology cannot, electron microscopy
remains the gold standard. In these studies, we were not able to resolve small axons <200 nm
in diameter and based on data from parallel electron microscopy studies, this appears to be
nearly half of the total population of axons in the corpus callosum and external capsule as
determined in this study and by others (Olivares et al. 2001). Further, considering that we were
also not able to resolve all large diameter axons, it may be that the rabbit polyclonal anti-tubulin
antibody chosen for these studies does not label all axonal populations. Testing additional
tubulin antibodies may shed light on this issue. On the other hand, we were not able to
determine how the differential preparation and handling of tissue for EM versus AT may have
contributed, in part, to this discrepancy. Thus direct quantitative comparison between EM and
AT may not be entirely appropriate. Ideally, such a study would be performed in the same
tissue sections—prior to embedding in LR White, tissue would be incubated in osmium
tetroxide. After immunofluorescence, lead citrate and uranyl acetate would be applied to the
tissue sections and scanning electron would be performed. This correlative electron microscopy
approach has been reported by Micheva and colleagues and may be a future direction for
validation of axonal injury measures in array tomography (2007).
Additional studies to be performed include further validating this method and developing
a protocol to apply stereological approach to the quantification of injury. For future validation,
not only should injured axons be measured in corpus callosum and external capsule of mice
subjected to varied levels of injury (Figure 4.10), but early and late timepoints should be
examined. Qualitatively, injury appears to result in reduced tubulin-positive axons. If this is truly
the result of axon injury and not an artifact of tissue preparation, then at an early timepoint <24
hours post-injury there should be more tubulin labeling than at a later timepoint >1 month post75

injury. Moreover, current efforts are aimed at applying stereological principles to the collection
and analysis of data from array tomography sections. In the future, 3-4 sections will be
collected along the anterior-posterior axis of each tissue block. From each section, 6-8 images
will be collected and 8-10 20 x 20 µm crop boxes from each image will examined so that a
minimum of 100-200 areas will be analyzed per mouse. All areas chosen for analysis will be
randomly selected using a grid. This approach will ensure a rigorous and unbiased
measurement of axonal injury throughout the volume of the injured corpus callosum and
external capsule.
Finally, future studies may also use this method to study other aspects of axonal injury in
both traumatic brain injury and other conditions. Labeling myelin basic protein, for example
could be used not only to determine if myelinated axons are preferentially injured in rcTBI, but
could also be used to investigate demyelinating disorders such as multiple sclerosis. Given the
ability to discriminate individual axons in large areas of tissue, it may be possible to detect early
signs of demyelination, and discern the effects of therapeutic or genetic manipulations on
disease progression. Also, given our ability to detect abnormally phosphorylated tau species
using multiple antibodies, a clear direction of this work is to apply this method to the detection of
tau alterations after traumatic brain injury. Previously, our lab has observed abnormal
accumulations of phosphorylated intra-axonal tau following moderate-severe injury (Tran, et al.
2011a; Tran, et al. 2011b). Considering the sensitivity of this technique, it will be interesting to
use arrays to measure intra-axonal tau in less severe injury models such as rcTBI. Last, an
exciting direction is to use this method to detect axon degeneration in tissue from human
patients where it may be possible to answer key questions about Chronic Traumatic
Encephalopathy or Alzheimer’s disease through quantitation of axon injury or loss and
correlative analysis with clinical measures.
To summarize, we have adapted array tomography to identify injured axons in tissue
from two different experimental TBI mouse models. Several markers are available for
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examining different aspects of axonal integrity including tubulin, neurofilaments, APP, myelin
basic protein, and phospho-tau species. Future studies will be aimed at using this method
quantitatively in both mouse models and in human tissue.
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CHAPTER 5

Acute Reduction of Microglia does not Alter Axonal Injury in a Mouse
Model of Repetitive Concussive Traumatic Brain Injury

5.1 INTRODUCTION
While 91% of athletes will recover from symptoms of concussion within a week, there is
increasing awareness of the long-term consequences of suffering one or more concussions,
particularly among retired professional football players and boxers. (Corsellis et al. 1973;
Mortimer 1985; Roberts et al. 1990; Geddes, et al. 1999; Guo, et al. 2000; Guskiewicz et al.
2003; McCrea et al. 2003; Guskiewicz, et al. 2005; McKee et al. 2009) While the origins of
these long-term effects are unknown, studies in post-mortem samples from human TBI and from
individuals known to have received multiple concussive injuries have consistently revealed the
presence of degenerating axons and inflammation months to years after the initial
insult.(Oppenheimer 1968; Adams, et al. 1982; Blumbergs, et al. 1989; Gultekin, et al. 1994;
Chen et al. 2009; Goldstein et al. 2012; Johnson et al. 2013a; McKee, et al. 2013a) These
processes have also been viewed in vivo using diffusion tensor imaging to visualize white
matter injury in concussed individuals and using PET ligands to the peripheral benzodiazepine
receptor to confirm the presence of microglia and macrophage in TBI patients.(Chappell, et al.
2006; Zhang, et al. 2006; Zhang et al. 2010; Cubon et al. 2011; Henry et al. 2011;
Ramlackhansingh et al. 2011; Bazarian, et al. 2012) Our group and others have developed
mouse models of mild repetitive concussion and have also observed the presence of injured
axons within white matter and the accumulation of glial cells.(Laurer et al. 2001; Uryu et al.
2002; Creeley et al. 2004; Creed et al. 2011; Shitaka et al. 2011; Mouzon, et al. 2012)
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Interestingly, in our repetitive closed-skull injury model we have observed that the accumulation
and activation of microglia within white matter regions precedes the degeneration of axons as
visualized by silver staining.(Shitaka et al. 2011) Altogether, these data have led us to
hypothesize that microglia and macrophage may contribute to secondary axon injury processes
following concussion.
To address this hypothesis we used a CD11b-TK transgenic mouse model to reduce the
numbers of microglia within the corpus callosum and external capsule. CD11b-TK mice express
a mutated form of thymidine kinase (TK) from herpes simplex virus under the CD11b
promoter.(Gowing, et al. 2006) When mice are treated with the nucleotide analog ganciclovir or
its more soluble prologue, valganciclovir, the drug is metabolized by cells expressing thymidine
kinase into a toxic product that leads to cell death. Valganciclovir will only become toxic to
CD11b+ cells expressing herpes simplex virus thymidine kinase and is not toxic to genetically
wild-type mice such as the CD11b-TK -/- littermate controls. Research from other groups has
shown that daily intraperitoneal (IP) injection of ganciclovir into these mice effectively depletes
circulating macrophages and prevents proliferation of microglia in the brain.(Heppner, et al.
2005; Gowing et al. 2006) Here we show that intracerebroventricular (ICV) delivery of different
doses of valganciclovir resulted in a dose-dependent reduction of microglial cells in mice
subjected to repetitive closed-skull injury. The effects of reducing the microglial population on
both acute and sub-acute axon degeneration after injury were assessed by silver staining. We
found that reducing the number of microglial/macrophage cells had little effect on the amount of
axon degeneration at either 7 days or 21 days post-injury.
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5.2 METHODS
Animals
CD11b-TK mice were acquired from Jean-Pierre Julien at Laval University (Quebec,
CA). CD11b-TK mice express herpes simplex virus thymidine kinase under the CD11b
promoter expressed in microglia and macrophage. Male CD11b-TK +/- founder mice were
crossed to C57bl/6j female mice (cat# 000664, JAX). The resulting offspring were genotyped
using previously published methods.(Gowing et al. 2006) Mice carrying the CD11b-TK
transgene were termed CD11b-TK+/- mice, and littermates not carrying the transgene were
termed CD11b-TK -/- mice and are genetically wildtype. All mice were housed under a 12 hour
light-dark cycle and given food and water ad libitum in accordance with the protocols of the
Animal Studies Committee at Washington University in Saint Louis.
Osmotic pumps
Alzet osmotic pumps (cat#1002, #2004) with flow rates of 0.25 µl/hour were used for
these experiments. A complete description of pump assembly can be found elsewhere.(DeVos,
et al. 2013) Briefly, cannula tubing (cat#312VT) and osmotic pump connector cannula
(cat#3280PM/SP, cut 2.5 mm below pedestal) were purchased from Plastics One. Pump
reservoirs were filled with either valganciclovir (cat#SML0191, Sigma) in 0.9% sterile saline
(NaCl) or with 0.9% NaCl. Osmotic pump flow tubes were stripped of their plastic caps and the
flow tubes were connected to one-inch lengths of cannula tubing. The other end of the cannula
tubing was attached to the osmotic pump connector cannula. The entire assembly was primed
by placing the reservoir in conical tubes containing 0.9% NaCl and tubes were stored at 37°C
for 36-48 hours prior to implantation. This longer priming step was deemed necessary because
cannula tubing was not filled with drug—preliminary experiments with 1.5% Evan’s blue solution
in saline showed that it takes ~36 hours for solution to travel from the reservoir of 14 day 0.25
µl/hour pumps to the end of the cannula under these conditions.
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Surgical procedures
Six to eight-week-old CD11b-TK +/- and wild-type littermate controls were used in all
experiments. Mice were randomly assigned to either NaCl or valganciclovir treatment groups.
For implantation of osmotic pumps, mice received inhaled isofluorane anesthesia and the head
was fixed in a stereotaxic frame. Temperature was regulated using a heat pad (Sun
microsystems II). A midline incision was made to expose the skull and a small (0.9mm) burr
hole was drilled contralateral to the rcTBI impact site at A/P -0.84 mm relative to bregma, ML
+1.5 mm relative to midline at bregma. Pumps were implanted subcutaneously and a drop of
cyanoacrylate glue was applied to the bottom of the plastic portion of the cannula. A cannula
guide was used to drive the metal osmotic pump connector cannula through the burr hole into
the lateral ventricle (D/V -2.5 mm) and to hold it firmly in place for 1-2 minutes while the glue
set. The top of the cannula was trimmed and the incision was sutured closed. Mice received
antibacterial ointment and were placed on a heat pad for recovery. Once animals were
ambulatory they were housed individually to prevent cagemates from tampering with pumps.
Seven days after pump implantation, pumps were removed, fitted with new cannulas,
placed in individual conical tubes containing 0.9% NaCl and 0.01% sodium azide (NaN3) and
stored at 37°C. Mice then received two repetitive closed skull injuries 24 hours apart as
described previously.(Shitaka et al. 2011) Briefly, a rubber tip was fitted on an electromagnetic
impact device which was used to impact the skull with the tip centered at A/P -1.8, M/L -1.5
bregma to a depth of -3.3 mm . Sham injured mice underwent the same surgical procedures
but did not receive impacts. Immediately following the second impact, pumps were rinsed in
filtered phosphate buffered saline (PBS) and re-implanted as described above to resume drug
delivery.

81

Histology
Mice were sacrificed by isofluorane overdose and decapitation either 7 days or 21 days
after the first repetitive closed-skull injury. All mice were perfused with 10 milliliters cold 0.03%
heparin in PBS. Brains were then removed and placed in 4% paraformaldehyde (PFA) for 2448 hours at 4°C and then in 30% sucrose in PBS for 24-48 hours at 4°C. Once equilibrated in
sucrose, they were frozen on dry ice and sliced into 50 µm sections on a freezing microtome.
Serial sections were collected in cryoprotectant (30% ethylene glycol, 15% sucrose, 0.03 M
phosphate buffer) and stored at 4°C until use.
For floating immunohistochemistry was performed on sections to visualize rabbit
polyclonal anti-Iba-1 (cat# 019-19741, Wako), chicken polyclonal anti-GFAP (cat#ab4674,
Abcam), rabbit polyclonal anti-β-APP (cat# 512700, Invitrogen), or mouse monoclonal RM014
(cat# 34-1000, Novex). For this, sections were washed 3 times for 5 minutes in TBS, incubated
in 0.03% hydrogen peroxide (H2O2) for 10 minutes, washed 3 times for in TBS, then blocked for
30 minutes in either 3% normal goat serum (NGS, cat#S-1000, Vector Labs) or 3% normal
donkey serum (NDS, cat#017-000-121, Jackson ImmunoResearch) in 0.25% Triton-X tris
buffered saline (TBS-X). Following blocking, primary antibodies were applied at a 1:1000
dilution in blocking solution and incubated overnight at 4°C with gentle shaking. The following
day, sections were again washed, incubated one hour at room temperature in either biotinylated
goat anti-rabbit IgG (cat#BA-1000, Vector Labs), biotinylated donkey anti-chicken IgG (cat#703065-155, Jackson ImmunoResearch) secondary antibodies were diluted 1:1000 in TBS-X,
washed again, then incubated in 1:400 ABC reagent (cat#PK-6100, Vector Labs) in TBS for
another hour. Finally, sections were washed and placed in 3-3’-diaminodebzidine
tetrahydrochloride (DAB; cat# D5905) for 5-6 minutes. After development in DAB the sections
were washed, placed on slides and allowed to air dry, and coverslipped with cytoseal (cat#
8312-4, Richard-Allan Scientific). For RM014 staining specifically, the following modifications to
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the above protocol were made 1) sections were blocked in 1:10 mouse serum, 2) the primary
antibody was incubated 1:2 with biotinylated goat anti-mouse Fab IgG (cat#115-007-003,
Jackson ImmunoResearch) for 20 minutes prior to application to the sections overnight and 3)
the secondary antibody was unnecessary, sections were immediately incubated in ABC on day
2.
Adjacent sets of floating sections were subjected to silver staining (cat#PK301,
NeuroSilver Kit II, FD Neurotech) following the manufacturer’s instructions with minor
modifications, as previously reported(Shitaka et al. 2011). Sections were incubated for 5 days
in paraformaldehyde prior to silver staining and were only incubated in solution C once for 2
minutes.
For cresyl violet staining, sections were rinsed in TBS twice for 5 minutes then mounted
on glass slides. Once air-dried, they were placed in cresyl violet solution (cat#PS102-1, FD
Neurotech) for 5 minutes then rinsed and coverslipped following manufacturer’s protocol.
For TUNEL-NeuN double-immunofluorescence (IF) 50 µm free floating sections washed
with TBS and incubated for 15 minutes with 0.02 mg/ml proteinase K in TBS. A positive control
for TUNEL labeling was generated by incubating a tissue section in 1 µg/ml DNAse I for 20
minutes at room temperature. Sections were then washed and blocked in 3% NGS in TBS-X
for 30 minutes and incubated overnight in 1:1000 rabbit polyclonal anti-NeuN (cat# ABN78,
Millipore) in blocking solution. The following day, sections were washed and incubated in
donkey anti-rabbit IgG Cy3 (cat# 711-165-152, Jackson ImmunoResearch) for 1 hour at room
temperature in the dark. Sections were then washed, mounted on glass slides, and allowed to
air dry for 1 hour. A hydrophobic barrier was drawn with a PAP pen around each section and
TUNEL staining was performed according to FragEL DNA Fragmentation Detection Kit (cat#
QIA39, Calbiochem) manufacturer’s instructions. Double IF images were captured using a
Zeiss Axiovert 200 laser scanning confocal microscope.
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Electron Microscopy
For electron microscopy, mice were perfused with 10 mls of PBS-Heparin followed
immediately by 10 mls of 1% PFA, 1% Glutaraldehyde in 0.1 M sodium cacodylate buffer.
Brains were fixed using the same solution for 1 hour, then sliced into 2-3 1 mm coronal slabs
per mouse. Slabs were fixed for 5 days before being incubated in 1% osmium tetroxide in
sodium cacodylate buffer overnight, followed by dehydration in ascending ethanol series, and
embedding Polybed 812 (cat# 08792, Polysciences, Inc.). Embedding media was cured for 24
hours in a dessicator and then in a 60°C oven for 4 8 hours. Semithin sections stained with
toluidine blue were prepared using glass knives to identify the region of corpus callosum and
external capsule ipsilateral to injury in each coronal slab. Tissue was then thin sectioned (7090 nm) on a Leica Ultracut E Microtome, stained with 4% uranyl acetate and Reynolds lead
citrate, and viewed on a Jeol 100C Electron Microscope. Three-five grids were prepared from
each block of tissue and two blocks (1 mm separation) were prepared from each animal. At
least one grid from each block was qualitatively assessed blinded to injury status or genotype
for evidence of axonal injury.

Stereological quantification and optical density measurements
For all histological analysis, the region of interest (ROI) was defined to include corpus
callosum and external capsule underlying the impact site. For each mouse, the ROI began with
the most anterior section containing hippocampal dentate gyrus and ended with the most
posterior section containing corpus callosum fibers that cross midline. This yielded 3-4 sections
for analysis per animal. The midline served as the medial boundary for the ROI, while the
lateral boundary was formed by drawing a horizontal line between the ventral hippocampus and
dorsal thalamus in each coronal section.
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Iba-1 stereological methods have been previously published.(Shitaka et al. 2011) In
brief, stereological quantification was performed blinded to genotype or drug treatment status
using StereoInvestigator’s (MicroBrightfield) optical fractionator technique. The ROI was traced
in each section and a 180 x 180 µm grid size and 80 x 80 µm counting frame was applied
determine the number of Iba-1 positive cells in the corpus callosum and external capsule. This
ensured Gunderson’s coefficient of error was <0.1.
For quantification of silver staining, 20x images were captured of all sections using the
Olympus Nanozoomer Whole Slide Imaging System as previously reported.(Shitaka et al. 2011)
From the Nanozoomer file, 1.25x .tiff images of sections containing the dentate gyrus of the
hippocampus and corpus callosum were exported and opened in Image J (NIH). Background
(gold color) was subtracted from each image using the color splitter and image calculator
functions so that only the grey-black silver deposits were visible. ROIs were traced as
described for Iba-1 analysis on 32-bit images and measurements were taken to acquire mean
grey values corresponding to the intensity of silver staining (0-255) within each ROI. Three
serial sections were averaged from each animal to produce a final silver staining value. Optical
density measurements were also taken blinded to genotype and drug treatment status.
For GFAP optical density measurements, 5x images of corpus callosum and external
capsule were captured using the Nanozoomer. The .tiff files were converted to 32-bit images in
Image J and positive signal on each image was selected using Li’s Minimum Cross Entropy
thresholding method, a function of the Auto Threshold plugin. ROIs were selected and drawn
as described for Iba-1 stereology and silver staining. The summarize function under analyze
particles was used to acquire the area fraction occupied by positive GFAP signal. These values
were averaged from three serial sections and the resulting value is reported.
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qPCR
Quantitative polymerase chain reaction (qPCR) was performed to determine gene
expression levels of interleukin 1β (IL1-β), interleukin 6 (IL6), inducible nitric oxide synthetase
(iNOS), chemokine (C-C motif) ligand 2 (CCL2), and tumor necrosis factor α (TNFα).
Immediately following sacrifice, brains were harvested and a 2 mm coronal slice was collected.
The anterior-most portion of the slice corresponded to the anterior end of the hippocampus.
The section was further dissected by making a cut parallel to the interface between
hippocampus and thalamus, and only the dorsal section (approximately 30 mg) was reserved
for qPCR. The sections were frozen on crushed dry ice and stored at -80°C. Tissue was later
lysed in Qiazol (Qiagen) and disrupted using a rotor-stator homogenizer following the
manufacturer’s protocol for homogenization of fatty tissues. The final RNA pellet was
resuspended in 100 µl RNAse-free water and further purified using an RNeasy Kit (Qiagen).
DNAse was applied to the column to remove genomic DNA contamination. For cDNA
preparation, 1 µg RNA was used in each RNA-cDNA reaction (High Capacity RNA-to-cDNA Kit,
Applied Biosystems). For each qPCR reaction, 1 µl of undiluted cDNA was added to 15 µl
Syber Green PCR Master Mix (Applied Biosystems), 13 ul ddH20, and 1 µl 10 mM forward and
reverse primers (Table 1). Samples were loaded on a MicroAmp Fast Optical 96-Well Reaction
Plate (Applied Biosystems) and qPCR was carried out on a 7500 fast real-time PCR system
(Applied Biosystems). The following conditions were used: 95°C for 10 min followed by 40
cycles of 95°C for 15 sec and 60°C for 1 min.
∆∆Ct values were calculated by normalizing the expression of each gene to the
geometric mean of three reference genes (hprt, pgk1, gapdh). Subsequently, these target gene
values were normalized to the arithmetic mean values in untreated naïve mice (n=4).
Exponential transform was performed to achieve fold change measures of each gene where 1 is
equal to naïve mice.
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Table 5.1 Primer sequences used for qPCR.
Encoded
Protein
PGK1

Accession
Number
NM_008828.2

GAPDH

NM_008084

HPRT1

NM_013556.2

IL1-β

NM_008361.3

IL6

NM_031168.1

iNOS

NM_010927

CCL2

NM_011333

TNFα

NM_013693

Direction

5’-3’

Forward
Reverse
Forward
Reverse
Forward
Reverse
Forward
Reverse
Forward
Reverse
Forward
Reverse
Forward
Reverse
Forward
Reverse

ctccgctttcatgtagaggaag
gacatctcctagtttggacagtg
catggacttccgtgttccta
gcggcacgtcagatcca
cctaagatgagcgcaagttgaa
ccacaggactagaacacctgctaa
acggaccccaaaagatgaag
ttctccacagccacaatgag
caaagccagagtccttcagag
gtccttagccactccttctg
tggtccgcaagagagtgct
cctcattggccagctgctt
aggtgtcccaaagaagctgta
atgtctggacccattccttct
cttctgtctactgaacttaggg
caggcttgtcactcgaattttg

Amplicon
Size (bp)
117
55
86
139
150
108
85
134

Data analysis and statistics
All data were analyzed and graphed using GraphPad (Prism). Shapiro-Wilks normality
tests were applied to determine if data were normally distributed. Rank transformations were
applied to data that failed normality tests. In experiments with two test groups, student’s t-tests
were used. Two-way ANOVAs were used in all other cases except analysis of sham mice with
or without cannulation, in which case a one-way ANOVA was performed. Post-hoc
comparisons between CD11b-TK +/- and -/- mice were pre-specified. Statistical significance
was defined as p<0.05 for t-tests and ANOVAs and p<0.0167 for post-hoc tests.
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5.3 RESULTS
5.3.1 Acute effects of microglia on axonal injury in mice receiving low-dose valganciclovir (7d)
Previous reports indicate that daily systemic administration of valganciclovir causes
hematopoetic toxicity and is fatal to CD11b-TK +/- mice within 10 days (Gowing et al. 2006). On
the other hand, delivery of the drug directly into the brain can result in microglial reduction
without the toxicity seen after IP injection (Simard, et al. 2006). Continuous administration is
required as macrophages will rapidly repopulate areas of microglial depletion in the absence of
the drug (Varvel, et al. 2012). As our goal was to test the effects of microglial depletion on
axonal injury at timepoints between one week and one month following injury, we chose to
administer valganciclovir continuously by intracerebroventricular (ICV) osmotic pump. However,
since there is deformation of the brain during the brain injury, we chose to remove the pumps
during the 24 hours required for the rcTBI procedure to prevent additional injury of the brain
caused by the cannula (Figure 5.1). For initial experiments a valganciclovir concentration of 1
mg/ml was chosen as it has been shown by other groups to be effective in reducing microglial
cells(Simard et al. 2006; Grathwohl, et al. 2009).

Figure 5.1 Experimental design. CD11b-TK +/- or -/- controls were treated with either
valganciclovir or saline by intracerebroventricular (ICV) osmotic pump for 7 days prior to injury.
Pumps were then removed and a closed-skull or sham injury was performed (day 0). Twentyfour hours later a second injury was delivered. Pumps were immediately reimplanted and drug
or saline treatment was resumed for another 7 days (acute time point) or 21 days (sub-acute
time point).
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Within the ipsilateral corpus callosum and external capsule, treated CD11b-TK +/- mice
(n=13) had a 35% reduction in the number of microglial cells compared to littermate controls
(n=11) at the 7 day time point after injury (one-tailed student’s t-test, p=0.008; Figure 5.2 A-D,
G). To control for the effects of injection of vehicle alone, the experiment was repeated with
additional groups that received 0.9% NaCl (Figure 5.3 A; CD11b+/- valganciclovir n=9, NaCl
n=7; CD11b-TK -/- valganciclovir n=6, NaCl n=8). An effect of genotype (p=0.0359) and
treatment (p=0.0226) was seen, but not an effect of genotype x treatment (two-way ANOVA,
p=0.1039; Figure 5.3 A). Planned comparisons revealed a significant difference between
valganciclovir treated CD11b-TK +/- versus littermate controls (p=0.0110; Figure 5.3 A), no
difference between the two genotypes receiving vehicle alone (p=0.7096), and a significant
difference between CD11b-TK +/- valganciclovir treated and vehicle treated mice (p=0.0057).
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Figure 5.2 Treatment of CD11b-TK +/- mice with ICV low-dose valganciclovir (1 mg/ml)
reduces microglia but does not affect silver staining 7 days following rcTBI. Iba-1 staining
in treated CD11b-TK -/- (A, C) and +/- (B, D) mice. (C, D) Higher magnification views of Iba-1
staining in corpus callosum ipsilateral to injury (region boxed in A, outlined with red dashed line).
Silver staining in valganciclovir treated CD11b-TK -/- (E) and +/- (F) mice. (G) Stereological
quantification of Iba-1-positive microglia in CD11b-TK +/- mice shows a ~35% reduction
compared to controls (one-tailed student’s t-test, **p<0.01. Dashed line indicates sham levels).
(H) Silver staining in white matter was unchanged (A.U.= arbitrary units). (Error bars represent
standard error of the mean).

We then used silver staining to assess injured axons in mice with reduced numbers of
microglia. No difference in the intensity or distribution of silver staining was observed in either
the first (two-tailed student’s t-test, p=0.8292; Figure 5.2 E-F, H) or the second groups of mice
(two-way ANOVA, genotype p=0.8478, treatment p= 0.6147, genotype x treatment p = 0.2769;
Figure 5.3 B). We have previously shown that silver staining is a sensitive method to assess
axonal injury in this repetitive concussive injury model.(Shitaka et al. 2011)

Figure 5.3 Low-dose valganciclovir (1 mg/ml) but not saline reduces microglia and has
no effect on silver staining 7 days after injury in an independent cohort of mice. (A) Iba-1
staining (B) silver staining in corpus callosum and external capsule of CD11b+/- and -/- mice
receiving either drug or vehicle treatment (A.U.= arbitrary units, *p<0.05, **p<0.01, n.s. = not
significant). (Error bars represent standard error of the mean).
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5.3.2 Dose-response of microglia to valganciclovir treatment in CD11b-TK mice
We reasoned that a modest reduction in the number of microglial cells within the white
matter may not be adequate to produce an effect on the extent of axonal injury. We therefore
next tested higher doses of valganciclovir in mice that received rcTBI to increase the amount of
microglial depletion. Using the same injection paradigm as before, mice were treated with either
2 (n=3), 5 (n=3), 10 (n=5), or 50 mg/ml (n=8) of valganciclovir (Figures 5.4 and 5.5). At 5-7
days post-injury (14 days after initial pump implantation), CD11b-TK +/- mice in the 50 mg/ml
group became lethargic, had difficulty walking, and a 50% mortality rate. Wild-type littermate
controls treated identically with 50 mg/ml valganciclovir (n=6) appeared normal. Upon
histological examination, intraparenchymal hemmorhages and extensive tissue loss within the
hippocampus and thalamus were apparent in the treated CD11b-TK +/- mice (Figure 5.4 A-B).
Mice that received intermediate doses of 2, 5, or 10 mg/ml appeared normal physically and
histologically (Figure 5.5 A-F). Therefore, 10 mg/ml was selected for future experiments as this
dose consistently resulted in microglial depletion in the hemisphere opposite injection near the
corpus callosum and external capsule (Figure 5.5 E, F).

Figure 5.4 High-dose (50 mg/ml) valganciclovir treatment was toxic in CD11b-TK +/- mice
7 days post-injury. (A) An Iba-1 stained section near the cannula site (dashed line) shows
depletion of microglia but also numerous microhemorrhages (arrows). (B) Cresyl violet staining
in a section posterior to valganciclovir injection shows extensive tissue loss in the hippocampus
and thalamus (dashed oval).
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Figure 5.5 Valganciclovir dose-response in CD11b-TK mice 7 days post-injury. Iba-1
stained whole sections (A, C, E) and higher-magnification images (box A) corresponding to the
region of interest assessed for iba-1 depletion by stereology (outlined with red dashed line, B, D,
F). CD11b-TK +/- mice treated with 2 (A, B), 5 (C, D), or 10 (E, F) mg/ml valganciclovir.
Microglial depletion is most prominent ipsilateral to cannulation and drug delivery (right).
Arrowheads indicate region of microglial reduction in cortex of hemisphere opposite drug
infusion.
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5.3.3 Acute effects of intermediate dose valganciclovir on axonal injury (7d)
A separate cohort of mice was treated with 10 mg/ml valganciclovir and examined 7
days after rcTBI (Figure 5.6 A-F). At 7 days post-injury, the number of Iba-1 positive cells
within the corpus callosum and external capsule ipsilateral to injury was 56% reduced in CD11bTK +/- (n=7) compared to littermate controls (n=7; one-tailed student’s t-test, p=0.0004; Figure
5.6 A, B, E). Again, no significant reduction in the amount of silver staining was observed (twotailed student’s t-test, p=0.6045; Figure 5.6 C, D, F).
To determine if other aspects of axonal injury were affected by microglial depletion, other
injury markers were assayed in adjacent tissue sections for APP and neurofilament compaction
(Figure 5.7 A-D). APP is a marker of fast axonal transport that accumulates in axonal swellings
within hours of axonal injury (Gentleman et al. 1993; Sherriff et al. 1994). The neurofilament
antibody RM014 has been used to detect neurofilament compaction, an indicator of cytoskeletal
disruption in degenerating axons (Stone et al. 2001). Both of these markers were present near
the site of cannulation in all mice (Figure 5.7 A, B), but were sparse and detected infrequently
in more posterior regions ipsilateral to injury (Figure 5.7 C, D). Most commonly they occurred in
white matter tracts overlying the lateral ventricle, which may be a particularly vulnerable region
in this model. However, no qualitative difference was observed between genotypes, indicating
that these markers of axonal injury were not affected by microglial depletion..
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Figure 5.6 Acute intermediate dose valganciclovir (10 mg/ml) reduces Iba-1 but not silver
staining in CD11b-TK mice 7 days after rcTBI. Iba-1 staining in corpus callosum (outlined
with red dashed line) in treated CD11b-TK -/- (A) and +/- (B) mice. Silver staining in adjacent
sections from CD11b-TK -/- (C) and +/- (D) mice. (E) Iba-1 was reduced by 56% in CD11b-TK
+/- mice compared to controls (one-tailed student’s t-test, ***p<0.001). (F) No change in silver
staining was observed (A.U.= arbitrary units, n.s. = not significant). (Error bars represent
standard error of the mean).
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Figure 5.7 Amyloid precursor protein (APP) and neurofilament (RM014) labeling in an
injured CD11b-TK -/- mouse treated with 10 mg/ml valganciclovir and sacrificed 7 days
post-injury. APP and labeling was prominent at the site of cannulation (dashed line) -0.5 mm
relative to bregma (A, B). Only sparse axonal swellings were detectable in the contralateral
hemisphere (injured side) in the corpus callosum and external capsule corresponding to the
region of interest assessed for axonal injury in these experiments (C, D). Insets show higher
magnification of labeling in boxed regions in A and C.

To further confirm that no subtle alterations in axonal injury severity are occurring after
microglial depletion, qualitative electron microscopy was carried out in a sham littermate control
treated with 10 mg/ml valganciclovir (n=1; Figure 5.8 A-C), injured littermate controls treated
with 10 mg/ml valganciclovir (n=2; Figure 5.9 A-C), or CD11b-TK +/- mice treated with 10
mg/ml valganciclovir (n=2; Figure 5.10 A-C). The frequency and characteristics of axonal
injury 7 days post-injury were assessed. Corpus callosum and external capsule ipsilateral to
injury directly beneath the impact site were analyzed. In sham injury with 10 mg/ml
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valganciclovir treatment, most axons displayed a normal appearance, with intact myelin sheaths
and regularly spaced microtubules and neurofilaments (Figure 5.8 A, B). However, occasional
swollen axons displayed organelle accumulation consistent with injury and were likely artifacts
of cannulation (Figure 5.8 C).In contrast, the effects of repetitive concussive TBI were more
dramatic. In both CD11b-TK +/- and -/- mice injured and treated with valganciclovir axonal injury
was a prominent feature within the corpus callosum and external capsule. Notably, small
myelinated axons displayed abnormal morphology with organelle accumulation, cytoskeletal
disorganization, and axolemma collapse (Figures 5.9-10). These features are all consistent
with Wallerian degeneration. Overall, injury levels were approximately the same as reported
previously in this model.(Shitaka et al. 2011) No overt differences were detected between
CD11b-TK +/- and -/- mice. These observations were confirmed by a second, blinded observer
(Dr. Krikor Dikranian). These observations further confirm that axonal injury was not affected by
microglial depletion.

97

Figure 5.8 Normal axonal ultrastructure in a cannulated sham CD11b-TK -/- mouse
treated with10 mg/ml valganciclovir and sacrificed 7 days post sham injury. (A, B) Axons
in the corpus callosum near the cingulum display organized cytoskeletal elements and intact
myelin sheaths. (C) In a region containing axons cut parallel to the predominant direction of the
corpus callosum. an asterisk indicates a swollen unmyelinated axon with abnormal organelle
accumulation. Note nearby axons appear relatively intact, however.
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Figure 5.9 Ultrastructural abnormalities in an injured CD11b-TK -/- littermate control
mouse treated with 10 mg/ml valganciclovir and sacrificed 7 days post-injury. (A)
Arrowheads indicate regions of end stage axonal degeneration in corpus callosum near the
cingulum where the axolemma has completely collapse. Asterisks denote examples of
myelinated and unmyelinated axons with organelle accumulation. (B) A myelinated axon
undergoing Wallerian degeneration (asterisk). (C) A region of relatively healthy appearing
axons in corpus callosum.
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Figure 5.10 Ultrastructural abnormalities in an injured CD11b-TK +/- mouse treated with
10 mg/ml valganciclovir and sacrificed 7 days post-injury. (A) Arrowheads indicate regions
of end stage axonal degeneration in corpus callosum near the cingulum where the axolemma
has completely collapsed. The asterisk denotes a swollen axon undergoing late stage
degeneration and arrows indicate examples of axons containing densely packed intracellular
aggregates. (B) Arrow indicates an axon cut parallel to the predominant direction of the corpus
callosum with abnormal accumulation of electron-dense intra-axoplasmic material in a region of
relatively normal axons (asterisk). (C) Asterisk indicates an axon undergoing axolemma
collapse.
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5.3.4 Sub-acute effects of low and intermediate dose valganciclovir on axonal injury (21d)
Next we sought to determine if longer-term reduction of microglia alters the evolution of
axonal injury over time (Figures 5.11 and 5.12). We have previously reported that silver
staining abnormalities persist out past 49 days (Shitaka et al. 2011). We chose to analyze mice
at 21 days post-injury because this would allow us to treat mice with valganciclovir for one
month (28 days) and would not require that the osmotic pumps be replaced—a procedure
requiring additional surgery. In the low dose experiment, mice were treated with 1 mg/ml
valganciclovir (CD11b+/- n=7, -/- n=6) or 0.9% NaCl (CD11b+/- n=5, -/- n=5; Figure 5.11).
Overall, analysis of microglial activation by two-way ANOVA revealed no effect of genotype
(p=0.3307) or treatment (p=0.9511), but a significant genotype x treatment interaction
(p=0.0118). Additionally, a significant reduction of microglial cells in the corpus callosum and
external capsule of about 35% in valganciclovir treated CD11b-TK +/- mice compared to
valganciclovir treated littermate controls was observed (p =0.0099, Figure 5.11 A, B, E). No
difference was seen in NaCl treated mice between genotypes (p=0.2488). The difference
between microglial cells in valganciclovir treated vs NaCl treated CD11b-TK +/- mice was not
quite statistically significant (p=0.0547; Figure 5.11 E). Again, as in the acute experiments, no
difference was seen across groups in the amount of silver staining (Figure 5.11 C, D, F).
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Figure 5.11 Treatment with low dose valganciclovir (1 mg/ml) but not saline reduces Iba-1
but not silver staining in corpus callosum 21 days after rcTBI. Iba-1 staining in
valganciclovir treated CD11b-TK -/- (A) and +/- (B) mice. Silver staining in valganciclovir treated
CD11b-TK -/- (C) and +/- (D) mice. (E) Iba-1 was reduced by 35% in CD11b-TK +/- mice
compared to -/- controls (one-tailed student’s t-test, **p<0.01). (F) No change in silver staining
was observed (A.U.= arbitrary units, n.s. = not significant). (Error bars represent standard error
of the mean).
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An additional group of either CD11b-TK +/- mice (n=6) or littermate controls (n=8)
received the intermediate 10 mg/ml valganciclovir and was sacrificed 21 days post-injury (Figure
12A-D). Though the mice did not display an overtly abnormal behavioral phenotype, histological
examination revealed tissue loss similar to that seen with the 50 mg/ml dose. Thus, the
duration of drug administration at intermediate doses can also produce a toxic effect in CD11bTK mice. Due to the clear toxicity of the drug, Iba-1 and silver staining were not quantified in
these animals.

Figure 5.12 Sub-acute treatment with intermediate dose valganciclovir is toxic in injured
CD11b-TK mice. 28 days total treatment resulted in tissue loss as visualized by cresyl violet in
the hippocampus and thalamus of injured CD11b-TK +/- (A) but not -/- (B) mice. Iba-1 staining
shows the extent of microglial depletion in CD11b-TK+/- (C) and not in a CD11b-TK -/- (D)
littermate control mouse subjected to rcTBI.
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5.3.5 TUNEL-labeling in mice treated with intermediate dose valganciclovir
Given the apparent toxicity of intermediate dose valganciclovir (10 mg/ml) in CD11b-TK
mice treated for 21 days post-injury, we performed TUNEL-labeling to determine if this
intermediate dose induces apoptosis in neurons 7 days post-injury (Figure 5.13 A-B). Sections
from CD11b-TK +/- (n=7) and -/- (n=7) mice treated with valganciclovir were double-labeled for
TUNEL and NeuN, a neuron-specific marker. The hippocampal CA3 ipsilateral to cannulation
and drug infusion was the focus of these investigations as this is a region significantly affected
by toxicity by 21 days post-injury. However, no apoptotic neurons were detected here (or in any
other area) at 7 days post-injury. This would indicate that neurodegeneration begins later than
day 7 post-injury. As a positive control to assess the sensitivity of our TUNEL labeling, we
treated adjacent sections with DNAase-I to induce DNA nicks. This caused prominent TUNEL
staining (Figure 5.13C). Thus, the lack of TUNEL staining in the valganciclovir treated mice is
likely to accurately indicate a lack of apoptotic injury.

5.3.6 Effect of cannulation on silver staining
To determine whether cannulation produces axonal injury that may be masking the
potentially beneficial effects of microglial depletion, we next determined the level of silver
staining in CD11b-TK -/- sham mice alone (n=5; Figure 5.14 A, C), CD11b-TK -/- sham mice
receiving ICV saline by osmotic pump (n=5; Figure 5.14 B, D), and CD11b-TK +/- sham mice
receiving intermediate dose valganciclovir by osmotic pump (n=5; Figure 5.14 E, G ). No
difference was observed between groups (one-way ANOVA, p=0.7006; Figure 5.14 F). This
result indicated that contralateral cerebroventricular cannulation did not produce detectible
axonal injury in the ipsilateral corpus callosum region of interest.
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Figure 5.13 Double immunofluorescence for TUNEL (green) or NeuN (red) in CA3 does
not indicate neuronal apoptosis in injured mice treated with 10 mg/ml valganciclovir and
sacrificed 7 days post-injury. TUNEL labeling was not observed in NeuN+ cells in the
hippocampal CA3 of CD11b -/- (A) or +/- (B) mice. A positive control for TUNEL labeling was
generated by incubating adjacent sections in DNAse I to induce double-stranded DNA breaks
(C). All images were acquired using the same settings on a laser scanning confocal
microscope.
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Figure 5.14 Cannulation does not contribute to silver staining in the region of interest
assessed for axonal injury. Silver staining was performed in sections from CD11b-TK -/- mice
that underwent the sham procedure alone (A, C) or the sham procedure plus cannulation and
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treatment with saline (NaCl, B, D). Silver staining was also performed in sections from CD11bTK +/- mice that underwent the sham procedure plus cannulation and treatment with 10 mg/ml
valganciclovir (E, G). All mice were sacrificed 7 days post sham injury. (F) No difference in
silver staining was observed between groups. (A.U. arbitrary units).

5.3.7 Astrocyte response in valganciclovir treated mice
To confirm that only microglial numbers are being altered in this model, we analyzed the
numbers of GFAP-positive astrocytes in regions of microglial depletion. We did not see any
change in the numbers of GFAP-positive astrocytes in the corpus callosum and external
capsule of mice treated with 1 mg/ml valganciclovir or 0.9% NaCl for 14 days (two-way ANOVA,
genotype p= 0.6028, treatment p=0.9339, genotype x treatment p=0.7852; Figure 5.15 A-C).
Similarly, there were no apparent changes in astrocytes due to valganciclovir treatment within
grey matter areas.

5.3.8 Inflammatory response in valganciclovir treated mice
To determine how the inflammatory response was affected by microglial depletion in the
setting of traumatic brain injury, RNA was purified from injured and uninjured mice acutely
treated (14 days total) with 10 mg/ml valganciclovir and the amount of TNFα, IL-1β, IL6, iNOS,
and CCL2 mRNA was determined by qPCR (Figure 5.16 A-E). Injury alone appeared to result
in at most modest (<5-fold) increases in expression of these genes (rcTBI vs. sham CD11b -/mice; Figure 5.16 A-E). Surprisingly, treatment of CD11b +/- mice with valganciclovir produced
substantially greater changes in inflammatory gene expression in both injured and uninjured
mice. Qualitatively, only TNFα appear to be increased to a greater extent in in CD11b-TK +/injured vs. uninjured mice (Figure 5.16 E). Thus, while valganciclovir treatment of CD11b-TK
mice reduces microglial cells, it may also drastically alter the inflammatory environment in this
model.
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Figure 5.15 Astrocytes 7 days after rcTBI in mice treated with 1 mg/ml valganciclovir or
NaCl. GFAP staining in treated CD11b-TK -/- (A) and +/- (B) mice. (C) No differences in GFAP
optical density was observed between groups.
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Figure 5.16 qPCR measurement of inflammatory gene expression. Relative expression of
(A) Ccl2, (B) Il1β, (C) Il6, (D) iNOS, and (E) Tnfα in each mouse was normalized first to the
geometric mean of 3 reference genes (Hprt, Pgk1, Gapdh) and then to arithmetic mean of the
uninjured, naïve mice (n=4; dashed line).
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5.4 DISCUSSION
In summary, we found that a reduction of the microglial population within the corpus
callosum and external capsule by 35-56% neither increases nor decreases the extent of silver
staining abnormalities. The most likely interpretation is that while microglia migrate to and
proliferate around areas of axonal injury, overall they remain neutral in regards to the early
processes of axon degeneration.

We also provide further evidence that the CD11b-TK mouse

line is a powerful tool for manipulating the microglial and macrophage response, but show that
the dose of valganciclovir must be carefully determined to prevent unintended, non-specific
toxicity and altered inflammatory gene expression in the central nervous system.
These studies are important because to our knowledge, there are no previous reports
directly addressing the relationship between microglia and axon injury following in vivo mild
repetitive traumatic brain injury. The contribution of microglia to other aspects of injury has
been explored in more severe, brain injury models. Other researchers have used minocycline
to reduce microglial activation, where it was reported to reduce brain lesion volume, caspase 1
activation, and cerebral edema after closed-skull TBI in mouse(Sanchez Mejia, et al. 2001; Bye,
et al. 2007; Homsi, et al. 2009; Homsi, et al. 2010). However, only one of these studies
measured axonal injury (by APP immunohistochemistry), and similar to results reported here, no
difference was observed between minocycline treated and vehicle treated mice despite a 59%
reduction in microglial activation(Homsi et al. 2010). In another study in rats, administration of
anti-inflammatory drug ibuprofen for four months after TBI worsened performance on Morris
Water Maze, a test of spatial learning and memory, compared to vehicle-treated rats.(Browne,
et al. 2006) . The effect of treatment on microglial activation and axonal injury was not
assessed.
In the present study, we reduced the number of microglia present in white matter tracts
and assayed axonal injury using multiple injury markers and electron microscopy. This study is
limited, however, in that we cannot rule out the possibility of functional consequences to the
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depletion of microglia, independent of histological abnormalities.(Reeves et al. 2005) In
addition, this study is also limited in that it is possible that the maximum reduction of the
microglial population by 56% was not enough to produce an effect on white matter integrity.
The remaining microglia may be able to compensate for the loss by ramping up production of
secreted factors. Indeed, qPCR analysis revealed considerably more TNF-α, IL1-β, IL6, iNOS,
and CCL2 mRNA following valganciclovir treatment. These factors may directly impair axons or
modulate the inflammatory response in a complex fashion.(Ashki, et al. 2006; Davies, et al.
2006; Morganti-Kossmann, et al. 2007) Given this increase, it is remarkable that more severe
silver staining abnormalities were not detected. This could indicate that axons are resilient to
many aspects of the inflammatory response. An important line of future investigation will involve
elucidating the full time course of the changes in cytokine expression in response to injury and
in response to valganciclovir administration. Whether microglia and macrophages were directly
responsible for the increases in secreted cytokine mRNA or whether the reduction in microglia
induced expression by other cell types was not examined. Another alternative explanation for
our results is that there could be both beneficial and harmful subtypes of microglia that are
approximately evenly reduced by the experimental manipulations resulting in a net neutral effect
on white matter.(Kigerl, et al. 2009) A final alternative explanation could be that any beneficial
effects of microglial reduction were offset by the upregulation of inflammatory gene expression
in response to the valganciclovir treatment.
This study was also limited in that it did not assess the specific contribution of the
resident microglial population versus peripheral macrophages to injury. In this injury model,
however, we have not observed IgG accumulation or a large population of CD45+hi, CD11b+
cells (unpublished observations) that would be indicative of infiltration of peripheral
macrophages. Thus, while peripheral macrophages may be present in rcTBI brains, most Iba-1
positive cells are likely resident microglia.
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While these data indicate microglial cells are likely neutral overall in regards to axon
injury following repetitive concussion in the acute and subacute phase, it remains mysterious
why microglial cells migrate to the corpus callosum and external capsule and remain activated
long-term. Activated microglia and macrophage have been observed in corpus callosum and
other brain regions in human TBI patients several months or years after injury, indicating this is
not a mouse-specific phenomenon.(Oppenheimer 1968; Ramlackhansingh et al. 2011; Johnson
et al. 2013a) As these are phagocytic cells, it may be that ongoing axon degeneration results in
debris that stimulates the microglial response. Microglial clearance of this debris may be neither
beneficial nor harmful in the relatively short time scale assessed in these experiments, but could
play an important role in long-term chronic sequelae of injury including axonal sprouting and
regeneration not assessed here.(Hosmane et al. 2012) Indeed, microglia are important sources
of brain derived neurotrophic factor (BDNF) and other neurotrophins that stimulate axonal
sprouting and may be central to recovery from injury.(Batchelor et al. 2002; Venkatesan, et al.
2010) Future work may help to address these questions and provide deeper insight into the
biological function of microglia after injury. Other studies may also address the effect of
microglial reduction in more severe brain injury, where the role of microglial cells may be
distinct.(Jiang, et al. 2012; Loane, et al. 2014)
A technical note regarding the toxicity of valganciclovir in CD11b-TK mice warrants
discussion. It was surprising that valganciclovir administration at intermediate and high doses
produced such widespread tissue loss in CD11b-TK mice. Work from Grathwohl and
colleagues has previously reported that administration of 50 mg/ml valganciclovir can produce
microhemorrhages following one month of treatment.(Grathwohl et al. 2009) Their group was
using an independently derived line of CD11b-TK mice. Mice used in our experiments were
generated in the lab of Jean-Pierre Julien and the thymidine kinase gene contains a mutation
resulting in increased sensitivity to drug treatment. This increased sensitivity could explain why
10 mg/ml was sufficient to produce toxicity after 28 days and 50 mg/ml increased mortality by
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50% after 14 days of treatment in our experiments. The underlying cause of this toxicity is
unknown; the profoundly upregulated cytokine mRNA levels detected by qPCR may indicate
either a cause or an effect of the toxicity. Repeating experiments in other transgenic mouse
models of microglial depletion/manipulation (Table A2 in the Appendix) may aid in determining
whether this phenomenon is specific to the CD11b-TK model or is a consequence of microglial
depletion after rcTBI. Use of some of these other mouse lines, such as the MAFIA or
CX3CR1CreER line may also be more amenable to the study of the long-term effects of microglia
in traumatic brain injury (Burnett, et al. 2004; Parkhurst, et al. 2013).
Altogether, the finding that microglia appear to be neutral in regards to injury is an
important consideration for the design of future therapeutics. This could indicate that drugs
specifically targeting axonal injury may be more useful following concussive-type injuries than
those targeting microglial cells. Alternatively, methods to more completely prevent the
activation and/or proliferation of microglial cells without toxicity should be sought for further
studies.
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CHAPTER 6
Use of Pharmacological Compounds to Manipulate the Microglial
Response after Repetitive Concussive Injury

6.1 INTRODUCTION
The pathological processes that lead to long-term consequences of multiple concussions
are unclear. Primary mechanical damage to axons during concussion is likely to contribute to
dysfunction. Secondary damage has been hypothesized to be induced or exacerbated by
inflammation. The main inflammatory cells in the brain are microglia, a type of macrophage.
Between 4 and 7 days after repetitive concussive traumatic brain injury (rcTBI) in mouse,
microglial cells increase more than three-fold in the corpus callosum and external capsule and
persist for at least 7 weeks post-injury (Shitaka et al. 2011). Concomitantly, axonal injury in
these regions is evident by silver staining and electron microscopy 7 days post-injury and
similarly persists for at least 7 weeks (Shitaka et al. 2011). This brings to question what the role
of microglia is in relation to axonal injury after concussion. Here, we sought to use a
pharmacological approach to reduce the microglial response in white matter following injury and
determine if this cell type contributes to axonal injury.
Numerous compounds have been used in experimental models to manipulate microglia,
and many of these have been summarized in Table A3 of the appendix. Based on previous
literature, 5 different compounds were chosen to test: mac-1-saporin, minocycline, (RS)-2chloro-5-hydroxyphenylglycine (CHPG), brilliant blue g (BBG), and microRNA-124 (miRNA124). Mac-1-saporin is an antibody to CD11b (Mac-1), a receptor found on all microglia and
macrophage, bound to the toxin saporin. Binding of the antibody to CD11b-positive cells is
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reported to lead to internalization of the toxin and subsequent microglial/macrophage cell death
(Dommergues, et al. 2003; Garcia-Alloza, et al. 2007; Zhao, et al. 2007). Minocycline, an
antibiotic used for acne and other bacterial infections, has been reported to be an inhibitor of
microglial activation in several disease and injury models including traumatic brain injury.
Minocycline has also been used in clinical trials for amyotrophic lateral sclerosis (ALS),
Huntington’s disease, and multiple sclerosis (Kim, et al. 2009). The mechanism of
minocycline’s action on microglial cells is not well characterized, though it has been reported
that it interferes with p38 kinase, interrupting signaling cascades that stimulate microglial
proliferation and cytokine synthesis, and that it inhibits caspase-1, caspase-3, inducible nitric
oxide synthetase and matrix metalloproteinases (Greenwald, et al. 1992; Amin, et al. 1996;
Chen, et al. 2000; Hua, et al. 2005). CHPG, on the other hand, is an antagonist of metabotropic
glutamate receptor 5 (mGluR5) which is constitutively expressed on microglia and macrophage.
Stimulation of mGluR5 with CHPG has been reported to prevent proliferation, nitric oxide and
TNFα synthesis in microglial cultures activated with bacterial lipopolysaccharide (Byrnes, et al.
2009a). These effects were also observed when CHPG was delivered intrathecally following
spinal cord injury (Byrnes, et al. 2009b). The fourth compound tested, brilliant blue g, is a
selective antagonist of the ATP-gated ionotropic purinoreceptor P2X7R. P2X7R is primarily
expressed on microglia and macrophage and ATP activation results in proliferation and
increased synthesis of TNFα, IL1β, and reactive oxygen species via the p38/NFκB pathway
(North 2002; Monif, et al. 2009). Like CHPG, BBG was administered intrathecally in rats after
spinal cord injury and microglial number was reported to reduce the number of OX42-positive
microglia in spinal cord by nearly 50% at 14 days post-injury. Finally, miRNA-124 was chosen
because it has been observed to be dramatically reduced in activated microglia (Ponomarev, et
al. 2011). Increasing miRNA-124 expression suppressed inflammation-induced injury in a
model of multiple sclerosis.
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In the present studies, each compound or its vehicle was administered to mice that
received repetitive closed skull injuries (rcTBI) and the number of iba-1-positive cells was
quantified by stereology at acute timepoints. Silver staining was used to assess axonal injury.
Altogether, it was determined that despite experimental evidence suggesting these
pharmacological approaches effect microglia in other experimental models, none reduced iba-1positive cells in white matter tracts after rcTBI. This may reflect the complex nature of the
inflammatory response to axonal injury and provide insight into the basic biology of microglia.

6.2 METHODS
Animals
In all experiments, 6-8 week old C57/bl6j mice were purchased from Jackson and used for
experiments. All mice were housed under a 12-hour light/dark cycle and given food and water
ad libitum in accordance with the Animal Studies Committee at Washington University in Saint
Louis.

Surgical procedures
Repetitive closed-skull injury was performed as previously described using an
electromagnetic impactor fitted with a rubber tip. Two impacts were delivered 24 hours apart.
In mice receiving continuous intracerebroventricular (ICV) drug infusion, osmotic pumps were
implanted immediately following the second injury. For this, a 0.9 mm burr hole was drilled at
A/P -0.84 mm relative to bregma M/L +1.5 mm right of midline at bregma. A plastic cannula
was secured with cyanoacrylate glue to the skull at a depth of 2.5 mm. This cannula was
attached to an osmotic pump via vinyl tubing. The 7 day osmotic pumps used in this experiment
had flow rates of 0.5 µl/hour (Model 1007D, DuRect) and were implanted subcutaneously.
Bolus injections of mac-1-saporin or vehicle were delivered by bolus injection using a 10 µl
syringe (701RN, Hamilton) fitted with a 1.5” 33 ga needle (Hamilton). A nanoinjector pump was
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used to deliver drug at a rate of 0.3 µl/min. After injection, the needle was left in place for 5
minutes before being slowly retracted. The burr hole was then sealed with dental wax. After
the end of surgical procedures, the incision was sutured closed, antibiotic ointment was applied,
and mice were allowed to recover from anesthesia on a heat pad before returning to their
cages. All mice with osmotic pumps were singly housed. All drug treatments were
administered in the lateral ventricle ipsilateral to injury to minimize the contribution of
cannulation or bolus injection to axonal injury in the region of interest within the opposite
hemisphere.

Drug preparation and administration
Mac-1-saporin (Mac-1-SAP) was purchased from Advanced Targeting Systems (cat# IT06). The stock solution of 1.7 µg/µl in phosphate buffered saline (PBS) was injected ICV
without dilution so that mice received either 2, 4, or 9 µg of Mac-1-SAP or an equal volume of
0.01 M PBS.
For minocycline experiments, minocycline hydrochloride (cat# M9511, Sigma-Aldrich)
was dissolved in 0.01 M PBS and heated at 37°C for 30 minutes to dissolve. To determine the
dose-response of microglia to minocycline, intraperitoneal (IP) injections of 5, 20, 45 or 90
mg/kg or PBS were performed immediately following injury and again daily until mice sacrifice.
In a follow-up experiment, mice were pretreated with 45 mg/kg minocycline 1 hour prior to injury
and received IP injections every 12 hours until sacrifice.
For CHPG experiments, (RS)-2-Chloro-5-hydroxyphenylglycine sodium salt (cat# 3695,
Tocris Bioscience) was dissolved in 1% dimethylsulfoxide, 0.9% saline and 5, 10, or 20 mM
CHPG or vehicle was loaded into osmotic pumps. For BBG (cat# B-0770, Sigma-Aldrich) was
dissolved in 0.9% saline and osmotic pumps were filled with 1, 10, or 100 µM or saline. In
miRNA-124 experiments, hsa-miR-124 was purchased from Ambion (cat# 4464066, mirVana).
5 nmol of miRNA124 was dissolved in 0.9% saline, encapsulated in 14% Lipofectamine 2000,
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and loaded into osmotic pumps. Pumps were primed overnight at 37°C in saline prior to
implantation after injury.
Histology
All mice were sacrificed 4 or 7 days after the first closed-skull injury by deep isofluorane
anesthesia followed by cardiac perfusion with ice cold 0.03% heparin in PBS. Brains were
removed and immersion fixed for 24 hours in 4% paraformaldehyde, then equilibrated in 30%
sucrose in PBS for 24 hours prior to sectioning on a freezing microtome. Eight sets of 50 µm
thick sections, corresponding to a sampling interval of 400 µm throughout the brain were
collected as previously described. Rabbit anti-iba-1 (Wako) was used to label microglia and
macrophage following immunohistochemical methods described in Chapter 5 and in Shitaka et
al (2001). Likewise, silver staining was performed on adjacent sections as described previously.

Quantitative analysis of histology
The number of iba-1-positive cells in the corpus callosum were quantified by stereology.
3-4 sections per mouse were analyzed, beginning with the anterior-most section containing
corpus callosum overlying the hippocampus. The optical fractionator method was used, with a
grid size of 180 x 180 and a counting frame of 80 x 80. All iba-1-positive cell bodies in corpus
callosum and external capsule ipsilateral to injury were counted.
For optical density quatification of silver staining, digital images of all slides were
captured using the Nanozoomer whole slide imaging system (Hamamatsu). Background was
reduced from each image and the amount of silver deposits in the region of interest (ROI) was
determined by mean grey value for each of 3-4 sections per mouse. ROI parameters for silver
staining were the same as for iba-1 stereology. Detailed methods can be found in Chapter 5.
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6.3 RESULTS
6.3.1 Mac-1-saporin reduces iba-1 and silver staining but displays off-target toxicity
Administration of 9 µg of Mac-1-SAP was initially tested as this was a similar dose to one
used by Garcia-Allonza and colleagues to eliminate microglia in an Alzheimer’s disease mouse
model. Mice received either Mac-1-SAP (n=7) or vehicle (n=8) and were sacrificed 4 days postinjury (Figure 6.1 A-F). At this timepoint, the number of iba-1-positive cells in the corpus
callosum and external capsule was reduced by 49% (one-tailed student’s t test p=0.0145,
Figure 6.1 A, B, E). Silver staining in this region was reduced by 68% (two-tailed student’s t test
p=0.0003, Figure 6.1 C, D, F). Cresyl violet staining was performed in these mice and in
additional mice that were treated with Mac-1-SAP and sacrificed 7 days post-injury (n=3, Figure
6.2 A-C). This revealed cell loss Mac-1-SAP treated mice in the hippocampal CA3 that was
apparent at 4 days (Figure 6.2 B) and severe at 7 days (Figure 6.2 C). Thus, it appears that
treatment with Mac-1-SAP results in non-specific neurotoxicity. Such widespread cell loss likely
contributes to the reduction in silver staining seen in mice 4 days post-injury.
In a second experiment, mice were treated with lower doses (2 and 4 µg; n=3 per
group), sacrificed at 7 days, and iba-1 immunohistochemistry was performed (Figure 6.3 A, B).
At both of these lower doses, tissue integrity was evidently compromised. Additionally, these
doses did not appear to reduce iba-1-positive cells in the injured hemisphere.
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Figure 6.1 Mac-1-SAP treatment reduced iba-1 and silver staining at 4 days post-injury.
Mice were treated with vehicle (A, C) or 9 µg (B, D). (E) Quantification of iba-1 by stereology
revealed a significant decrease in the number of cells present in the corpus callosum and
external capsule. (F) Silver stainined was also reduced as measured by optical density.
(*p<0.05, ***p<0.001, a.u. = arbitrary units, error bars represent standard error of the mean)
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Figure 6.2 Mac-1-Saporin treatment leads to neuron loss in the hippocampal CA3. Cresyl
violet stained sections from mice sacrificed 4 days post-injury treated with vehicle (A) appear
normal while mice treated with 9 µg Mac-1-SAP (B) have reduced cellularity in the CA3. Cell
loss in the CA3 (arrowheads denote region of greatest loss) and blood brain barrier compromise
was marked at 7 days (C).
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Figure 6.3 Lower doses of Mac-1-SAP were also toxic at 7 days post-injury. Iba-1 labeling
was reduced in the injected hemisphere (right side) of mice treated with both 2 µg (A) and 4 µg
(B). Tissue was evidently compromised and diaminobenzidine labeled intraparenchymal
hemorrhages (arrows).
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6.3.2 Minocycline treatment does not reduce the number of microglia or the amount of silver
staining in the corpus callosum and external capsule after injury
A separate cohort of mice received 5, 20, 45, or 90 mg/kg minocycline (n=5 per group)
daily by intraperitoneal injection immediately following the second injury. Compared to mice
injected with vehicle alone, treatment with minocycline had no effect on the number of iba-1positive cells at any dose 7 days post-injury (one way ANOVA p=0.0540, Figure 6.4 A-F). Two
individuals from each group were randomly selected for silver staining which also indicated no
difference between groups (Figure 6.5 A-F).
In rodents, the half-life of minocycline has been reported to be as short as 3 hours and
reaches peak concentrations in the brain at 1 hour post-IP injection. A second group of mice
(n=3 per group, Figure 6.6 A-C) was subject to a more aggressive treatment paradigm and
received IP injections of 45 mg/kg minocycline 1 hour before the first injury and again every 12
hours for 7 days. Quantification of iba-1 in corpus callosum and external capsule did not reveal
any differences between minocycline and vehicle treated mice (one-tailed student’s t test
p=0.2902, Figure 6.6 C).

123

Figure 6.4 Minocycline administration does not alter iba-1 labeling at any dose. Mice that
received vehicle (A), 5 (B), 20 (C), 45 (D), or 90 (E) mg/kg all had similar numbers of iba-1positive cells in the corpus callosum and external capsule. No differences were observed by
stereological analysis. (Dashed red line indicates corpus callosum, error bars are ± SEM)
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Figure 6.5 Silver staining does not reveal any differences in mice treated with
minocycline. Mice that received vehicle (A), 5 (B), 20 (C), 45 (D), or 90 (E) mg/kg all had
similar silver staining in the corpus callosum and external capsule. No differences were
observed by optical density measurement. (Dashed red line indicates corpus callosum, error
bars are ± SEM)
125

Figure 6.6 Treatment with minocycline every 12 hours beginning 1 hour prior to injury did
not alter the number of iba-1-positive cells. Mice treated with vehicle (A) or 45 mg/kg
minocycline (B) had similar numbers of iba-1-positive cells in the corpus callosum and external
capsule 7 days post-injury. No difference was evident by iba-1 sterology (C). (Dashed red line
indicates corpus callosum, error bars are ± SEM).

6.3.3 CHPG does not suppress microglial numbers or silver stain abnormalities in white matter.
Another cohort of mice was then treated with 5 (n=3), 10 (n=4), or 20 (n=3) mM CHPG
by ICV osmotic pump implanted immediately following the second injury. Mice were sacrificed 7
days after injury and the number of iba-1 positive cells in the corpus callosum and external
capsule were quantified by stereology (Figure 6.7 A-E). Though a slight trend was observed,
compared to controls treated it did not reach significance (one way ANOVA p=0.3546, Figure
6.7 E). Similarly, silver staining was not altered by treatment (one way ANOVA p=0.5389,
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Figure 6.8 A-E). Another cohort of mice (n=3 per group, data not shown) was treated with 50
mM CHPG or vehicle and did not have reduced iba-1 (one-tailed student’s t test, p=0.4351) or
silver staining (two-tailed student’s t test p=0.9563) 7 days post-injury.
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Figure 6.7 The number of iba-1-positive microglia is unchanged by CHPG in injured mice.
Mice treated with vehicle (A) or 5 (B), 10 (C), or 20 (D) mM CHPG had similar numbers of iba-1positive cells in the corpus callosum and external capsule 7 days post-injury. No difference was
evident by iba-1 sterology (E). (Dashed red line indicates corpus callosum, error bars are ±
SEM).
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Figure 6.8 Silver staining was not altered by CHPG at any dose. Mice treated with vehicle
(A) or 5 (B), 10 (C), or 20 (D) mM CHPG had similar levels of silver staining in the corpus
callosum and external capsule 7 days post-injury. No difference was evident by optical density
measurement (E). (Dashed red line indicates corpus callosum, error bars are ± SEM).
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6.3.4 Brilliant Blue G does not reduce microglia or alter silver staining after injury.
In the fourth set of experiments, vehicle (n=4), 1 (n=4), 10 (n=4), or 100 (n=5) µM
brilliant blue g (BBG) was administered continuously by osmotic pump immediately following
injury. The number of microglial cells in the corpus callosum and external capsule did not
appear to be altered 7 days after injury (Figure 6.9 A-D). One-way ANOVA of iba-1 stereology
did not reveal any change (p=0.7493 Figure 6.9 E). Silver staining was similarly unaffected by
BBG treatment (p=0.2960, Figure 6.10 A-E).
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Figure 6.9 Brilliant Blue G does not reduce iba-1-positive cells in injured mice. Mice
treated with vehicle (A) or 1 (B), 10 (C), or 100 (D) µM CHPG had similar numbers of iba-1positive cells in the corpus callosum and external capsule 7 days post-injury. No difference was
evident by iba-1 sterology (E). (Dashed red line indicates corpus callosum, error bars are ±
SEM).
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Figure 6.10 Silver staining was not altered by Brilliant Blue G. Mice treated with vehicle (A)
or 1 (B), 10 (C), or 100 (D) µM CHPG had similar silver staining in the corpus callosum and
external capsule 7 days post-injury. No difference was evident by optical density measurement
(E). (Dashed red line indicates corpus callosum, error bars are ± SEM).
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6.3.5 Exogenous miRNA-124 does not suppress microglia numbers in white matter.
miRNA-124 liposomes were prepared and injected ICV by osmotic pump immediately
following injury. Each mouse received a total of 11 µg miRNA or vehicle and was sacrificed 7
days post-injury (Figure 6.11 A-C). Though there was a trend towards reduced microglia in the
corpus callosum and external capsule, it did not reach significance at 7 days post-injury (onetailed student’s t test p=0.1035). Silver staining was not assessed. To determine whether
lipofectamine containing vehicle alone effects the number of iba-1-positive cells, the experiment
was repeated in injured mice treated with vehicle containing lipofectamine (n=5) or saline only
(n=4, Figure 6.11 D). This revealed no significant difference in the number of iba-1-positive
cells between groups (two-tailed student’s t test, p=0.1045).
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Figure 6.11 miR-124 does not reduce iba-1-positive cells in injured mice. Mice treated with
vehicle (A) or miR-124 (B had similar numbers of iba-1-positive cells in the corpus callosum and
external capsule 7 days post-injury (C). No change in the number of iba-1 cells was seen due
to lipofectamine containing vehicle alone (D). (Dashed red line indicates corpus callosum, error
bars are ± SEM).

6.4 DISCUSSION
Here, we tested several different compounds in the repetitive closed-skull injury (rcTBI)
model to determine their ability to reduce the microglial response in the corpus callosum and
external capsule. Treatment with a range of doses of minocycline, CHPG, or BBG failed to
reduce the number of iba-1-positive cells at 7 days post-injury. Further, silver staining was not
altered by these drugs, indicating that unmeasured changes to the inflammatory response
outside of microglial number alone do not significantly alter silver stain-positive axonal injury.
Similarly miR-124 treatment did not produce a significant alteration to microglial number. Mac1-SAP, on the other hand, did reduce the number of microglia, but also exhibited non-specific
neurotoxicity which has not been previously reported.
There are both strengths and limitations in these studies that should be addressed. One
strength is the use of stereological approach to quantify microglia and macrophage in white
matter. Previous reports using these compounds rely on optical density or non-stereological
counts of microglia and macrophage per area of tissue. Stereology has several advantages
over these methods including 1) removing user bias in selection of counting fields 2) allowing
specific identification and quantification cell bodies and 3) avoiding confounds due to variability
in staining intensity from sample to sample. A second strength is the use of a range of
compounds that should affect inflammation through a variety of mechanisms. Thus, the failure
to alter iba-1-positive cells in white matter is unlikely to be due to the targeting of a single
pathway. Likewise different routes of drug administration—intracerebral bolus injection,
continuous infusion, or intraperitoneal injection—and different experimental timelines were tried
to increase the likelihood of altering the microglial response.
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However, there are also several limitations. First, the sample sizes in these experiments
were small. As such, we cannot rule out the possibility that small effects on the number of
microglial cells were missed. However, as the overall goal of the experiment was to find a
compound that would reduce the microglial response by 50% or more, it is reasonable to
conclude that none of the compounds produced a large effect. Similarly, because iba-1
stereology was the only method used to measure the microglial response, the overall effect of
these drugs on other aspects of inflammation, including cytokine production, phagocytosis, and
expression of other markers was not determined. Consequentially, compounds may have
modified other more subtle characteristics of the microglial response. If these changes did
occur, however, they appear to be neutral in regards to axonal injury in this model as assessed
by silver staining. Of note, no morphological changes were observed in microglia in mice
treated with minocycline, CHPG, BBG, or miR-124.
Last, only the effect of these drugs on microglia within the white matter was measured.
Assessing changes in microglial cells within grey matter is outside the current scope of this
study, but may be an important consideration in the future. In particular, if drugs did reduce
microglial number in grey matter regions, it would be interesting to determine why white matter
was not affected. Differences in the diffusion of different compounds into white matter versus
grey matter have been observed (Lieberman, et al. 1995; Prabhu, et al. 1998). Here, the ability
of these drugs to penetrate throughout brain regions was not determined and may be one
possible explanation of the results. In experiments where drug was delivered by ICV injection,
preliminary experiments from our lab using fluorescent dextrans and Evan’s blue (data not
shown), and from others indicate that compounds can diffuse from ventricles into the
neighboring parenchyma and white matter tracts (Konsman, et al. 2000). Additionally,
differences between gene and protein expression differences in microglia in white matter versus
grey matter have not been characterized though the morphology of cells in different regions is
distinct. It is possible that white matter residing cells have inherently different sensitivity to drug
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treatment. Pursuing these topics may increase our understanding of the basic biology of
microglial cells.
Overall, the inability to reproduce previously published results and alter the microglial
response in this model has several implications. Foremost, it points to the need for more
rigorous statistical methods and experimental testing, including the use of multiple cohorts of
mice to verify that the effects of drug treatment have not arisen by chance. Unbiased
quantification methods, such as stereology, should be used in all cases. Second, others have
reported that microglial phenotype is heavily determined by the sequence of signaling received
by microglia (Perry, et al. 2014). In these studies, treatments that occurred following injury
(CHPG, BBG, miR-124) may have failed because microglial cell activation was already
“primed”. Thus, it may be necessary to pretreat microglia to prevent their activation post-injury.
This warrants further investigation as it has clear implications for clinical therapeutic design.
Finally, how biomechanical forces alone may alter the microglial phenotype is unknown, though
in one in vitro study it was determined that mechanical stretch induces chloride channel currents
that can alter microglial morphology (Eder, et al. 1998). Future studies may address this effect
in the context of traumatic brain injury.
Altogether, the development of new compounds that can minimize microglial activation
in a variety of disease and injury settings is needed. Better understanding of microglial biology
will be required and importantly, understanding how concussive injury activates the
inflammatory response will be central to these future investigations.
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CHAPTER 7
Human Apolipoprotein E4 Worsens Acute Axonal Pathology but not
Amyloid-beta Immunoreactivity following Traumatic Brain Injury in
3xTG-AD Mice

7.1 INTRODUCTION
Clinical studies have revealed an increased risk of poor outcome following TBI in
patients with one or more APOE4 alleles (Mayeux, et al. 1995; Jordan, et al. 1997; Teasdale, et
al. 1997; Friedman, et al. 1999; Kutner, et al. 2000; Teasdale, et al. 2005). The largest of these
studies demonstrated that the effect of APOE genotype was significant only in younger patients
(Teasdale et al. 2005). ApoE is a major lipid carrier in the brain (Mahley 1988), and there have
been multiple mechanisms proposed to account for the effect in TBI and other brain injuries
(Verghese, et al. 2011). One hypothesis is that APOE genotype affects secondary
neurodegenerative processes following TBI. This hypothesis is based on the ideas that 1)
APOE4 is a major genetic risk factor for Alzheimer’s disease (Corder, et al. 1993; Strittmatter, et
al. 1993), 2) TBI is a major environmental risk factor for dementia of the Alzheimer’s type
(Plassman et al. 2000; Jellinger 2004), and 3) ApoE has been shown to interact with two key
Alzheimer’s disease proteins, Aβ and tau (Bu 2009). Supporting this hypothesis, human mutant
APP transgenic mice with the APOE4 allele show greater accumulation of Aβ chronically
following TBI (Hartman, et al. 2002). However, APOE genotype can affect acute outcomes
following TBI (Nicoll, et al. 1995; Friedman et al. 1999; Liaquat, et al. 2002; Smith, et al. 2006)
and Aβ and tau pathologies can accumulate rapidly following TBI (Roberts, et al. 1991; Roberts,
et al. 1994; Smith, et al. 2003a; Ikonomovic, et al. 2004; Uryu, et al. 2007). While ApoE isoform
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specific differences have been studied in mouse models of TBI, few studies have addressed
interactions between ApoE genotype on acute Aβ deposition following injury (Sabo, et al. 2000;
Laskowitz, et al. 2010; Mannix, et al. 2011). Furthermore, the interaction between APOE
genotype and tau pathology has not been investigated to our knowledge.
Recently, we showed that 3xTG-AD mice carrying three human familial AD mutations
(PS1M146V, tauP301L, and APPSWE) develop both acute amyloid beta and tau pathology following
injury (Tran et al. 2011a; Tran et al. 2011b). We hypothesized that in the presence of the
APOE4 allele, both acute Aβ and tau pathology after injury would be exacerbated. To test this,
we crossed 3xTG-AD transgenic mice to mice that have the human APOE2, -E3, and -E4
alleles knocked-in (Sullivan, et al. 1997a; Oddo, et al. 2003). The results of stereological
analysis suggest that APOE genotype may not affect acute Aβ or tau pathology after injury.
Instead, APOE genotype appears to result in increased numbers of injured axons as evident by
APP-positive white matter varicosities. Considering this surprising finding, we confirmed that
the APOE4 genotype worsens post-traumatic axonal injury in non-3xTG-AD mice expressing
human APOE alleles. Altogether, this indicates a primary role for ApoE in acute post-traumatic
axonal injury that appears to be unrelated to its interactions with Aβ or tau.

7.2 METHODS
Animals
Female 3xTG-AD mice were initially acquired from Frank LaFerla and were bred to male
ApoE targeted replacement mice (ApoE-TR) of all 3 isoforms (Fig. 1). Heterozygotes from two
separate crosses were mated to avoid sibling matings. The resulting litters were screened for
quadruple homozygotes by PCR using previously published methods (Sullivan et al. 1997a;
Oddo et al. 2003). Since the tau and APP alleles co-segregate in the 3xTG-AD line whereas
the PS1 and ApoE alleles segregate independently, 1 out of 64 mice born were expected to be
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homozygous for all four transgenes (Figure 7.1). We produced at least 4 of these quadruple
homozygotes for each genotype to establish the 3xTG-ApoE2, -ApoE3, and –ApoE4 lines.
Non-sibling quadruple homozygotes were then mated to yield the experimental mice used for
the current study. All mice were housed on a 12 hour light-dark cycle with food and water ad
libitum in accordance with the Animal Studies Committee at Washington University in St. Louis.

Figure 7.1 Generation of 3xTG-ApoE mice. For each of the three human ApoE alleles, two
independent lines of 3xTg-ApoE heterozygotes were initially produced from 3xTg-AD and ApoE
targeted replacement homozygotes (ApoE-TR: ApoEX+/+ represents either ApoE2, ApoE3, or
ApoE4 homozygote mice). Non-sibling heterozygotes were mated, and 1 out of 64 mice was
expected to be homozygous at all 4 alleles. Quadruple homozygotes were selected by PCR
and used as the initial founders of each 3xTG-ApoE line.

Controlled Cortical Impact (CCI)
Two to three-month-old male and female ApoE-TR mice (Sullivan, et al. 1997b) and six
to eight-month-old male and female 3xTG-ApoE mice were used in the following experiments.
17 3xTG-ApoE2, 13 3xTG-ApoE3, and 11 3xTG-ApoE4 mice were randomly assigned to either
injury or sham groups and a 2 mm controlled cortical impact was performed as described
previously (Brody et al. 2007). Additional injury groups included 5 ApoE2, 5 ApoE3, and 5
ApoE4 mice. Briefly, mice were anesthetized with isofluorane and placed in a stereotaxic
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frame. A rectal probe and heat pad was used to maintain constant body temperature. A midline
incision was made to expose the skull and a 5 mm circular burr was used to perform a
craniotomy over the left somatosensory cortex. A 3 mm steel impactor tip was then aligned to
+1.5 mm (A/P), relative to lambda and -1.2 mm (M/L) relative to midline. An electromagnetic
device delivered an impact to the brain to a depth of 2 mm (5 m/s, 100 ms dwell time). The
contusion was irrigated with saline and plastic skull cap was affixed with suture glue to cover the
craniotomy. Sham mice underwent the same surgical procedure but did not receive an impact.
Mice were allowed to recover on a heat pad before being returned to their cage.

Immunohistochemistry.
24 hours following CCI, mice were deeply anesthetized with isofluorane and perfused
with 0.3% heparin in phosphate buffered saline (PBS). Brains were dissected and fixed in 4%
paraformaldehyde (PFA) for 24 hours and then equilibrated in 30% sucrose PBS. All sections
were sliced 50 µm thick on a freezing microtome. Every 6th section (300 microns), was then
stained for APP (Zymed, 0.25 µg/ml), Aβ40 (Invitrogen, 0.5 µg/ml), Aβ42 (Invitrogen, 0.5 µg/ml),
total human tau (Thermo Scientific, 1 µg/ml), or pS199 tau (Invitrogen, 1:1000). Three minutes
of 70% formic acid retrieval was used to unmask epitopes for Aβ40 and Aβ42 and ten minutes
of formic acid for pS199 tau. All other staining methods were followed as published (Tran et al.
2011a).

Stereology
Stereology was performed blinded to genotype using a Nikon Eclipse 80i microscope
with a motorized stage. Both the optical fractionator and space balls probes in
StereoInvestigator version 8.2 were used for analysis. Regions of interest were drawn under a
4x objective as previously described for fimbria, pericontusional corpus callosum and external
capsule, and hippocampal CA1 beginning with most anterior section containing both blades of
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the dentate gyrus and including the following 3-4 sections per mouse (Mac Donald et al. 2007b;
Tran et al. 2011a). All counts were performed using a 60x lens. For APP and tau, a grid size of
200 x 200 and counting frame of 40 x 40 were used. For Aβ40 and Aβ42, a 200 x 200 grid and
80 x 80 counting frame were used. For pS199 tau, a 200 x 200 grid and 50 x 50 counting frame
were used. For the space balls hemispherical probe, a radius of 17 µm was used. In all cases,
a guard depth of 5 µm and a probe height of 17 µm was used. These parameters ensured that
the Gunderson’s coefficient of error was below 0.15 in all cases.

Statistics
Scatter plots were constructed and Shapiro-Wilk tests were performed to assess for
evidence of non-normally distributed data. All data was normally distributed except for APP
stereology in ApoE4 mice (p-value <0.05). In this case, a Kruskal-Wallis one-way ANOVA was
performed followed by Mann-Whitney U tests. All other data was analyzed by two-way
ANOVAs (injury and genotype) with Bonferroni’s corrections for multiple comparisons.
Significance was determined as p<0.05 for two-way ANOVAs and p<0.01 for all post-hoc
comparisons. Planned comparisons included injured versus sham mice for each genotype and
comparisons of injured 3xTG-ApoE4 mice to injured 3xTG-ApoE2 and -ApoE3 mice. This
resulted in a total of 5 planned comparisons for each analysis.

7.3 RESULTS
7.3.1 APOE genotype alters the extent of axonal injury
Amyloid precursor protein (APP) is a marker of fast axonal transport failure that
accumulates in injured axons at the location of disrupted microtubules (Koo, et al. 1990;
Gentleman et al. 1993; Tang-Schomer et al. 2012). For these experiments, APP was used to
assay axonal injury (Figure 7.2, A, D, E, J, K, P, Q, V, Fig. 3, A-C). 3xTG-ApoE sham
operated mice did not have axons containing APP, in contrast with CCI injured mice at 24
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hours. At 24 hours post-injury, APP positive axons were visible in corpus callosum, external
capsule, and ipsilateral fimbria (Fig. 2 A). Stereological quantification of APP+ axons in fimbria
revealed main effects of genotype (p=0.001), injury (p<0.000001), and a genotype x injury
interaction (Figure 7.2 V; p=0.0006). Planned post-hoc comparisons indicated that injured
3xTG-ApoE4 mice have significantly greater numbers of APP-positive axonal varicosities in
ipsilateral fimbria compared to injured 3xTG-ApoE2 (p=0.00016), and injured 3xTG-ApoE3 mice
(p=0.00002).
Considering this unexpected result, this experiment was repeated using ApoE-TR mice.
Stereological quantification of APP+ axons (Figure 7.3 A-C) in pericontusional corpus callosum
and external capsule revealed an effect of genotype (p =0.005) where ApoE4 mice have more
APP-positive axons that ApoE3 (p=0.008) mice but not ApoE2 mice (p=0.056). Thus, we
confirmed the finding that ApoE4 expressing mice have greater APP-positive axonal injury in
two separate mouse models.

7.3.2 Injury results in increased intra-axonal amyloid-β in all genotypes
Since APP is cleaved by secretases to produce amyloid beta in injured axons (Smith et
al. 2003a; Tran et al. 2011a), adjacent sets of serial sections were stained for Aβ40 (Figure 7.2,
B, F, G, L, M, R, S, W) and Aβ42 (Figure 7.2, C, H, I, N, O, T, U, X). Similar to APP, Aβ40 and
Aβ42 were seen in injured mice but not in shams. Analysis of Aβ40 revealed a main effect of
injury (Figure 7.2, W; p<0.000001), but no effect of genotype (p=0.26) or genotype x injury
interaction (p=.094). There appeared to be a trend towards increased Aβ40 in 3xTg-ApoE4
mice, but this did not reach statistical significance. Similarly, analysis of Aβ42 also revealed a
main effect of injury (Figure 7.2, X; p=0.000001), but no effect of genotype (p=0.4192) or
genotype x injury interaction (p=0.5639).
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Figure 7.2 APP and Aβ immunohistochemistry in 3xTG-ApoE mice. Representative
coronal slice images of APP (A), Aβ40 (B), and Aβ42(C) staining from an injured 3xTG-ApoE2
mouse. Higher magnification images of fimbria (box) from injured (D, F, H) and sham (E, G, I)
3xTG-ApoE2 stained for APP (D, E), Aβ40 (F, G), and Aβ42 (H, I). 3xTG-ApoE3 injured (J, L,
N) and sham (K, M, O) stained for APP (J,K), Aβ40 (L, M), and Aβ42 (N,O). 3xTG-ApoE4
injured (P, R, T) and sham (Q, S, U) stained for APP (P, Q), Aβ40 (R, S), and Aβ42 (T, U).
Stereological quantification of axonal varicosities containing APP (V), Aβ40 (W), or Aβ42 (X).
Error bars represent standard error. (**p<0.01, ***p<0.001).
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Figure 7.3 APP immunohistochemistry in ApoE-TR mice. Representative images from
pericontusional corpus callosum (C.C) and external capsule (E.C.) of ApoE3 (A) and ApoE4 (B)
mice stained for APP. Stereological quantification of axonal varicosities containing APP (C).
Error bars represent standard error. (**p<0.01).

7.3.3 APOE genotype alters somatodendritic and intra-axonal tau in 3xTG-AD mice
The microtubule stabilizing protein tau also accumulates in the hippocampal CA1 and in
the fimbria following injury in 3xTG-AD mice (Tran et al. 2011a). To image accumulation of tau
in 3xTG-ApoE mice, an antibody that recognizes total human tau was used to label a 4th set of
serial sections (Figure 7.4, A-B, D-G, J-M, P-S). Similar to 3xTg-AD mice, tau was observed
in the somatodendritic compartment of hippocampal CA1 neurons. Length of these tau-positive
neurites was measured using stereological methods. This revealed a main effect of genotype
(Figure 7.4, V; p=0.006), but no effect of injury (p=0.52) or genotype x injury (p=0.96). 3xTGApoE4 sham and injured mice had significantly more accumulated tau than 3xTG-ApoE3 mice
(p=0.009), but the difference with 3xTG-ApoE2 mice was not statistically significant after
correction for multiple comparisons (p=0.013).
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Total human tau was also assessed in the fimbria (Figure 7.4, B, F, G, L, M, R, S, W).
Stereological analysis again revealed a main effect of genotype (Fig. 4, W; p=0.000003), but no
effect of injury (p=0.94) or genotype x injury (p=0.31). Notably, both injured and sham 3xTGApoE4 mice had greater tau accumulation in axons than either 3xTG-ApoE2 (p=0.0002) or
3xTG-ApoE3 mice (p=0.000005).
To test whether APOE genotype effects phosphorylation of tau, a 5th set of adjacent
sections was also stained for phospho-serine199 (pS199) tau (Figure 7.4, C, H, I, N, O, T, U).
Similar to total human tau, pS199 tau was observed in the hippocampal CA1 and fimbria at 24
hours post injury (Figure 7.4, C). Main effects of genotype (Figure 7.4, X; p=0.0069) and injury
(p=0.0092) were observed, but no there was no genotype x injury interaction effect (p=0.3097).
Only the difference between injured and sham levels of pS199 tau in 3xTG-ApoE3 mice
reached statistical significance, however. No difference was seen between injured and sham
3xTG-ApoE2 and 3xTG-ApoE4 mice or between injured 3xTG-ApoE4 mice and the other
genotypes.
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Figure 7.4 Tau immunohistochemistry. Representative coronal slice images of total human
tau (A, B) and pS199 tau (C) staining from a 3xTG-ApoE2 mouse. Higher magnification images
of boxed region from injured (D, F, H) and sham (E, G, I) 3xTG-ApoE2 stained for total tau in
CA1 (D, E), or total tau in fimbria (F, G), and pS199 tau (H, I) in fimbria. 3xTG-ApoE3 injured (J,
L, N) and sham (K, M, O) stained for total tau in CA1 (J, K), or in fimbria (L, M), and pS199 tau
in fimbria (N,O). 3xTG-ApoE4 injured (P, R, T) and sham (Q, S, U) stained for total tau in CA1
(P, Q), or in fimbria (R, S), and pS199 tau in fimbria (T, U). Stereological quantification of the
length of neurites containing tau in the CA1 (V), and axonal varicosities in fimbria containing
either tau (W) or pS199 tau (X). Error bars represent standard error. (n.s.= not significant,
**p<0.01, ***p<0.001).
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7.4 DISCUSSION
To summarize, 24 hours following moderate controlled cortical impact, 3xTG-AD mice
with the APOE4 allele have greater APP accumulation within axons than mice with the APOE2
or APOE3 alleles. ApoE4 targeted replacement mice without other human transgenes were
also found to have greater APP accumulation compared to ApoE3 targeted replacement mice.
This suggests that modulation of the severity of axonal injury may be a primary contributor to
the APOE genotype effect on outcomes following TBI. However, contrary to our hypothesis
regarding neurodegenerative pathology following TBI, APOE genotype had no effect on the
intra-axonal accumulation of Aβ40 or Aβ42; there was a similar increase in Aβ in all 3
genotypes. Also surprisingly, there was no interaction between injury and APOE genotype on
tau pathology; indeed, more total human tau was found in the somatodendritic and axonal
compartments of 3xTG-ApoE4 mice regardless of injury status.
Altogether, the 3xTG-ApoE mouse TBI model has similarities with and differences from
the 3xTG-AD TBI model reported previously (Tran et al. 2011a; Tran et al. 2011b). Both
recapitulate key aspects of acute human TBI pathology, displaying axonal varicosities
containing APP, Aβ, and tau (Uryu et al. 2007). Mice expressing only ApoE or PDAPP-ApoE
mice have also been studied in the setting of traumatic brain injury (Hartman et al. 2002;
Crawford, et al. 2009b; Mannix et al. 2011). However, neither of these models produced these
three types of pathology. Notably, in the 3xTG-AD mice both Aβ and tau pathologies increased
acutely following TBI, but in 3xTg-ApoE mice, only amyloid beta but not tau was affected by
acute TBI. The absence of a TBI-related exacerbation of tau pathology may be due to a
protective effect of all 3 human ApoE isoforms compared with endogenous mouse ApoE, as has
been reported for Abeta pathology in another AD mouse model (Holtzman, et al. 1999).
One possible explanation for these results is that the axons of 3xTG-ApoE4 mice are
more susceptible to injury. This may represent a loss of function of ApoE4 in the setting of
traumatic brain injury, similar to that seen in ApoE deficient mice (Chen, et al. 1997; Lynch, et
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al. 2002; Namjoshi, et al. 2013). Alternately, it may represent a toxic gain of function of ApoE4.
Others have proposed that ApoE4 may undergo a cleavage step to produce a toxic fragment
that induces mitochondrial dysfunction and neuronal death (Chang, et al. 2005). Studies
comparing axonal injury in hemizygous ApoE4+/- mice may help differentiate between a loss or
gain of function. Interestingly, our group recently showed that wild-type mice treated with
COG1410, an ApoE-mimetic, following controlled cortical impact have fewer APP-positive axons
in pericontusional white matter 3-7 days after injury compared to saline treated mice (Jiang et al.
2012). As COG1410 is a modified peptide sequence from human ApoE3, this could indicate
that ApoE4 lacks an axon-protective effect found in the other two isoforms.
Another possible interpretation of these results is that ApoE affects the production,
processing, or trafficking of APP specifically. For example, ApoE4 has been shown to be more
efficient at recycling APP from the cell surface back into the endocytic pathway (Ye, et al. 2005).
Additional markers of axonal injury and complementary injury models will be required to
determine whether there is a specific APP effect or a general effect on axonal injury. Thus,
interpretation of the main finding from this study, that ApoE4 mice displayed more APP
accumulations following injury than the other genotypes, is limited by our current understanding
of the role of ApoE in axon biology.
It is also notable that both sham and injured 3xTG-ApoE4 mice have more total human
tau staining but not pS199 tau than mice expressing either ApoE2 or ApoE3. Further
characterization of phospho-tau epitopes may contribute to a clearer picture of tau pathology in
this model. Increased total human tau in 3xTG-ApoE4 is not unexpected given several previous
lines of research. First, ApoE4 fragments have been shown to induce tau accumulation (Huang,
et al. 2001; Brecht, et al. 2004). Impaired ApoE4 binding to ApoE receptors in mice may cause
dysregulation of tau kinases such as GSK3β and greater accumulation of the protein at baseline
(Ohkubo, et al. 2003). Other researchers have reported that ApoE is produced in neurons
following injury and neuronal production of apoE4 contributes to tau hyperphosphorylation and
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microtubule instability (Horsburgh, et al. 1996; Tesseur, et al. 2000a; Tesseur, et al. 2000b).
We have not addressed the question of neuronal apoE production following traumatic brain
injury. Last, apoE2 and apoE3 have been shown in vitro to bind tau and prevent
hyperphosphorylation, while apoE4 lacks this ability (Strittmatter, et al. 1994). As the current
study did not address the production of apoE in neurons following injury, it is unknown whether
neuronal apoE production is the mechanism of tau accumulation occurring in this model.
However, it is unlikely to be a major contributor since no significant difference was detected
between sham and injured 3xTG-ApoE4 tau or pS199 tau levels; sham mice are not expected to
have neuronal apoE expression.
This study was limited in that APP immunohistochemistry was the only method
employed to assess axonal injury. Additional markers of axonal injury including neurofilament
immunohistochemistry, silver staining, electron microscopy, electrophysiology, and diffusion
tensor imaging will be of interest to determine whether there is a global effect of APOE
genotype on axonal injury or whether the effects are limited to the processing underlying
abnormal APP accumulation (i.e. failed fast axonal transport). Functional tests such as Morris
Water Maze will also be useful to understand the implications of increased APP accumulation
within the fimbria. Further, biochemical studies will be necessary to determine the effects of
APOE genotype on specific assembly forms of amyloid beta and tau following TBI. Last, a full
characterization of the time course for both amyloid beta and tau pathology will be helpful for
interpreting these results and assessing the utility of these mouse lines. Such analysis may
also uncover chronic effects of APOE genotype on amyloid beta and tau deposition that were
not apparent in this initial acute injury analysis. Clearly, this will be the first of many studies
required to address all of the issues in the field, and a complete characterization is beyond the
scope of this paper.
Another potential limitation is the choice of the 3xTG-AD line of mice. While these mice
have been informative in studying amyloid beta and tau dynamics following moderate TBI,
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overexpression of these transgenes may mask some of the effects of ApoE genotype in injury.
Mice expressing both human amyloid precursor protein and tau under endogenous promoters
may be an alternative to the 3xTG-AD model for future studies (Andorfer, et al. 2003; Guo, et al.
2012).
Altogether, these results demonstrate that it is feasible to produce mouse models for
studying interactions between APOE genotype and important aspects of human acute
neurodegenerative pathology following traumatic brain injury. Considering the finding that
APOE4 genotype contributes to increased axonal injury, this research has important
implications for targeted therapeutics to benefit susceptible APOE4 carrying populations
following TBI. Future research will seek to use this model for pharmacogenetic studies and to
further understand how APOE genotype modifies axonal injury in both moderate TBI and less
severe repetitive closed skull injury models (Shitaka et al. 2011).
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CHAPTER 8
Conclusions and Future Directions

8.1 SUMMARY
To characterize the repetitive closed-skull traumatic brain injury (rcTBI) mouse model,
histological, electrophysiological, and advanced magnetic resonance imaging (MRI) methods
were used. Two key observations were made 1) rcTBI results increased activation and
proliferation of microglia and 2) there is histological evidence of axonal injury from APP, NF200,
SMI-32, and silver staining in the absence of overt cell loss or damage. Interestingly, silver
staining appears to have the greatest sensitivity to axonal injury at 7 days, while other
immunohistochemical markers labeled the greatest amount of injury at 2 days. Further,
electrophysiological compromise of axons was evident at 7 days, where compound action
potential amplitude in both myelinated and unmyelinated axons was reduced. Diffusion tensor
imaging in this mouse model revealed acute abnormalities in injured white matter. Decreases in
mean diffusivity and axial diffusivity at 7 days suggest that analysis of individual components of
the diffusion tensor may be the most sensitive to mild traumatic axonal injury. Altogether, these
features are in line with what is known about characteristics of human traumatic brain injury and
both in vivo and ex vivo human concussion studies (Oppenheimer 1968; Blumbergs et al. 1994;
Niogi et al. 2010; Ramlackhansingh et al. 2011; Johnson et al. 2013a; Johnson et al. 2013b).
Factors that might influence the extent of axonal injury after concussion were also
explored. To determine how the robust upregulation of microglial activity may contribute to ongoing processes of axonal injury, rcTBI was performed in the valganciclovir-inducible CD11b-TK
mouse model of microglial depletion. At 7 day and 21 days, a 35% reduction in microglia had
no effect on the amount of silver staining in white matter tracts. A 56% reduction also failed to
alter silver staining or axonal injury evident by electron microscopy 7 days post-injury.
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Unexpectedly, this model resulted in intraparenchymal hemorrhages with long-term or highdose valganciclovir treatment. Altogether, based on these data, it does not appear that
microglia contribute to acute and sub-acute axonal injury.
In a separate set of experiments, I attempted to manipulate the microglial response
using Mac-1-SAP, minocycline, CHPG, BBG, or miR-124. With the exception of Mac-1-SAP,
the number of microglia was unaffected by drug treatment after injury. In the case of Mac-1SAP, a CD11b targeted toxin, cell loss and intraparenchymal hemorrhages were pronounced at
7 days. Whether or not this toxicity is due to a similar mechanism seen in CD11b-TK mice or
related to the metabolization of Mac-1-SAP is unknown. Overall, this indicates a need for better
microglial-targeting compounds.
Last, data was presented from a more severe controlled cortical impact (CCI) injury
model where presence of the human apolipoprotein E4 allele worsened axonal injury acutely
after impact. Surprisingly, APOE4 expression did not affect acute accumulation of Aβ or tau in
axons. This suggests that APOE may be one contributing factor to axonal injury and poor
outcome following traumatic brain injury.

8.2 FUTURE DIRECTIONS
One clear direction of this research is to explore the connection between functional
axonal injury and behavioral outcomes. In this work, I show that injured mice have Morris Water
Maze deficits and reduced compound action potential velocities. Other work in the lab has
found that mice also have impairments in tasks such as the tail suspension and social
recognition tests (Klemenhagen, et al. 2013). An intriguing possibility is that axonal injury may
be the substrate for behavioral deficits and it would be informative to directly test this
hypothesis. This could be done by making use of the inherent variability in the injury model.
Individuals would be prescreened into “high” injury and “low” injury groups using behavioral
tests performed within the first 2-3 days post-injury. Pairs of sham and injured mice could be
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tested in a single day of hidden platform Morris Water Maze, tail suspension, social recognition,
and/or rotarod testing. Low injury mice would be defined as having behavior test scores within 1
standard deviation of a group of sham control mice. High injury mice would have test scores of
more than 1 standard deviation. I would expect that the high injury mice would have reduced
compound action potential velocities at 7 days post-injury and that low injury mice would be
similar to shams. Further, following electrophysiology, slices could be embedded in gelatin and
re-sectioned on a freezing microtome (see protocol in appendix) so that correlations between
behavioral, electrophysiological, and histological parameters like silver staining could be
examined.
If mice with the greatest behavioral deficits also have functional and histological
changes, then follow up experiments could examine manipulating axonal injury severity and the
effect this has on behavioral tests. For example, in Chapter 7, I observed that mice with the
ApoE4 allele have increased axonal injury after moderate-severe TBI compared to mice with
ApoE2 or 3. I would expect that after repetitive concussive injury, ApoE4 mice would have
increased silver staining compared to E2 and E3 mice and that ApoE4 they would also have the
greatest behavioral deficits. Administration of an ApoE mimetic drug, such as COG1410, may
alleviate these deficits in ApoE4 mice (Laskowitz, et al. 2007; Jiang et al. 2012). In addition,
such a study would shed light on whether or not ApoE4 affects axons through a toxic gain of
function or a loss of function mechanism. If COG1410 can prevent increased axonal injury in
ApoE4 mice, then it would appear that ApoE4 is a loss of function mutation. If COG1410 has no
effect, then it is likely ApoE4 works through a toxic gain of function, such as the release of a
toxic cleavage product (Chang et al. 2005).
Alternately, if electrophysiology and histology do not correlate with any behavioral
measures, it would suggest that future experiments and therapeutic design should target
aspects of repetitive concussion other than axons. Other areas of investigation should include
looking at changes to synapses. To date, no comprehensive study has examined the effects of
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concussive brain injury on synaptic structure, due in large part to the availability of highthroughput quantitative methods for investigation. More recently, however, array tomography
has been used to address these questions (Micheva et al. 2007; Kay et al. 2013). In this
method, tissue is embedded in plastic resin similar to preparation for electron microscopy.
Serial 70-100 nm sections are cut in ribbons, “arrays”, on an ultramicrotome using a large
diamond knife. These arrays can then be immunofluorescently labeled with antibodies to
synaptic proteins and individual structures can be counted. Unlike using traditional 10 micron
thick or larger tissue sections, physically sectioning allows considerably improved z-axis
resolution. The tools and methods are currently in place in the lab to perform these studies.
Specifically it would be informative to investigate how activated microglia may alter
synaptic structure and behavior. Microglia are important mediators of synaptic pruning during
development, and it is becoming increasingly apparent that they play an active role at the
synapse in the adult brain (Paolicelli, et al. 2011; Schafer, et al. 2012; Parkhurst et al. 2013;
Zhan, et al. 2014). Recently, it was reported that release of microglial BDNF at the synapse is
an important event in the learning response, as it helps regulate synapse formation and
elimination (Parkhurst et al. 2013). How might this process be affected by concussions—or
multiple concussions? Synaptic alterations though to be the underlying basis for schizophrenia
and autism and it is intriguing to consider that trauma-induced synaptic changes might
contribute to behavioral alterations or cognitive impairments after concussion. Interestingly, in
the larger TBI population, individuals with a history of TBI are at increased risk for developing
psychiatric disorders (Orlovska et al. 2013). How milder injuries might contribute to synaptic
alterations and subtle behavioral change (or the more striking behavioral and personality
changes seen in Chronic Traumatic Encephalopathy) is an exciting direction for future
investigations.
In sum, these experiments will all test the underlying assumption (of this research and of
the TBI field in general) that axonal injury is the central pathological process taking place in mild
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or concussive TBI. While axonal injury may prove to be a key aspect of these mild injuries, this
assumption may be an artifact of our ability to detect pathology. Designing experiments to
directly test this assumption will be important for therapeutic development to reduce the longterm consequences of these injuries.

8.3 CONCLUDING REMARKS
With the increasing public awareness of the risks associated with concussion, more
talented scientists will be attracted to this area of research and it is my hope that this work be
used as a starting point for future investigations into the nature of repetitive concussive
traumatic brain injury. Here, I found that microgIia do not play a role early on in the process of
axon degeneration, but it remains to be answered why microglial cells remain present in white
matter tracts for several weeks (or in humans, years) post-injury or how they might modulate
long-term outcomes, contribute to synaptic alterations, and initiate behavioral changes. I have
also reported that apolipoprotein E genotype influences the severity of axonal injury immediately
following TBI, and it will be necessary to repeat these studies in the repetitive closed-skull injury
model and to determine by what mechanism APOE exerts its effects on axonal injury.
Altogether, have detailed how this rcTBI mouse model can be used in future investigations to
explore the effects of genetic or environmental factors on concussive injury and I have
presented an experimental approach for assessing injury including immunohistochemistry,
electrophysiology, behavior, and diffusion tensor MRI.
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APPENDIX
TABLE A1: REVIEW OF EXPERIMENTAL MODELS OF MILD TRAUMATIC BRAIN INJURY AND CONCUSSION IN RAT
AND MOUSE
Reference
Nilsson et
al. 1990

Organism
rat

Kanayama
et al. 1996
Tang et al.
1997
Han et al.
2000
Laurer et
al. 2001

rat
mouse
mouse
mouse

DeFord et
al. 2002

mouse

Uryu et al.
2002

mouse

Zohar et al.
2003
Creeley et
al. 2004
Conte et
al. 2004

mouse

Longhi et
al. 2005

mouse
mouse

mouse

Injury Description
Single mild 1.5 or 2.5
mm controlled cortical
impact (piston)
7x daily 1.0 atm fluid
percussion injuries
Single weight drop
injury
Single weight drop
(Tang et al.)
2x daily pneumatic
impacts with rubber tip
1-4x weight drop
injuries (50 g, 100 g,
150 g masses)
2x daily pneumatic
impacts with rubber tip
(Laurer et al.)
20, 25, or 30 g single
weight drop injury
3x 21 g daily weight
drop injuries
2x daily pneumatic
impacts with rubber tip
(Laurer et al.)
1x or 2x pneumatic
impacts with rubber
tip, 3, 5, or 7 day
interval (Laurer et al.)

Endpoints
240
minutes
1 week, 1
month
12 hours—
3 weeks

3, 7, 14,
21, 28, 56
days
3 hours, 2
and 12
days
2 days, 9
or 16
weeks
7, 30, 60,
or 90 days

8 weeks

72 hours
and 1 week

Main findings
Performed microdialysis and measured energy metabolites
after injury, GABA, taurine, glutamate and aspartate were all
altered over 240 minute timecourse.
Abnormal MAP2, tau, and neurofilament (IHC) in perikarya
and impaired behavior (novel environment)
46% mortality, 23% skull fracture, edema, impaired MWM
performance, cell loss (Cresyl violet)
Widespread neurodegeneration in CA2/3 and increased
GFAP in APOE-/- mice
Impaired rotarod, no change in MWM. Reduced neuroscore
that recovered by 14 days. APP in thalamus at 28 days, no
cell loss or MAP2 loss
Determined weight drop parameters that resulted in 100%
survival, no skull fractures, no cell loss (cresyl violet),
repetitive injury produced MWM impairments
Repetitive injury increased amyloid deposition in Tg2576
mice. Slight MWM deficits 16 weeks after repetitive injury
but not single injury. No cell loss, sparse GFAP.
Injury impaired MWM performance in all groups that last to
90 days. No histological abnormalities (MRI)
Contra-coup argyrophilic injury. Small group differences in
MWM (increased path length to platform)
Vitamin E supplementation for 8 weeks post injury reduced
MWM deficits and amyloid deposition in Tg2576 mice.
Mice have MWM deficits with up to a 5 day injury interval
between 2 hits, not in the single hit group. Fluorojade B in
ipsilateral cortex, increased APP in white matter
(semiquantitative analysis), reduced MAP2
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Reference
Milman et
al. 2005

Organism
mouse

Tashlykov
et al. 2007
Abdel Baki
et al. 2009

mouse
rat

Injury Description
30 g single weight
drop injury (Zohar et
al.)
15,20,25,30 g weight
drop (Zohar et al.)
Single controlled
cortical impact (1.0
mm, 3 m/s or 2.5 mm,
4 m/s)
1x or 3x ballistic
weight impactor,
unfixed, helmeted
head (Viano et al.)
Single 30 g weight
drop (Zohar et al.)

Hamberger
et al. 2009

rat

Israelson et
al. 2009

mouse

Viano et al.
2009

rat

Spain et al.
2010

mouse

Creed et al.
2011

mouse

Single pneumatic
impact with 5mm
metal tip, midline
between lambda and
bregma

Davidsson
et al. 2011

rat

Single rotational
acceleration (0.3-2.1
Mrad/s

1x or 3x (every 6
hours) ballistic weight
impacts, unfixed,
helmeted head
Single mild (0.9 atm)
fluid percussion injury

Endpoints
7, 30, 60,
90 days

Main findings
Deficits in swimming T maze, forced swim tests, and
passive avoidance at sporadic intervals post-injury

72 hours

Apoptosis after injury

7 days or 3
weeks

No difference in open field and passive avoidance.
Increasingly difficult avoidance tests were used to
discriminate sham, mild, and moderate TBI groups.

10 days

Multiple injuries produced NF200 accumulation, increased
gfap, hemorrhages and edema.

4, 22
hours, 3
and 7 days
1, 4 or 10
days

Increased transcription of genes involved in inflammation
(qPCR)

4, 24, 72
hours, 4
and 6
weeks
24 hours,
3, 7, 14
days

No difference in MWM performance, few injured neurons
(H&E), increased APP in external capsule at 24 hours and
in thalamus at 4 and 6 weeks. No clear changes in myelin

2 hours-7
days

11-33% of rats had focal brain injury or hemorrhage and
increased bleeding after 3 hits. Head acceleration reached
450g to 1750g without skull fracture.

MWM deficits on days 1-3 post-injury but not 4-6. Increased
APP in corpus callosum and external capsule at 24 hours
and 3 days, increased SMI-32 at 24 hours. Increased
axonal Fluorojade B at 7 and 14 days. Reduced myelinated
axon CAP amplitude at 24 hours and 14 days. Increased
unmyelinated axon refractoriness at 14 days.
1.0 Mrad/s2 or above produced axonal injury (APP, silver),
upregulated Cox2, elevated serum S100β
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Reference
Goldstein
et al. 2012
Kane et al.
2012

Organism
mouse

Meehan et
al. 2012

mouse

Mouzon et
al. 2012

mouse

Shultz et al.
2012

rat

Hylin et al.
2013

rat

Single mild (1-1.5 atm) 5 days
fluid percussion injury

Mannix et
al. 2013

mouse

Ojo et al.
2013

mouse

Selwyn et
al. 2013

rat

1x, 5x, 7x 54 g weight
drop unfixed head,
daily, weekly,
biweekly, or monthly
1x or 5x EM impact
with 5mm metal tip
every 48 hrs (Mouzon
et al.)
Single mild (1.2 atm)
fluid percussion injury

mouse

Injury Description
Single blast injury,
unfixed head
5x or 10x daily weight
drop in unrestrained
mouse
1x, 3x, 5x, or 10x 54 g
weight drop, unfixed
head

Endpoints
2 weeks

1x or 5x
electromagnetic
impact with 5mm
metal tip every 48 hrs
1x, 3x, or 5x (1-1.5
atm) fluid percussion
injury every 5 days

24 hours,
10 days

4 hours, 5
and 30
days
24 hours, 1
month, 1
year

24 hours or
8 weeks

2 days, 2
months, 6
months or
1 year
3 weeks

3, 24 or 72
hours, 5, 7,
9, 14, 16 or
21 days

Main findings
Increased GFAP, SMI-31, tau labeling in cortex and
hippocampus
Increased GFAP, increased tau phosphorylation at 30 days
(Western Blot), mixed results in rotarod testing
Mice that received weekly impacts performed worse on
MWM but mice that received monthly impacts did not.
Deficits were apparent when testing began at 24 hours or 1
month post-injury. Small n per group.
1x and 5x injuries had impaired rotarod and Barnes maze
performance, increased APP, GFAP, microglia in corpus
callosum and brainstem.
5x group had impaired elevated plus maze and forced swim
test, 3x and 5x had impaired MWM. No changes in beam
walk, open-field or social behavior tasks. 3x and 5x had
more microglia in injured cortex. Large areas of cortical
damage in 3x and 5x groups.
1.0 atm injury did not cause motor or MWM deficits. 1.5 atm
had mild motor deficits, impaired MWM, altered cerebral
perfusion, reduced FA in cingulum, increased silver staining,
APP, iba-1, and GFAP in corpus callosum.
Daily and weekly impacts resulted in impaired MWM
performance but biweekly or monthly did not. No T2weighted MRI abnormalities. No effect of ApoE4 allele in
MWM performance
5x but not 1x injury appeared to increase tau pathology in
human tau knock-in mouse line (immunohistochemistry,
CP13, RZ3, PHF1). Increased GFAP and CD45. Neuronal
injury in CA3 (cresyl violet).
Injury resulted in transient reduction in glucose uptake
between 24 hours and 5 days (PET). Motor impairments in
beam walk and peg walk. No change in Barnes maze.
Possible axonal loss or white matter damage 10 days postinjury. Reduces MAPs in cortex at 10 and 21 days.
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Reference
Mouzon et
al. 2014

Organism
mouse

Injury Description
1x or 5x
electromagnetic
impact with 5mm
metal tip every 48 hrs

Endpoints
6, 12, or 18
months

Main findings
5x injury mice performed poorly on Barnes maze at all
timepoints. No difference in rotarod or elevated plus maze.
Iba-1, gfap, and occasional APP was present in corpus
callosum at 12 months post-injury. No Aβ or tau changes.
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TABLE A2: TRANSGENIC MOUSE LINES FOR MICROGLIAL DEPLETION
Mouse line

Refs

Experimental
Model
Mouse EAE,
Alzheimer’s mice
(APPswe/PS1 &
APP23)
Nerve axotomy,
cortical stab,
ischemia,
Alzheimer’s mice
(APPswe/PS1)

CD11b-TK
(Zurich,
Switzerland)

(Heppner et al.
2005; Grathwohl
et al. 2009; Varvel
et al. 2012)

CD11b-TK
(Quebec,
Canada)

(Gowing et al.
2006; Simard et
al. 2006;
LalancetteHebert, et al.
2007)

IL34 -/-

(Wang, et al.
2012)

CSF1R -/-

(Ginhoux, et al.
2010)

MAFIA

(Burnett et al.
2004)

P2Y12 -/-

(Haynes, et al.
2006)

Microglial culture,
in vivo cortical
laser ablation
injury

p38α -/-

(Bachstetter, et al.
2013)

Mouse controlled
cortical impact

CX3CR1CreER

(Parkhurst et al.
2013)

Result

Mechanism

Specificity

Reduced EAE symptoms,
reduced number of
microglia by up to 90%, did
not alter Aβ
Reduced EAE symptoms,
reduced number of
microglia by up to >75%,
bone marrow microglia
reduced Aβ plaques
Mice have ~80% fewer
microglia
Mice fail to develop
microglia
70% loss of macrophage in
blood, spleen, lung and
thymus, >90% loss in bone
marrow and peritoneum
Microglia failed to extend
processes towards
nucleotides or injured areas

Herpes simplex virus
thymidine kinase induces
toxicity in CD11b cells after
valganciclovir administration
Herpes simplex virus
thymidine kinase induces
toxicity in CD11b cells after
ganciclovir administration

Yes, will
selectively
deplete
monocytes
Yes, will
selectively
deplete
monocytes

IL34 is required for normal
microglial development
CSF1R is required for
microglial development
FKBP-fas induces apoptosis
in Csf1r expressing cells after
administration of AP20187

Langerhans cells
are also affected
Osteoclasts are
all affected
Will deplete
macrophage and
dendritic cells.

P2Y12 signaling is required
for microglial chemotaxis in
response to nucleotides

Microglia do not have
altered morphology after
brain injury but do have
upregulated cytokine
production.
99% reduction of microglia
(by flow cytometry and iba-1
immunohistochemistry) by
day 1 after diphtheria toxin

Lack of phospho-p38α inhibits
microglia activation

No, also found
on platelets but
not found on
peripheral
macrophage
No, p38α is
ubiquitously
expressed
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Tamoxifen-inducible cre
recombinase drives
expression of diphtheria toxin
receptor. Administration of
diphtheria toxin depletes
microglia

Yes

TABLE A3: PHARMACOLOGICAL COMPOUNDS USED TO MANIPULATE MICROGLIA
Compound

Refs

Mac-1Saporin

(Dommergues et
al. 2003; GarciaAlloza et al.
2007; Zhao et al.
2007)
(Bye et al. 2007;

Minocycline

CHPG

Brilliant Blue
G

Kim et al. 2009)
(Movsesyan, et
al. 2004; Byrnes
et al. 2009a;
Byrnes et al.
2009b)
(North 2002;
Monif et al.
2009)

Experimental
Model
Rat spinal cord
injury, cortical stab,
PSAPP mice

Result

Mechanism

Specificity

Application of Mac-1-Sap
reduced microglial number

Binds to CD11b and toxin is
internalized

Yes, will only
bind to
monocytes

TBI, ischemia, ALS,
etc.

Reduced microglial
activation by histology and
ELISA
Treatment reduced TNFα,
NO, ROS

No clear mechanism, thought
to act through P38 but could
be indirect
Agonist of mGluR5, blocks
expression of NADPH
oxidase in microglia

No, may work
through
neurons
No, mGluR5
present on
other cell types

Primary microglial
cultures, spinal
cord injury
Mouse EAE

Reduced microglial
markers, TNFα, iNOS,
NADPH oxidase
Peripheral miR-124
suppressed EAE

Selective P2X7 receptor
antagonist

LPS activated
microglial cell
cultures
MCAo

Fractalkine suppressed
TNFα, NO, IL-6

Not clear, may be NF-κB

Primarily
expressed in
macrophage
No, miR-124
regulates many
pathways
Yes

No effect on microglial
activation, contrary to in
vitro results
Reduced microglial
activation
Reduced CD45, CD11b

No clear mechanism, could
be indirect

No

No clear mechanism, could
be indirect
Multiple targets

No

Reduced TNFα after LPS in
vitro and in vivo
Injected into spinal cord,
blocked hyperalgesia
Injected into lateral
ventricle, reduced
perivascular macrophage

MLK inhibitor seems to work
through P38/JNK
Inhibits glial Krebs cycle
enzyme
Ingested by phagocytic cells
to induce toxicity

Rat spinal cord
injury

miR-124

(Ponomarev et
al. 2011)

CX3CL1

(Mizuno, et al.
2003)

D-JNKI1

(Benakis, et al.
2010)

COG1410

(Laskowitz et al.
2007)

Mouse TBI

Ibuprofen

(Yan, et al.
2003)
(Lund, et al.
2005)

Tg2576 mice

CEP-1347
Fluorocitrate
Chlodronate
Liposomes

(Hassel, et al.
1992; Watkins,
et al. 1997)
(Polfliet, et al.
2001; Hawkes,
et al. 2009)

LPS stimulated cell
cultures and mice
Formalin
hyperalgesia
Wild-type rats,
TgCRND8 mice

173

Inhibition of C/EBP-α and
PU.1 (transcription factors)

No
No
NA
Yes, but limited
penetration in
brain

PROTOCOL: RE-SECTIONING BRAIN SLICES FOR HISTOLOGY
Adapted from (Crawford, et al. 2009a)
Gelatin Recipe (for 100 mls)
7.5g gelatin
15g sucrose
to 100ml with ddH2O
1) Heat to 50°C to dissolve gelatin and sugar. Ali quot in plastic conicals and store at 4°C.
2) To use gelatin, reheat to 35-40°C.
3) Place drop of warm gelatin in a cryomold (cat#62534-25, E.M.S.) and immediately place
the slice on top of the gelatin. Use a paintbrush to smooth the surface of the section so
that it is flat—it helps to do this over ice so that the gelatin will start to firm up and adhere
to the slice.
4)

Cover with a second layer of gelatin—do not allow the first layer to completely set
before doing this as the layers will separate later.

5) Allow gelatin blocks to cool for 1 hour at 4°C. Then remove the cryomolds and trim
some of the excess gelatin from around the slice with a razor blade.
6) Once blocks have chilled, remove from cryomolds and place in 4% PFA overnight
7) Transfer to 30% sucrose PBS overnight.
8) Section on a freezing microtome you normally would, taking care to line up the face of
the section as best as you can with the blade—this should yield 3-4 good 50 micron
sections per 300-400 micron slice.
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